<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma - Tomita, Y - 2020 | Cochrane Library</title> <meta content="Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma - Tomita, Y - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012078.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma - Tomita, Y - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012078.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012078.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma" name="citation_title"/> <meta content="Yoko Tomita" name="citation_author"/> <meta content="The Queen Elizabeth Hospital and University of Adelaide" name="citation_author_institution"/> <meta content="yoko80619@yahoo.com" name="citation_author_email"/> <meta content="Max Moldovan" name="citation_author"/> <meta content="South Australian Health and Medical Research Institute" name="citation_author_institution"/> <meta content="Rachael Chang Lee" name="citation_author"/> <meta content="Adelaide Cancer Centre" name="citation_author_institution"/> <meta content="Amy HC Hsieh" name="citation_author"/> <meta content="The Queen Elizabeth Hospital and University of Adelaide" name="citation_author_institution"/> <meta content="Amanda Townsend" name="citation_author"/> <meta content="The Queen Elizabeth Hospital and University of Adelaide" name="citation_author_institution"/> <meta content="Timothy Price" name="citation_author"/> <meta content="The Queen Elizabeth Hospital and University of Adelaide" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD012078.pub2" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/11/19" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012078.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012078.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012078.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adenocarcinoma [mortality, pathology, *therapy]; Antineoplastic Agents [adverse effects, *therapeutic use]; Combined Modality Therapy [methods]; Docetaxel [therapeutic use]; Esophageal Neoplasms [mortality, pathology, *therapy]; *Esophagogastric Junction; Immunotherapy [adverse effects, *methods]; Irinotecan [therapeutic use]; Neoplasm Recurrence, Local [therapy]; Paclitaxel [therapeutic use]; Placebos [therapeutic use]; Progression-Free Survival; Quality of Life; Randomized Controlled Trials as Topic; Salvage Therapy [*methods]; Stomach Neoplasms [mortality, pathology, *therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012078.pub2&amp;doi=10.1002/14651858.CD012078.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012078.pub2&amp;doi=10.1002/14651858.CD012078.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012078.pub2&amp;doi=10.1002/14651858.CD012078.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012078.pub2&amp;doi=10.1002/14651858.CD012078.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012078.pub2&amp;doi=10.1002/14651858.CD012078.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012078.pub2&amp;doi=10.1002/14651858.CD012078.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012078.pub2&amp;doi=10.1002/14651858.CD012078.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012078.pub2&amp;doi=10.1002/14651858.CD012078.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012078.pub2&amp;doi=10.1002/14651858.CD012078.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012078.pub2&amp;doi=10.1002/14651858.CD012078.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012078.pub2&amp;doi=10.1002/14651858.CD012078.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012078.pub2&amp;doi=10.1002/14651858.CD012078.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012078.pub2&amp;doi=10.1002/14651858.CD012078.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012078.pub2&amp;doi=10.1002/14651858.CD012078.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012078.pub2&amp;doi=10.1002/14651858.CD012078.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012078.pub2&amp;doi=10.1002/14651858.CD012078.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012078.pub2&amp;doi=10.1002/14651858.CD012078.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012078.pub2&amp;doi=10.1002/14651858.CD012078.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012078.pub2&amp;doi=10.1002/14651858.CD012078.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012078.pub2&amp;doi=10.1002/14651858.CD012078.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012078.pub2&amp;doi=10.1002/14651858.CD012078.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012078.pub2&amp;doi=10.1002/14651858.CD012078.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012078.pub2&amp;doi=10.1002/14651858.CD012078.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="9mpoajSI";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012078\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012078\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012078\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012078\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","pt","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012078.pub2",title:"Salvage systemic therapy for advanced gastric and oesophago\\u2010gastric junction adenocarcinoma",firstPublishedDate:"Nov 19, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gut Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9mpoajSI&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012078.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012078.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012078.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012078.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012078.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012078.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012078.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012078.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012078.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012078.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4934 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012078.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012078.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012078.pub2/full#CD012078-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012078.pub2/full#CD012078-sec-0117"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012078.pub2/full#CD012078-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012078.pub2/full#CD012078-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012078.pub2/full#CD012078-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012078.pub2/full#CD012078-sec-0017"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012078.pub2/full#CD012078-sec-0042"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012078.pub2/full#CD012078-sec-0106"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012078.pub2/appendices#CD012078-sec-0122"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/table_n/CD012078StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/table_n/CD012078StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012078.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012078.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012078.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012078.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012078.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012078.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012078.pub2/information#CD012078-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Yoko Tomita</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012078.pub2/information#CD012078-cr-0005">Max Moldovan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012078.pub2/information#CD012078-cr-0006">Rachael Chang Lee</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012078.pub2/information#CD012078-cr-0007">Amy HC Hsieh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012078.pub2/information#CD012078-cr-0008">Amanda Townsend</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012078.pub2/information#CD012078-cr-0009">Timothy Price</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/information/en#CD012078-sec-0131">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 19 November 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012078.pub2">https://doi.org/10.1002/14651858.CD012078.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012078-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012078-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012078-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012078-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012078-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012078-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012078-abs-0001" lang="en"> <section id="CD012078-sec-0001"> <h3 class="title" id="CD012078-sec-0001">Background</h3> <p>Salvage systemic therapy has become the new standard of care in patients with advanced gastric and oesophago‐gastric junction (OGJ) adenocarcinoma, following disease progression on first‐line fluoropyrimidine and platinum‐containing chemotherapy. Pharmacological agents proven to be effective in this setting include both chemotherapy and biological therapy, however, the consensus on the best salvage systemic therapy has not been reached. </p> </section> <section id="CD012078-sec-0002"> <h3 class="title" id="CD012078-sec-0002">Objectives</h3> <p>To assess the effects of systemic chemotherapy and biological therapy, either alone or in combination, on overall survival (OS) and progression‐free survival (PFS) in patients with advanced gastric and OGJ adenocarcinoma, whose disease has progressed on, or relapsed after first‐line fluoropyrimidine and platinum‐containing chemotherapy. Adverse events (AEs), tumour response rate (TRR) and quality of life (QoL) associated with systemic chemotherapy and/or biological therapy were additionally assessed. </p> </section> <section id="CD012078-sec-0003"> <h3 class="title" id="CD012078-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, trial registries and proceedings of the major oncology conferences up to October 2020. We additionally handsearched the reference lists of studies. No language restriction was applied. </p> </section> <section id="CD012078-sec-0004"> <h3 class="title" id="CD012078-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) comparing salvage systemic therapy (chemotherapy and/or biological therapy) and either another type of salvage systemic therapy, placebo, best supportive care (BSC) or no treatment in patients with gastric and OGJ adenocarcinoma refractory to first‐line fluoropyrimidine and platinum‐containing chemotherapy. </p> </section> <section id="CD012078-sec-0005"> <h3 class="title" id="CD012078-sec-0005">Data collection and analysis</h3> <p>Two review authors independently performed selection of eligible studies and the primary author extracted study characteristics and outcome data from included studies. We assessed the quality and risk of bias of eligible studies according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>. We expressed pooled estimates of effect using hazard ratio (HR) calculated using an inverse variance random‐effects model for time‐to‐event data, and risk ratio (RR) calculated using Mantel‐Haenszel random‐effects model for binary data. The certainty of evidence was graded using GRADEpro. </p> </section> <section id="CD012078-sec-0006"> <h3 class="title" id="CD012078-sec-0006">Main results</h3> <p>We identified 17 RCTs with 5110 participants for inclusion in this review. Tweenty‐nine studies are ongoing and twenty studies are awaiting classification. No studies examined the following comparisons: chemotherapy combined with biological therapy versus placebo, BSC or no treatment, chemotherapy combined with biological therapy versus biological therapy, biological therapy versus biological therapy and chemotherapy combined with biological therapy versus chemotherapy combined with biological therapy. </p> <p><b>Chemotherapy versus placebo, best supportive care or no treatment</b> </p> <p>Chemotherapy probably improves OS (HR = 0.66, 95% CI 0.52 to 0.83, moderate‐certainty evidence) based on two studies involving 547 participants and improves PFS (HR = 0.57, 95% CI 0.47 to 0.69, high‐certainty evidence) based on one study involving 507 participants over placebo and BSC. Chemotherapy probably increases serious AEs (SAEs) (RR = 1.38, 95% CI 1.20 to 1.59, moderate‐certainty evidence) based on one study involving 503 participants. </p> <p><b>Biological therapy versus placebo, best supportive care or no treatment</b> </p> <p>Biological therapy improves OS (HR = 0.55, 95% CI 0.41 to 0.73, high‐certainty evidence) and probably improves PFS (HR = 0.33, 95% CI 0.19 to 0.57, moderate‐certainty evidence) over placebo based on three studies involving 781 participants. There is currently insufficient evidence for increased SAEs from biological therapy (RR = 1.14, 95% CI 0.95 to 1.37, low‐certainty evidence) based on two studies involving 638 participants. </p> <p><b>Chemotherapy versus biological therapy</b> </p> <p>This comparison only considered immunotherapy. There is probably no evidence of a difference for OS (HR = 0.82, 95% CI 0.66 to 1.02, moderate‐certainty evidence) between chemotherapy and immunotherapy, and immunotherapy probably reduces PFS (HR = 1.27, 95% CI 1.03 to 1.57, moderate‐certainty evidence) based on one study involving 395 participants. SAEs may be less frequent with immunotherapy compared to chemotherapy (RR = 0.41, 95% CI 0.30 to 0.57, low‐certainty evidence). </p> <p><b>Chemotherapy combined with biological therapy versus chemotherapy</b> </p> <p>Addition of biological therapy to chemotherapy probably does not improve OS (HR = 0.93, 95% CI 0.83 to 1.04, moderate‐certainty evidence) and we are uncertain whether it improves PFS (HR = 0.87, 95% CI 0.74 to 1.02, very low‐certainty evidence) based on seven studies involving 2743 participants. We are similarly uncertain whether combined chemotherapy and biological therapy increases SAEs (RR = 1.17, 95% CI 0.95 to 1.44, very low‐certainty evidence) based on four studies involving 1618 participants. </p> <p><b>Chemotherapy versus chemotherapy</b> </p> <p>There is no evidence of a difference for OS and PFS between irinotecan and paclitaxel (HR = 1.13, 95% CI 0.86 to 1.48, low‐certainty evidence for OS; HR = 1.14, 95% CI 0.88 to 1.48, low‐certainty evidence for PFS) based on one study involving 219 participants. Similarly, there is no evidence to indicate improved OS and PFS from addition of another chemotherapy to docetaxel (HR = 1.05, 95% CI 0.72 to 1.54, low‐certainty evidence for OS; HR = 0.75, 95% CI 0.52 to 1.09, low‐certainty evidence for PFS) based on two studies involving 121 participants. Grade ≥ 3 neutropenia occurred commonly with both mono‐ and poly‐chemotherapy except for docetaxel‐S1 and EOX chemotherapy. </p> </section> <section id="CD012078-sec-0007"> <h3 class="title" id="CD012078-sec-0007">Authors' conclusions</h3> <p>Survival outcome of patients with advanced gastric and OGJ adenocarcinoma whose disease progressed on first‐line fluoropyrimidine and platinum‐containing chemotherapy can be improved by chemotherapy and biological therapy. Biological therapy, in particular, achieves this without clear increase in SAEs or QoL impairment. Whether biological therapy is preferred over chemotherapy is still unclear and there is no evidence of a difference for OS outcome, although immunotherapy may be associated with less SAEs. Addition of biological therapy to chemotherapy and poly‐chemotherapy are associated with frequent treatment‐related toxicity without clear survival benefit. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012078-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012078-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012078-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012078-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012078-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012078-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD012078-abs-0008">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012078-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD012078-abs-0006">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012078-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD012078-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012078-abs-0002" lang="en"> <h3>Which treatments work best for advanced stomach cancer that has not responded to standard chemotherapy? </h3> <p><b>What is advanced stomach cancer?</b> </p> <p>Gastric (stomach) cancer usually begins in the mucous‐producing cells lining the stomach. Oesophago‐gastric junction (OGJ) cancer starts where the food pipe (oesophagus) joins the stomach. Advanced cancer is cancer that has spread to nearby tissues, or to another part of the body, despite treatment. </p> <p>Treatments for gastric and OGJ cancer include:</p> <p>• operation to remove the cancer;</p> <p>• chemotherapy (medicines that kill cancer cells);</p> <p>• radiotherapy (radiation to kill cancer cells); and</p> <p>• biological therapy (medicines made from proteins and other substances that occur naturally in the body). </p> <p>Biological therapies include immunotherapy (medicines that help the immune system to recognise and kill cancer cells) and therapies that target something in, or surrounding, the cancer, such as the cancer's blood supply. Standard chemotherapy usually combines two medicines containing fluoropyrimidine and platinum. </p> <p>When standard chemotherapy for advanced cancer has not worked, further treatment aims to slow the growth of the cancer to help people live longer. Further treatments include: other chemotherapy medicines, biological therapies, and best supportive care (care that helps a person cope with life‐limiting illness and its treatment). </p> <p><b>Why we did this Cochrane Review</b> </p> <p>Stomach and OGJ cancer are difficult to treat. We wanted to find out which treatments work best to control these cancers and help people live longer, when standard chemotherapy has not worked. </p> <p><b>What did we do?</b> </p> <p>We searched for studies that looked at chemotherapy and/or biological therapies for advanced stomach or OGJ cancer that had not responded to standard chemotherapy. We looked for studies in which the treatment each person received was decided at random. These studies usually give the most reliable evidence about the effects of treatments. </p> <p><b>Search date</b> </p> <p>We included evidence published up to October 2020.</p> <p><b>What we found</b> </p> <p>We found 17 studies in 5110 people with advanced stomach or OGJ cancer. Studies compared further chemotherapy and/or biological therapies, given by mouth or through the bloodstream (systemic), with: </p> <p>• another systemic chemotherapy and/or biological therapy;</p> <p>• a placebo ('dummy' treatment);</p> <p>• best supportive care; and</p> <p>• no treatment.</p> <p>The studies looked at:</p> <p>• how long people lived;</p> <p>• any adverse (unwanted) effects; and</p> <p>• their quality of life (well‐being).</p> <p><b>What are the results of our review?</b> </p> <p>People probably live longer after further chemotherapy (irinotecan or trifluridine plus tipiracil) than with placebo treatment or best supportive care. But chemotherapy probably increases serious unwanted effects, including diarrhoea, fever, and lower numbers of red and white blood cells. </p> <p>People may live as long after irinotecan chemotherapy as after paclitaxel chemotherapy. Adding another chemotherapy (oxaliplatin or cisplatin) to docetaxel may not affect how long people live. </p> <p>People live longer after biological therapy (nivolumab, apatinib or regorafenib) than with placebo treatment. We did not find enough evidence about whether biological therapy increases unwanted effects. </p> <p>People given immunotherapy (pembrolizumab) probably live as long as people given chemotherapy (paclitaxel), but may not have as many unwanted effects as with chemotherapy. </p> <p>Combining chemotherapy with biological therapy probably does not help people live longer than chemotherapy alone, and we are uncertain whether it increases unwanted effects. </p> <p><b>How reliable are these results?</b> </p> <p>We are moderately confident that chemotherapy probably helps people to live longer than placebo treatment or best supportive care. We are confident that people live longer on biological therapy than placebo treatment. We think more evidence is unlikely to change this result. </p> <p>We are less confident about the results for unwanted effects. Some studies had missing data or did not report these; and in some studies people and their doctors knew which treatment was given, which could have affected the study results. These results are likely to change when more evidence becomes available. </p> <p><b>Conclusions</b> </p> <p>If advanced stomach or OGJ cancer has not responded to standard chemotherapy, further chemotherapy or biological therapy help people to live longer than placebo treatment, best supportive care, or no treatment. However, chemotherapy is more clearly associated with unwanted effects than biological therapy. </p> <p>We are unsure if biological therapies work better than chemotherapy, but they may cause fewer unwanted effects. Combining chemotherapy and biological therapies may cause more unwanted effects without giving any extra benefit. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012078-sec-0117" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012078-sec-0117"></div> <h3 class="title" id="CD012078-sec-0118">Implications for practice</h3> <section id="CD012078-sec-0118"> <p>Salvage systemic therapy, both chemotherapy and biological therapy, improves survival outcome of patients with advanced gastric and oesophago‐gastric junction (OGJ) adenocarcinoma following disease progression on fluoropyrimidine and platinum‐containing first‐line chemotherapy. Although our review indicated insufficient evidence to decide between irinotecan and paclitaxel monotherapies in terms of effects on overall survival (OS) and progression‐free survival (PFS) outcomes, paclitaxel is associated with fewer treatment‐related deaths and Grade ≥ 3 marrow suppression. Paclitaxel, therefore, may be preferred over irinotecan at least in the second‐line setting, unless its specific toxicity such as neuropathy contraindicates its use. Trifluridine/tipiracil probably has both OS and PFS benefits over placebo in the third‐ and fourth‐line settings and this drug may be used following progression of disease on paclitaxel and/or irinotecan again in appropriately selected patients. </p> <p>Biological therapy is an alternative option to chemotherapy and in the second‐line setting, both nivolumab and vascular endothelial growth factor receptor (VEGFR)‐targeted therapy such as apatinib and regorafenib were evaluated. In the third‐line setting our finding was limited to regorafenib. Only immunotherapy was compared to both placebo and chemotherapy in our review and there was no evidence of a difference for OS outcome between immunotherapy and paclitaxel with immunotherapy being possibly associated with reduced risk of SAEs, although the certainty of evidence for serious adverse event (SAE) analysis was low. Nivolumab and pembrolizumab may be reasonable options in patients who are vulnerable to toxicity associated with chemotherapy and tyrosine kinase inhibitors, bearing mind that OS benefit of pembrolizumab was evaluated in those with PD‐L1 CPS ≥ 1. </p> <p>Addition of biological therapy to chemotherapy probably does not improve OS outcome unless biological therapy acts through a mechanism other than those involving HER2 receptors based on a sensitivity analysis, and the effect is not affected by the geographical regions. Addition of biological therapy to chemotherapy is associated with frequent SAEs, however, it is uncertain whether it increases SAEs as the certainty of evidence for this analysis was very low. Combined chemotherapy and biological therapy may not be a preferred treatment for advanced gastric and OGJ adenocarcinoma in the salvage setting. Based on the available evidence it is uncertain whether poly‐chemotherapy improves OS, PFS or tumour response rate (TRR), and it rather increases Grade ≥ 3 neutropenia. Use of poly‐chemotherapy is generally not supported. </p> </section> <h3 class="title" id="CD012078-sec-0119">Implications for research</h3> <section id="CD012078-sec-0119"> <p>Although our review demonstrated survival benefit of both chemotherapy and biological therapy in patients with gastric and OGJ adenocarcinoma in the salvages setting, whether VEGFR‐target therapy such as apatinib and regorafenib is as efficacious as irinotecan and taxane monotherapy remains uncertain. This is because neither agent was examined by the study comparing chemotherapy and biological therapy in this review. The reported median overall survival (mOS) and median progression‐free survival (mPFS) were longer for irinotecan and taxane chemotherapy, however, future studies directly comparing these agents are needed to confirm this. </p> <p>The number of studies included in this review was small, partly due to our strict inclusion criteria. We defined included participants to have either gastric or OGJ adenocarcinoma, but not non‐OGJ oesophageal adenocarcinoma, and to have experienced disease progression on fluoropyrimidine and platinum‐containing first‐line chemotherapy. We felt these inclusion criteria are necessary to maximise the applicability of our findings to daily clinical practice. Difference in efficacy of systemic therapy has been suggested for different locations along oesophago‐gastric tract (<a href="./references#CD012078-bbs2-0147" title="ChauI , NormanAR , CunninghamD , OatesJ , HawkinsR , IvesonT , et al. The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials. Annals of Oncology2009;20(5):885-91. [PMID: 19164454]">Chau 2009</a>) and combination of fluoropyrimidine and platinum has now become the standard first‐line treatment for advanced gastric cancer including OGJ adenocarcinoma worldwide (<a href="./references#CD012078-bbs2-0151" title="CunninghamD , StarlingN , RaoS , IvesonT , NicolsonM , CoxonF , et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. New England Journal of Medicine2008;358(1):36-46. [PMID: 18172173]">Cunningham 2008</a>; <a href="./references#CD012078-bbs2-0160" title="KangYK , KangWK , ShinDB , ChenJ , XiongJ , WangJ , et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Annals of Oncology2009;20(4):666-73. [PMID: 19153121]">Kang 2009</a>). As a result, each systemic regimen was only examined by a single study except for taxane and irinotecan monotherapy which were administered to participants in 10 and two studies, respectively. </p> <p>The current trend in phase 3 cancer clinical trials is that new cancer therapeutics are examined in a single or a very small number of sufficiently‐powered international RCTs before being accepted as the new standard of care. This means the large number of patients are examined under the common protocol, potentially allowing for meaningful sub‐analyses such as those by ethnicity, geographical region, age group and biomarker expression. Careful consideration in determining inclusion and exclusion criteria is required so that the population examined represents patients encountered in daily clinical practice. Additionally, inclusion and reporting of quality of life (QoL) outcome is strongly encouraged for future studies given the small absolute survival benefit of systemic therapy for advanced gastric and OGJ adenocarcinoma in the salvage setting. </p> <p>Immunotherapy is characterised by the unconventional patterns of response or progression and this has raised statistical issues around the optimal study design, endpoints and statistical method for analysis in clinical studies evaluating them (<a href="./references#CD012078-bbs2-0153" title="FerraraR , PilottoS , CacceseM , GrizziG , SperdutiI , GiannarelliD , et al. Do immune checkpoint inhibitors need new studies methodology?Journal of Thoracic Disease2018;10(Suppl 13):S1564–S1580. [PMID: 29951307]">Ferrara 2018</a>). Studies with survival endpoints have traditionally been designed based on a proportional hazards model under the exponential distribution assumption presuming anything which affects the hazards does so by the same ratio at all times. Long‐term survival and delayed clinical effects of immunotherapy, however, as seen from the survival curves of nivolumab (<a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>) and pembrolizumab (<a href="./references#CD012078-bbs2-0012" title="ShitaraK , ÖzgüroğluM , BangYJ , BartolomeoMD , MandalàM , RyuMH , et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet2018;392(10142):123-33. [PMID: 29880231]">Shitara 2018</a>) in our review, promote conventional proportional hazards model to underestimate study duration and the statistical power required (<a href="./references#CD012078-bbs2-0148" title="ChenTT . Statistical issues and challenges in immuno-oncology. Journal for Immunotherapy of Cancer2013;21(1):18. [PMID: 24829754]">Chen 2013</a>). Traditional survival endpoints used in clinical trials such as OS and PFS with HR are sub‐optimal to capture key attributes of immunotherapy as mPFS can potentially underestimate the clinical benefit of immunotherapy with delayed clinical effect, while mOS frequently fails to provide information concerning the small subset of patients with prolonged survival benefit. This explains the opposing direction of HR associated with OS and PFS of pembrolizumab (<a href="./references#CD012078-bbs2-0012" title="ShitaraK , ÖzgüroğluM , BangYJ , BartolomeoMD , MandalàM , RyuMH , et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet2018;392(10142):123-33. [PMID: 29880231]">Shitara 2018</a>), which influenced our survival meta‐analysis for the comparison of chemotherapy versus biological therapy. Use of an alternative statistical method and survival measures have been proposed for future clinical trials concerning immunotherapy (<a href="./references#CD012078-bbs2-0148" title="ChenTT . Statistical issues and challenges in immuno-oncology. Journal for Immunotherapy of Cancer2013;21(1):18. [PMID: 24829754]">Chen 2013</a>). Statistical approach in performing meta‐analysis involving such studies may additionally need to be revised. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012078-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012078-sec-0008"></div> <div class="table" id="CD012078-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Chemotherapy versus placebo, best supportive care (BSC) or no treatment</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Chemotherapy compared to placebo, BSC or no treatment for advanced gastric and oesophago‐gastric junction adenocarcinoma</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> advanced gastric and oesophago‐gastric junction adenocarcinoma<br/><b>Setting:</b> second‐line and beyond<br/><b>Intervention:</b> chemotherapy<br/><b>Comparison:</b> placebo, BSC or no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with chemotherapy</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo, BSC or no treatment</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>mOS weighed for study size</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.66<br/>(0.52 to 0.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>547<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2 studies compared chemotherapy (irinotecan and trifluridine/tipiracil) to placebo or BSC. Heterogeneity was low (I<sup>2</sup> = 7%, P = 0.30). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5.6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3.5 months</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression‐free survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>mPFS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.57<br/>(0.47 to 0.69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>507<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared trifluridine/tipiracil to placebo.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2.0 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.8 months</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.38<br/>(1.20 to 1.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>503<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared trifluridine/tipiracil to placebo.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>797 per 1,000</p> <p>(693 to 918)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>577 per 1,000</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tumour response rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.17<br/>(0.63 to 7.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>435<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared trifluridine/tipiracil to placebo.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>97 per 1,000<br/>(28 to 335) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1,000</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.04<br/>(1.00 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>503<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared trifluridine/tipiracil to placebo.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>972 per 1,000<br/>(935 to 1,000) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>935 per 1,000</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval ;<b>HR:</b> hazard ratio; <b>mOS:</b> median overall survival; <b>mPFS:</b> median progression‐free survival; <b>RCT:</b> randomised controlled trial; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level for imprecision; 95% CI for the HR included null effect and appreciable benefit from chemotherapy. </p> <p><sup>2</sup> Downgraded by one level for imprecision; 95% CI for the RR included null effect and appreciable harm from chemotherapy. </p> <p><sup>3</sup> Downgraded by two levels for imprecision; the number of events analysed was small and 95% CI included both appreciable benefit and harm from chemotherapy. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012078-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Biological therapy versus placebo, best supportive care (BSC) or no treatment</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Biological therapy compared to placebo, BSC or no treatment for advanced gastric and oesophago‐gastric junction adenocarcinoma</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> advanced gastric and oesophago‐gastric junction adenocarcinoma<br/><b>Setting:</b> second‐ and third‐line<br/><b>Intervention:</b> biological therapy<br/><b>Comparison:</b> placebo, BSC or no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with biological therapy</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo, BSC or no treatment</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>mOS weighed for study size</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.55<br/>(0.41 to 0.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>781<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared nivolumab to placebo and 2 studies compared VEGFR‐targeted agents (apatinib and regorafenib) to placebo. Heterogeneity was moderate (I<sup>2</sup> = 55%, P = 0.08). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5.2 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3.9 months</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression‐free survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>mPFS weighed for study size</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.33<br/>(0.19 to 0.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>781<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared nivolumab to placebo and 2 studies compared VEGFR‐targeted agents (apatinib and regorafenib) to placebo. Heterogeneity was high (I<sup>2</sup> = 87%, P &lt; 0.0001). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2.1 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.3 months</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.14<br/>(0.95 to 1.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>638<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared nivolumab to placebo and the other study compared regorafenib to placebo. Heterogeneity was low (I<sup>2</sup> = 3%, P = 0.31). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>481 per 1,000<br/>(401 to 578) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>422 per 1,000</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tumour response rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 5.12 (1.23 to 21.27)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>687<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared nivolumab to placebo and 2 studies compared VEGFR‐targeted agents (apatinib and regorafenib) to placebo. Heterogeneity was low (I² = 13%, P = 0.33). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>470 per 1,000<br/>(113 to 1,000) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>92 per 1,000</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.08<br/>(1.00 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>491<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared nivolumab to placebo.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>906 per 1,000<br/>(839 to 981) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>839 per 1,000</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life (QoL</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>)Similar QoL was experienced by participants treated with biological therapy and placebo, except for improved insomnia and pain associated with apatinib and regorafenib treatment, respectively. More participants receiving regorafenib experienced diarrhoea, and sore throat and mouth. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>283<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>4 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>QoL was assessed in 2 studies comparing VEGFR‐targeted agents (apatinib and regorafenib) to placebo, using EORTC QLQ‐C30 +/‐ QLQ‐STO22 and EQ‐5D. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>HR:</b> hazard ratio; <b>mOS:</b> median overall survival; <b>mPFS:</b> median progression‐free survival; <b>RCT:</b> randomised controlled trial; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level for inconsistency; heterogeneity between studies was high. </p> <p><sup>2</sup> Downgraded by two levels for imprecision; the number of events analysed was small and 95% CI included both null effect and appreciable harm from biological therapy. </p> <p><sup>3</sup> Downgraded by two levels for imprecision; the number of events analysed was small and 95% CI was very wide. </p> <p><sup>4</sup> Downgraded by one level for attrition bias; less participants in the placebo arm completed QoL questionnaires post baseline. </p> <p><sup>5</sup> Downgraded by one level for imprecision; the number of events analysed was small. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012078-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Chemotherapy versus biological therapy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Chemotherapy compared to biological therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> advanced gastric and oesophago‐gastric junction adenocarcinoma<br/><b>Setting:</b> second‐line<br/><b>Intervention:</b> biological therapy<br/><b>Comparison:</b> chemotherapy </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with biological therapy</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Chemotherapy</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>mOS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.82<br/>(0.66 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>395<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared pembrolizumab to paclitaxel in PD‐L1 CPS ≥ 1 population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9.1 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8.3 months</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression‐free survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>mPFS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.27<br/>(1.03 to 1.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>395<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared pembrolizumab to paclitaxel in PD‐L1 CPS ≥ 1 population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.5 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4.1 months</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.41<br/>(0.30 to 0.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>570<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared pembrolizumab to paclitaxel.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>143 per 1,000<br/>(104 to 198) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>348 per 1,000</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tumour response rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.17<br/>(0.72 to 1.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>395<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared pembrolizumab to paclitaxel in PD‐L1 CPS ≥ 1 population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>159 per 1,000</p> <p>(98 to 255)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>136 per 1,000</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.63<br/>(0.56 to 0.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>570<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared pembrolizumab to paclitaxel.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>530 per 1,000</p> <p>(471 to 597)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>841 per 1,000</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>HR:</b> hazard ratio; <b>mOS:</b> median overall survival; <b>mPFS:</b> median progression‐free survival; <b>RCT:</b> randomised controlled trial;<b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level for imprecision; 95% CI included both null effect and appreciable benefit from biological therapy. </p> <p><sup>2</sup> Downgraded by one level for imprecision; 95% CI included both null effect and appreciable harm from biological therapy. </p> <p><sup>3</sup> Downgraded by one level for imprecision; the total number of events analysed was small. </p> <p><sup>4</sup> Downgraded by one level for risk of performance bias in <a href="./references#CD012078-bbs2-0012" title="ShitaraK , ÖzgüroğluM , BangYJ , BartolomeoMD , MandalàM , RyuMH , et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet2018;392(10142):123-33. [PMID: 29880231]">Shitara 2018</a>. </p> <p><sup>5</sup> Downgraded by two levels for imprecision; the number of events analysed was small and 95% CI included both appreciable benefit and harm from biological therapy. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012078-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Chemmotherapy combined with biological therapy versus chemotherapy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Chemmotherapy compared to chemotherapy combined with biological therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> advanced gastric and oesophago‐gastric junction adenocarcinoma<br/><b>Setting:</b> second‐ to fourth‐line<br/><b>Intervention:</b> chemotherapy combined with biological therapy<br/><b>Comparison:</b> chemotherapy </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with chemotherapy combined with biological therapy</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with chemotherapy</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>mOS weighed for study size</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.93<br/>(0.83 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2743<br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study each examined PARP inhibitor (olaparib), anti‐HER2 antibody (trastuzumab), cancer stem cell inhibitor (napabucasin), mTOR inhibitor (everolimus), anti‐VEGFR2 antibody (ramucirumab) and multi‐tyrosine kinase inhibitor (sunitinib) together with chemotherapy. The other study examined anti‐HER2 antibody conjugated with chemotherapy (trastuzumab‐emtansine). The control arm was taxane in all studies. Heterogeneity was moderate (I<sup>2</sup> = 36%, P = 0.15). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8.1 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7.2 months</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression‐free survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>mPFS weighed for study size</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.87<br/>(0.74 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2743<br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study each examined PARP inhibitor (olaparib), anti‐HER2 antibody (trastuzumab), cancer stem cell inhibitor (napabucasin), mTOR inhibitor (everolimus), anti‐VEGFR2 antibody (ramucirumab) and multi‐tyrosine kinase inhibitor (sunitinib) together with chemotherapy. The other study examined anti‐HER2 antibody conjugated with chemotherapy (trastuzumab‐emtansine). The control arm was taxane in all studies. Heterogeneity was high (I<sup>2</sup> = 71%, P = 0.002). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3.9 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3.1 months</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.17<br/>(0.95 to 1.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1618<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>3 5 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study each examined PARP inhibitor (olaparib), anti‐VEGFR2 antibody (ramucirumab) and multi‐tyrosine kinase inhibitor (sunitinib) together with chemotherapy. The other study examined anti‐HER2 antibody conjugated with chemotherapy (trastuzumab‐emtansine). The control arm was taxane in all studies. Heterogeneity was high (I<sup>2</sup> = 86%, P &lt; 0.0001). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>735 per 1,000</p> <p>(686 to 791)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>613 per 1,000</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tumour response rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.35<br/>(0.99 to 1.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2404<br/>(6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study each examined PARP inhibitor (olaparib), anti‐HER2 antibody (trastuzumab), cancer stem cell inhibitor (napabucasin), anti‐VEGFR2 antibody (ramucirumab) and multi‐tyrosine kinase inhibitor (sunitinib) together with chemotherapy. The other study examined anti‐HER2 antibody conjugated with chemotherapy (trastuzumab‐emtansine). The control arm was taxane in all studies. Heterogeneity was high (I<sup>2</sup> = 66%, P = 0.01). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>294 per 1,000</p> <p>(216 to 403)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>218 per 1,000</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/>(1.00 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1513<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study each examined PARP inhibitor (olaparib) and anti‐VEGFR2 antibody (ramucirumab). The other study examined anti‐HER2 antibody conjugated with chemotherapy (trastuzumab‐emtansine). The control arm was taxane in all studies. Heterogeneity was low (I<sup>2</sup> = 0%, P = 0.78). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>987 per 1,000</p> <p>(977 to 1000)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>977 per 1,000</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Quality of life (QoL)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Median time to deterioration of EORTC QLQ‐C30 global health status for olaparib‐paclitaxel vs placebo‐paclitaxel </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.88<br/>(0.74 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1154<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>4 8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>QoL was assessed by 2 out of 7 studies using EORTC QLQ‐C30 plus QLQ‐SOT22 or EQ‐5D‐3L. 1 study each investigated PARP inhibitor (olaparib) and anti‐VEGFR2 antibody (ramucirumab). The control arm was taxane in both studies. Meta‐analysis was performed for time to deterioration of EORTC QLQ‐C30 global health status. Heterogeneity was very low (I² = 0%, P = 0.47). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3.4 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2.4 months</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>HR:</b> hazard ratio; <b>mOS:</b> median overall survival; <b>mPFS:</b> median progression‐free survival; <b>RCT:</b> randomised controlled trial; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level for unclear risk of selection, attrition and reporting bias and confounders in <a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>, <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a> and <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a>. </p> <p><sup>2</sup> Downgraded by one level for risk of detection bias in <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>. </p> <p><sup>3</sup> Downgraded by one level for inconsistency; 95% CIs of some studies did not overlap. </p> <p><sup>4</sup> Downgraded by one level for imprecision; 95% CI included both null effect and appreciable benefit from chemotherapy combined with biological therapy. </p> <p><sup>5</sup> Downgraded by one level for imprecision; 95% CI included both null effect and appreciable harm from chemotherapy combined with biological therapy. </p> <p><sup>6</sup> Downgraded by one level for risk of performance bias in <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a> and <a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a>. </p> <p><sup>7</sup> Downgraded by one level for risk of performance and detection bias in <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>. </p> <p><sup>8</sup> Downgraded by one level for attrition bias in <a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a> and <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012078-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Chemotherapy versus chemotherapy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Chemotherapy compared to chemotherapy for advanced gastric and oesophago‐gastric junction adenocarcinoma</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> advanced gastric adenocarcinoma<br/><b>Setting:</b> second‐line<br/><b>Intervention:</b> chemotherapy<br/><b>Comparison:</b> chemotherapy </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with chemotherapy</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with chemotherapy</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival (non‐taxane monotherapy vs taxane monotherapy)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>mOS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.13<br/>(0.86 to 1.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>219<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared irinotecan to paclitaxel.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8.4 months (irinotecan)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9.5 months (paclitaxel)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival (taxane‐containing doublet therapy vs taxane monotherapy)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>mOS weighed for study size</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.05<br/>(0.72 to 1.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>121<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared docetaxel‐oxaliplatin to docetaxel and the other study compared docetaxel‐cisplatin and docetaxel‐S1 to docetaxel. Heterogeneity was moderate (I<sup>2</sup> = 44%, P = 0.17). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7.0 months (taxane‐containing doublet therapy)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8.8 months (docetaxel)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Overall survival (non‐taxane containing therapy vs another non‐taxane containing therapy)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>mOS (P = 0.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>107 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1 study compared FOLFIRI to EOX.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>18.5 months (FOLFIRI)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>19.3 months (EOX)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression‐free survival (non‐taxane monotherapy vs taxane monotherapy)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>mPFS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.14<br/>(0.88 to 1.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>219<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared irinotecan to paclitaxel.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2.3 months (irinotecan)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3.6 months (paclitaxel)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression‐free survival (taxane‐containing doublet therapy vs taxane monotherapy)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>mPFS weighed for study size</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.75<br/>(0.52 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>121<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared docetaxel‐oxaliplatin to docetaxel and the other study compared docetaxel‐cisplatin and docetaxel‐S1 to docetaxel. Heterogeneity was moderate (I<sup>2</sup> = 59%, P = 0.09). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3.4 months (taxane‐containing doublet therapy)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.6 months (docetaxel)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Progression‐free survival (non‐taxane containing therapy vs another non‐taxane containing therapy) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>mPFS (P = 0.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>107 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1 study compared FOLFIRI to EOX.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>8.1 months (FOLFIRI)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>7.4 months (EOX)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse effects</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Grade ≥ 3 neutropenia was common occurring in &gt; 20% of participants receiving both mono chemotherapy and polychemotherapy except for docetaxel‐S1 and EOX arms. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>448<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study each compared docetaxel‐cisplatin and docetaxel‐S1 to docetaxel, irinotecan to paclitaxel, docetaxel‐oxaliplatin to docetaxel and FOLFIRI to EOX. All 4 studies measured serious adverse events, however, none of them reported the total number of participants with any serious adverse events. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tumour response rate (non‐taxane monotherapy vs taxane monotherapy)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.65<br/>(0.34 to 1.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>179<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared irinotecan to paclitaxel.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>136 per 1,000</p> <p>(71 to 263) (irinotecan)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>209 per 1,000 (paclitaxel)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tumour response rate (taxane‐containing doublet therapy vs taxane monotherapy)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.47<br/>(0.56 to 3.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>121<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>5 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study examined both docetaxel‐cisplatin and docetaxel‐S1 and the other study examined docetaxel‐oxaliplatin. Control arm was docetaxel in both studies. Heterogeneity was very low (I² = 0%, P = 0.92). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>147 per 1,000</p> <p>(56 to 389) (taxane‐containing doublet therapy)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1,000 (taxane monotherapy)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tumour response rate (non‐taxane containing therapy vs another non‐taxane containing therapy) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.89<br/>(0.48 to 1.67) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>107<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared FOLFIRI to EOX chemotherapy.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>254 per 1,000</p> <p>(137 to 477) (FOLFIRI)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>286 per 1,000 (EOX)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Neutropenia, anaemia, diarrhoea and anorexia were some of the commonly experienced adverse events across all the studies. Neuropathy was associated with paclitaxel, docetaxel‐S1 and EOX treatment. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>448<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies measured any adverse events, however, none of them reported the total number of participants with any adverse events. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>No difference was observed for global QoL between docetaxel‐cisplatin, docetaxel‐S1 and docetaxel arms, however, worse QoL was reported for participants receiving the doublet chemotherapy for several symptom categories including physical functioning, fatigue and appetite loss. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>9 10</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study comparing docetaxel‐cisplatin to docetaxel‐S1 and docetaxel reported QoL. QoL was assessed using EORTC QLQ‐C30 and gastric modules QLQ‐STO22. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>HR:</b> hazard ratio; <b>mOS:</b> median overall survival; <b>mPFS:</b> median progression‐free survival; <b>RR:</b> Risk ratio; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by two levels for imprecision; the number of events analysed was small and 95% CI included both null effect and appreciable harm from irinotecan. </p> <p><sup>2</sup> Downgraded by two levels for imprecision; the number of events analysed was small and the 95% CI included both appreciable benefit and harm from taxane‐containing doublet therapy. </p> <p><sup>3</sup> Downgraded by two levels for imprecision; the number of events analysed was small and 95% CI included both null effect and appreciable benefit from taxane‐containing doublet therapy. </p> <p><sup>4</sup> Downgraded by two levels for imprecision; the number of events analysed was small and 95% CI included both appreciable benefit and harm from irinotecan. </p> <p><sup>5</sup> Downgraded by one level for unclear risk of selection bias, detection bias and confounders in <a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a> and <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>. </p> <p><sup>6</sup> Downgraded by two levels for imprecision; the number of events analysed was small and 95% CI included both appreciable benefit and harm from taxane‐containing doublet therapy. </p> <p><sup>7</sup> Downgraded by two levels for imprecision; the number events analysed was small and 95% CI included both appreciable benefit and harm from FOLFIRI. </p> <p><sup>8</sup> Downgraded by one level for performance bias in <a href="./references#CD012078-bbs2-0002" title="HironakaS , UedaS , YasuiH , NishinaT , TsudaM , TsumuraT , et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology2013;31(35):4438-44. [PMID: 24190112]">Hironaka 2013</a>. </p> <p><sup>9</sup> Downgraded by one level for attrition bias in <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>. </p> <p><sup>10</sup> Downgraded by two levels for imprecision; the number of events analysed was very small. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012078-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012078-sec-0009"></div> <p>A glossary of terms is provided in <a href="./appendices#CD012078-sec-0123">Appendix 1</a>. </p> <section id="CD012078-sec-0010"> <h3 class="title" id="CD012078-sec-0010">Description of the condition</h3> <p>Despite gradual decline in its occurrence during recent decades, gastric cancer remains a major health burden internationally. It is the fifth most common cancer and there were over one million incident cases in 2018 worldwide (<a href="./references#CD012078-bbs2-0152" title="FerlayJ , ErvikM , LamF , ColombetM , MeryL , PiñerosM , et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [05 Aug 2019] November 2018.">Ferlay 2018</a>). The condition is particularly prevalent in Eastern Asia where 60% of worldwide cases occur. Gastric cancer is the third most common cause of cancer‐related death; it contributed to 783,000 deaths in 2018 worldwide. Causes of gastric cancer are multifactorial, although infection with <i>Helicobacter pylori</i> (<i>H.pylori</i>) is considered to be the primary carcinogenic step. Other risk factors include smoking, high salt consumption, and processed meat intake as well as genetic polymorphisms in hosts (<a href="./references#CD012078-bbs2-0165" title="RawlaP , BarsoukA . Epidemiology of gastric cancer: global trends, risk factors and prevention. Przegla̜d Gastroenterologiczny2019;14(1):26-38. [PMID: 30944675]">Rawla 2019</a>). Histologically, 95% of gastric cancer demonstrates adenocarcinoma. </p> <p>Oesophago‐gastric junction (OGJ) cancer affects the border between the oesophagus and the stomach, and the vast majority of this type of cancer is adenocarcinoma. Unlike gastric adenocarcinoma, the incidence of OGJ adenocarcinoma has increased significantly since 1970 in Western countries. In England its age‐standardised incidence rose by 2.6 fold between the 1970s and 1990s, before plateauing (<a href="./references#CD012078-bbs2-0163" title="OffmanJ , PesolaF , SasieniP . Trends and projections in adenocarcinoma and squamous cell carcinoma of the oesophagus in England from 1971 to 2037. British Joural of Cancer2018;118(10):1391–8. [PMID: 29563637]">Offman 2018</a>). Because of its location, the definition and staging of OGJ cancer has been the source of controversy. In the eighth edition of the American Joint Committee in Cancer (AJCC) staging system, adenocarcinomas with epicentres no more than 2 cm into the gastric cardia are staged as oesophageal cancer, while those extending further are staged as stomach cancers (<a href="./references#CD012078-bbs2-0167" title="RiceTW , PatilDT , BlackstoneEH . 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. Annals of Cardiothoracic Surgery2017;6(2):119-30.">Rice 2017</a>). Risk factors for OGJ cancer include smoking, gastro‐oesophageal reflux disease, Barrett's oesophagus and obesity, while a diet high in fibre and <i>H.pylori</i> infection are inversely associated with the condition (<a href="./references#CD012078-bbs2-0146" title="Buas, MF, VaughanTL . Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. Seminars in Radiation Oncology2013;23(1):3-9. [PMID: 23207041]">Buas 2013</a>). The shifts in dietary practices towards increased fat intake and meat consumption, together with the decline in prevalence of <i>H.pylori</i> infection in Western countries, are thought to have contributed to the rise in OGJ cancer's incidence in these countries. Improved site classification of OGJ and gastric cardia adenocarcinoma may also explain this change (<a href="./references#CD012078-bbs2-0150" title="CorleyDA , KuboAI . Influence of site classification on cancer incidence rates: an analysis of gastric cardia carcinomas. Journal of the National Cancer Institute2004;96(18):1383-7. [PMID: 15367571]">Corley 2004</a>). </p> <p>Both gastric and OGJ cancers have a dismal prognosis. The five‐year survival rates of these cancers have been reported to be 32% and 20% in the USA, respectively (<a href="./references#CD012078-bbs2-0168" title="HowladerN , NooneAM , KrapchoM , MillerD , BrestA , Yu M et al (eds). SEER Cancer Statistics Review, 1975-2016. Available from https://seer.cancer.gov/csr/1975_2016/, based on November 2018 SEER data submission2019.">SEER 2018</a>)<b>.</b> Their high mortalities are explained by the majority of patients with these cancers presenting with either advanced disease or relapse following curative intervention. For both gastric and OGJ cancer, where radical resection remains the only treatment offering potential cure, the conditions are considered advanced if complete resection is not possible either due to local extension or the presence of distant metastases. Surgically curable early gastric cancers are usually asymptomatic and only infrequently detected outside screening programs. In many parts of the world where screening programs do not exist, more than 50% of gastric cancer cases are diagnosed at advanced stage (<a href="./references#CD012078-bbs2-0173" title="WesolowskiR , LeeC , KimR . Is there a role for second-line chemotherapy in advanced gastric cancer?Lancet2009;10:903-12. [PMID: 19717092]">Wesolowski 2009</a>). Similarly, more than 80% of patients with OGJ cancer have advanced disease at diagnosis (<a href="./references#CD012078-bbs2-0169" title="SiewertJR , FeithM , SteinHJ . Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographic-anatomic subclassification. Journal of Surgical Oncology2005;90(3):139-46. [PMID: 15895452]">Siewert 2005</a>). Prognoses of advanced gastric and OJG cancers are poor with the five‐year survival rate being less than 10%, however, selected patients still benefit from local and systemic therapies of palliative intention (<a href="./references#CD012078-bbs2-0168" title="HowladerN , NooneAM , KrapchoM , MillerD , BrestA , Yu M et al (eds). SEER Cancer Statistics Review, 1975-2016. Available from https://seer.cancer.gov/csr/1975_2016/, based on November 2018 SEER data submission2019.">SEER 2018</a>). </p> </section> <section id="CD012078-sec-0011"> <h3 class="title" id="CD012078-sec-0011">Description of the intervention</h3> <p>Systemic therapy refers to the treatment of cancer using pharmacological agents, whereby drugs commonly administered orally or intravenously travel through the bloodstream to reach and affect cancer cells around the body. There are currently two types of systemic pharmacological therapy utilised in the management of gastric and OGJ cancers: chemotherapy and biological therapy. While chemotherapy is a group of cytotoxic chemicals used against cancer, biological therapy involves the use of substances derived from living organisms. Biological therapy is categorised based on its mechanism of action and the main types of biological therapy currently in clinical use or having been evaluated in large clinical trials for stomach and OGJ cancers include anti‐HER2 antibody, vascular endothelial growth factor receptor (VEGFR)‐targeted therapy and immunotherapy. </p> <p>Fluoropyrimidine and platinum‐containing chemotherapy has been established as the backbone of first‐line systemic therapy for both advanced gastric and OGJ cancers, with some debate as to the benefit of additional taxane or anthracycline; however, the disease eventually progresses on the treatment (<a href="./references#CD012078-bbs2-0151" title="CunninghamD , StarlingN , RaoS , IvesonT , NicolsonM , CoxonF , et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. New England Journal of Medicine2008;358(1):36-46. [PMID: 18172173]">Cunningham 2008</a>; <a href="./references#CD012078-bbs2-0160" title="KangYK , KangWK , ShinDB , ChenJ , XiongJ , WangJ , et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Annals of Oncology2009;20(4):666-73. [PMID: 19153121]">Kang 2009</a>; <a href="./references#CD012078-bbs2-0172" title="Van CutsemE , MoiseyenkoVM , TjulandinS , MajlisA , ConstenlaM , BoniC , et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. Journal of Clinical Oncology2006;24(31):4991-7. [PMID: 17075117]">Van Cutsem 2006</a>). Gastric and OGJ cancers, which relapse shortly after the perioperative or adjuvant chemotherapy containing these two agents, are similarly considered to be resistant to this regimen. For patients whose disease has progressed on first‐line chemotherapy, best supportive care (BSC) was previously the main management approach. </p> <p>Salvage systemic therapy refers to second‐line and beyond chemotherapy and biological therapy, and they are administered following failure of first‐line systemic therapy. With an increasing number of studies being published supporting its benefit, second‐line pharmacological management of advanced gastric and OGJ cancer has now become the standard of care for patients with reasonable fitness (<a href="./references#CD012078-bbs2-0159" title="KanagavelD , FedyaninM , TryakinA , TjulandinS . Second-line treatment of metastatic gastric cancer: current options and future directions. World Journal of Gastroenterology2015;21(41):11621-35. [PMID: 26556991]">Kanagavel 2015</a>). Chemotherapy such as irinotecan and taxanes were the first to be demonstrated to improve survival of these patients following the failure of fluoropyrimidine and platinum‐containing therapy (<a href="./references#CD012078-bbs2-0030" title="FordHE , MarshallA , BridgewaterJA , JanowitzT , CoxonFY , WadsleyJ , et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncology2014;15(1):78-86. [PMID: 24332238]">Ford 2014</a>; <a href="./references#CD012078-bbs2-0040" title="KangJH , LeeSI , LimDH , ParkKW , OhSY , KwonHC , et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. Journal of Clinical Oncology2012;30(13):1513-8. [PMID: 22412140]">Kang 2012</a>; <a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a>). More recently, there has been a rapid emergence of several biological therapy agents with proven anticancer activity for advanced gastric cancer in the salvage setting, expanding the pharmacological options for these cancers (<a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>; <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>). </p> </section> <section id="CD012078-sec-0012"> <h3 class="title" id="CD012078-sec-0012">How the intervention might work</h3> <p>Salvage systemic therapy is administered with an intention to prolong and maximise quality of life (QoL). Both salvage chemotherapy and biological therapy have been demonstrated to delay progression of cancer growth and extend survival in a proportion of patients with gastric and OGJ cancers (<a href="./references#CD012078-bbs2-0030" title="FordHE , MarshallA , BridgewaterJA , JanowitzT , CoxonFY , WadsleyJ , et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncology2014;15(1):78-86. [PMID: 24332238]">Ford 2014</a>; <a href="./references#CD012078-bbs2-0040" title="KangJH , LeeSI , LimDH , ParkKW , OhSY , KwonHC , et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. Journal of Clinical Oncology2012;30(13):1513-8. [PMID: 22412140]">Kang 2012</a>; <a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>; <a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a>; <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>). These therapies can also improve or delay the deterioration of cancer‐related symptoms such as fatigue, nausea/vomiting, pain and the level of functioning experienced by patients (<a href="./references#CD012078-bbs2-0144" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. RAINBOW: a global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel patients with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma: Quality-of-life (QoL) results. Journal of Clinical Oncology2014;32(15_suppl,):4058-4058.">Al‐Batran 2014</a>; <a href="./references#CD012078-bbs2-0030" title="FordHE , MarshallA , BridgewaterJA , JanowitzT , CoxonFY , WadsleyJ , et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncology2014;15(1):78-86. [PMID: 24332238]">Ford 2014</a>; <a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a>; <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>). </p> <p>Salvage systemic therapy can cause treatment‐related adverse events (AEs) in some patients. The type and the extent of AEs experienced depend on the exact therapy administered and the risk factors held by individual patients. The list of such treatment‐related AEs includes anaemia, diarrhoea, fatigue, infection, loss of appetite, nausea/vomiting, neuropathy, skin rash and stomatitis. When selecting patients with gastric and OGJ cancer for salvage systemic therapy, the expected benefit of the therapy needs to be weighed against the potential toxicities. </p> </section> <section id="CD012078-sec-0013"> <h3 class="title" id="CD012078-sec-0013">Why it is important to do this review</h3> <p>There are now multiple studies supporting the benefit of salvage systemic therapy to improve the survival of patients with advanced gastric and OGJ cancer. Pharmacological agents proven to be effective in this setting include both chemotherapy and newly available biological therapy. Studies comparing the efficacy of these agents vary in size, comparator interventions, and consequently, and consensus on the best salvage systemic therapy has not been reached. There also remain uncertainties about risk‐benefit trade‐off of salvage systemic therapy due to the expected short survival of these patients and potential toxicities associated with treatment. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012078-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012078-sec-0014"></div> <section id="CD012078-sec-0015"> <h3 class="title" id="CD012078-sec-0015">Primary objective</h3> <p>To assess the effects of systemic chemotherapy and biological therapy, either alone or in combination, on overall survival (OS) and progression‐free survival (PFS) in patients with advanced gastric and OGJ adenocarcinoma, whose disease has progressed or relapsed on first‐line fluoropyrimidine and platinum‐containing chemotherapy. </p> </section> <section id="CD012078-sec-0016"> <h3 class="title" id="CD012078-sec-0016">Secondary objectives</h3> <p> <ol id="CD012078-list-0001"> <li> <p>To assess the effect of the aforementioned intervention on tumour response, AEs and QoL. </p> </li> <li> <p>To assess the impact of patients' geographical regions (East and South‐East Asia versus the rest of the world) on the survival benefit of salvage systemic therapy for advanced gastric and OGJ adenocarcinoma. </p> </li> <li> <p>To compare the survival benefit of salvage systemic therapy for advanced gastric and OGJ adenocarcinoma in the second versus third‐line and beyond setting. </p> </li> </ol> </p> </section> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012078-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012078-sec-0017"></div> <section id="CD012078-sec-0018"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012078-sec-0019"> <h4 class="title">Types of studies</h4> <p>We considered both blinded and open‐label randomised studies, in which a type of salvage systemic therapy is compared with either another type of salvage systemic therapy, placebo, BSC or no treatment. Quasi‐randomised studies were accepted as long as they were parallel‐group randomised studies. We included studies reported as full text or as abstract only as well as unpublished studies, if they met the other inclusion criteria. </p> </section> <section id="CD012078-sec-0020"> <h4 class="title">Types of participants</h4> <p>We included adults patients over 18 years of age with a histological or cytological diagnosis of locally advanced and unresectable or metastatic gastric and OGJ adenocarcinoma, whose disease had progressed on first‐line fluoropyrimidine and platinum‐containing palliative chemotherapy. Patients with disease progression on, or disease relapse within 6 months of fluoropyrimidine and platinum‐containing neoadjuvant/perioperative/adjuvant chemotherapy, who were no longer suitable for potentially curative surgery, were also included in the review. </p> <p>The original intention of this systemic review was to assess the effects of systemic therapy in patients with advanced gastric carcinoma, following progression on the standard first‐line chemotherapy. The decision to include OGJ adenocarcinoma in the review, however, was made based on the fact that the majority of clinical studies on advanced gastric cancer enrol patients with OGJ cancer and extracting the proposed primary endpoints for patients with gastric cancer alone was not always possible. OGJ cancer is commonly treated using the same approach as gastric cancer and distinguishing gastric cardia cancer involving OGJ from distal oesophagus and OGJ cancer extending inferiorly to involve gastric cardia remains controversial. In the most recent eighth edition of the American Joint Committee in Cancer (AJCC) staging system, the definition of cancer location for OGJ cancer has changed from the position of the upper edge of the cancer to its epicentre and some even suggest the genetic signature of OGJ cancers may be more accurate in determining the cell of origin for cancer staging rather than its gross location (<a href="./references#CD012078-bbs2-0156" title="HayakawaY , SethiN , SepulvedaAR , BassAJ , WangTC . Oesophageal adenocarcinoma and gastric cancer: should we mind the gap?Nature Reviews Cancer2016;16(5):305-18. [PMID: 27112208]">Hayakawa 2016</a>). </p> <p>We excluded studies with the following characteristics:</p> <p> <ul id="CD012078-list-0002"> <li> <p>studies in which patients have gastric or OGJ cancer other than adenocarcinoma in histology, unless these patients can be separated out for the purpose of outcome assessment; </p> </li> <li> <p>studies in which patients have oesophageal cancer other than OGJ cancer, unless these patients can be separated out for the purpose of outcome assessment; </p> </li> <li> <p>studies in which 10% or more of patients previously received chemotherapy which did not contain both fluoropyrimidine and platinum as first‐line therapy, unless these patients can be separated out for the purpose of outcome assessment; and </p> </li> <li> <p>studies which do not mention the Eastern Cooperative Oncology Group (ECOG) performance score (PS), and those in which 10% or more of patients have an ECOG PS more than 2, unless these patients can be separated out for the purpose of outcome assessment. </p> </li> </ul> </p> <p>When studies met the above listed exclusion criteria, we contacted investigators or study sponsors in order to obtain individual patient data for the purpose of primary and secondary outcome analysis and subgroup analysis where possible. </p> </section> <section id="CD012078-sec-0021"> <h4 class="title">Types of interventions</h4> <p>We included studies comparing systemically administered (parenteral or oral) chemotherapy and biological therapy, either alone or in combination, with or without BSC, to another systemically administered therapy, placebo, BSC or no treatment. </p> <p>We allowed the following co‐interventions in both experimental and control arms of studies, provided they were not part of the randomised treatment and administered for the purposes of symptom control alone: </p> <p> <ul id="CD012078-list-0003"> <li> <p>surgery; and</p> </li> <li> <p>radiotherapy.</p> </li> </ul> </p> </section> <section id="CD012078-sec-0022"> <h4 class="title">Types of outcome measures</h4> <p>We assessed following outcomes.</p> <section id="CD012078-sec-0023"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD012078-list-0004"> <li> <p>Overall survival (OS), defined as survival time from the start of the intervention until death from any cause. </p> </li> <li> <p>Progression‐free survival (PFS), defined as survival time without disease progression from the start of the intervention. </p> </li> <li> <p>Serious adverse events (SAEs), assessed using Common Terminology Criteria for Adverse Events (CTCAE) and defined as Grade ≥ 3. </p> </li> </ol> </p> <p>OS and PFS were chosen as the primary outcomes as they are considered to be the most clinically relevant efficacy assessment tools for patients and clinicians to decide on administration of the intervention. Disease progression for the purpose of determining OS and PFS was defined according to Response Evaluation Criteria in Solid Tumours (RECIST) or immune‐related Response Evaluation Criteria in Solid Tumours (irRECIST). irRECIST was developed to take account of pseudo‐progression, a feature unique to immunotherapy. It involves one‐dimensional measurement as in the case of RECIST, however, confirmation of disease progression is needed minimum four weeks after the first assessment indicating disease progression. </p> <p>SAEs are also important in predicting the tolerability of the intervention and for its benefit‐risk assessment. CTCAE Grade 3 AEs generally refer to any type of AEs which require medical intervention and/or hospitalisation, but are not life‐threatening, while Grade 4 AEs are those which are life‐threatening and Grade 5 AEs are those resulting in death. </p> </section> <section id="CD012078-sec-0024"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD012078-list-0005"> <li> <p>Tumour response rate (TRR), assessed using RECIST or irRECIST.</p> </li> <li> <p>Any adverse events (AAEs), assessed using CTCAE.</p> </li> <li> <p>QoL, assessed using validated tools.</p> </li> </ol> </p> <p>TRR was chosen for the secondary outcomes to assess the anticancer activity of the intervention. As patients included in this review generally had very limited prognoses, AAEs and QoL associated with the intervention were thought to be important aspects of their management. </p> <p>We aimed to compare the following treatment groups for the primary and secondary outcomes.</p> <p> <ol id="CD012078-list-0006"> <li> <p>Chemotherapy versus placebo, BSC or no treatment.</p> </li> <li> <p>Biological therapy versus placebo, BSC or no treatment.</p> </li> <li> <p>Chemotherapy combined with biological therapy versus placebo, BSC or no treatment.</p> </li> <li> <p>Chemotherapy versus biological therapy.</p> </li> <li> <p>Chemotherapy combined with biological therapy versus chemotherapy.</p> </li> <li> <p>Chemotherapy combined with biological therapy versus biological therapy.</p> </li> <li> <p>Chemotherapy versus chemotherapy.</p> </li> <li> <p>Biological therapy versus biological therapy.</p> </li> <li> <p>Chemotherapy combined with biological therapy versus chemotherapy combined with biological therapy. </p> </li> </ol> </p> <p>Reporting of the outcomes listed here was not an inclusion criterion for the review.</p> </section> </section> </section> <section id="CD012078-sec-0025"> <h3 class="title">Search methods for identification of studies</h3> <p>No restrictions were placed on the language of publication when searching the electronic databases or reviewing reference lists in identified studies. We translated abstracts of non‐English language papers and assessed them for potential inclusion in the review as necessary. </p> <section id="CD012078-sec-0026"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases:</p> <p> <ul id="CD012078-list-0007"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) (inception to Issue 9, 2020) (<a href="./appendices#CD012078-sec-0124">Appendix 2</a>) (which includes RCTs from Cochrane Gut Group Specialised Register); </p> </li> <li> <p>EMBASE (1974 to October 2020) (via Ovid) (<a href="./appendices#CD012078-sec-0125">Appendix 3</a>); and </p> </li> <li> <p>MEDLINE (1946 to October 2020) (via Ovid) (<a href="./appendices#CD012078-sec-0126">Appendix 4</a>). </p> </li> </ul> </p> <p>We additionally searched:</p> <p> <ul id="CD012078-list-0008"> <li> <p>WHO ICTRP (http://www.who.int/ictrp/en/) (<a href="./appendices#CD012078-sec-0127">Appendix 5</a>); and </p> </li> <li> <p>ClinicalTrials.gov (https://clinicaltrials.gov/) (<a href="./appendices#CD012078-sec-0128">Appendix 6</a>). </p> </li> </ul> </p> <p>Proceedings of the following oncology conferences were also handsearched (2000 to October 2020): </p> <p> <ul id="CD012078-list-0009"> <li> <p>American Society of Clinical Oncology Annual Meeting;</p> </li> <li> <p>American Society of Clinical Oncology Gastrointestinal Cancer Symposium; and</p> </li> <li> <p>European Society of Medical Oncology Congress.</p> </li> </ul> </p> </section> <section id="CD012078-sec-0027"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of all relevant primary studies and review articles for additional references. </p> </section> </section> <section id="CD012078-sec-0028"> <h3 class="title" id="CD012078-sec-0028">Data collection and analysis</h3> <section id="CD012078-sec-0029"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently screened for inclusion the titles and abstracts of all the studies we identified as a result of the search and coded them as 'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve'. We retrieved the full‐text study reports/publication and two review authors independently screened the full text and identified studies for inclusion. These authors also identified and recorded reasons for exclusion of the ineligible studies. We resolved any disagreement through discussion or, if required, we consulted a third person. We identified and excluded duplicates and collated multiple reports of the same study so that each study rather than each report was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram (<a href="#CD012078-fig-0001">Figure 1</a>) and <a href="./references#CD012078-sec-0138" title="">Characteristics of excluded studies</a> (<a href="./references#CD012078-bbs2-0161" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ2009;339:b2700. [DOI: 10.1136/bmj.b2700]">Liberati 2009</a>). </p> <div class="figure" id="CD012078-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012078-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD012078-sec-0030"> <h4 class="title">Data extraction and management</h4> <p>We used a standard data collection form for study characteristics and outcome data. One review author extracted study characteristics and outcome data from included studies. We extracted the following study characteristics. </p> <p> <ol id="CD012078-list-0010"> <li> <p>Methods: study design, total duration of study and run in, number of study centres, study setting, withdrawals, and date of study. </p> </li> <li> <p>Participants: number, mean age, age range, geographical location, gender, staging of disease, diagnostic criteria, inclusion criteria, exclusion criteria, and ECOG PS. </p> </li> <li> <p>Interventions: intervention, comparison, concomitant medications, and excluded medications.</p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected, and time points reported. </p> </li> <li> <p>Notes: funding for study and notable conflicts of interest of trial authors.</p> </li> </ol> </p> <p>We noted in <a href="./references#CD012078-sec-0137" title="">Characteristics of included studies</a> if outcome data were not reported in a usable way. One review author copied the data from the data collection form into the Review Manager file. We double‐checked that the data were entered correctly by comparing the study reports against the data presented in the systematic review. A second review author spot‐checked study characteristics for accuracy against the trial report. </p> </section> <section id="CD012078-sec-0031"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed risk of bias of each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012078-bbs2-0157" title="HigginsJP , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). Any disagreement was resolved by discussion or by involving a third assessor. We assessed the risk of bias according to the following domains. </p> <p> <ol id="CD012078-list-0011"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Imbalance in baseline characteristics across treatment arms.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other bias.</p> </li> </ol> </p> <p>We graded each potential source of bias as high, low or unclear risk and provided a justification for our judgment in the 'Risk of bias' table. We summarised the 'Risk of bias' judgements across different studies for each of the domains listed (<a href="#CD012078-fig-0002">Figure 2</a>). We considered attrition risk separately for QoL and the rest of the outcomes. Where information on risk of bias relates to unpublished data or correspondence with an author, we noted this in the 'Risk of bias' table. </p> <div class="figure" id="CD012078-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012078-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <p>When considering treatment effects, we took into account the risk of bias for the studies that contributed to that outcome. </p> </section> <section id="CD012078-sec-0032"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed time‐to‐event data (OS and PFS) as hazard ratios (HRs) with a 95% confidence intervals (CIs) and dichotomous data as risk ratios (RRs) with a 95% CIs. We planned to analyse continuous data as mean difference (MD) or standardised mean difference (SMD) with 95% CIs, ensuring that higher scores for continuous outcomes have the same meaning for the particular outcome, explaining the direction and reporting where the directions were reversed if this was necessary. </p> <p>We undertook meta‐analysis only where this was meaningful, i.e. if the treatments, participants and underlying clinical questions were similar enough for pooling to make sense. </p> <p>Where multiple study arms were reported in a single study and two comparisons (e.g. drug A versus placebo and drug B versus placebo) must be entered into the same meta‐analysis, we halved the control group to avoid double counting. </p> </section> <section id="CD012078-sec-0033"> <h4 class="title">Unit of analysis issues</h4> <p>We included studies with a parallel group design where participants are individually assigned to one of the treatment groups with a single observation for each outcome from each participant. The unit of analysis therefore was individuals assigned to each group. </p> </section> <section id="CD012078-sec-0034"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators or study sponsors in order to verify key study characteristics and obtain missing numerical outcome data where possible (e.g. when a study was identified as an abstract only). </p> </section> <section id="CD012078-sec-0035"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity secondary to clinical diversity was expected to be observed between the studies. This included variation in participants (age, ethnicity, baseline ECOG PS, volume of cancer, study eligibility), interventions (chemotherapy and/or biological therapy administered, intensity/dose, intervention in the control group) and outcomes (follow‐up duration), as well as variation in study methodology. We assessed heterogeneity among the studies in each analysis with visual inspection and statistically using the Chi‐square (Chi²) test and the I‐square (I²) statistic. We used a P value threshold of 0.10 to determine statistical significance for the Chi² test, and considered an I² of 30% or less to be low degree, 30% to 60% to be moderate degree, and 60% or more to be a high degree of heterogeneity. We recognised that there is uncertainty in the I² measurement when there are few studies in a meta‐analysis. </p> <p>When we identified substantial heterogeneity, we explored possible sources of heterogeneity using the pre‐specified sensitivity and subgroup analysis described below. </p> </section> <section id="CD012078-sec-0036"> <h4 class="title">Assessment of reporting biases</h4> <p>We attempted to contact study investigators asking them to provide missing outcome data. When this was not possible, and the missing data were thought to introduce serious bias, the impact of including such studies in the overall assessment of results was explored by a sensitivity analysis<b>. </b> </p> <p>As we were unable to pool more than ten studies for any of the meta‐analyses performed in this review, planned assessment using funnel plots to explore possible publication biases was not carried out. </p> </section> <section id="CD012078-sec-0037"> <h4 class="title">Data synthesis</h4> <p>We used Review Manager 5.4.1 (<a href="./references#CD012078-bbs2-0166" title="Copenhagen, The Nordic Cochrane Centre: The Cochrane CollaborationReview Manager (RevMan) Version 5.4.1. Copenhagen, The Nordic Cochrane Centre: The Cochrane Collaboration, 2020.">Review Manager 2020</a>) for pooling of data at a study level, and statistical analysis. Given the potential heterogeneity in the included studies as described above, we used a random‐effects model for both primary and secondary outcome analysis and subgroup analysis. </p> </section> <section id="CD012078-sec-0038"> <h4 class="title">'Summary of findings' tables</h4> <p>We created 'Summary of findings' tables using the following outcomes: OS, PFS, SAEs, TRR, AAEs and QoL. We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of a body of evidence as it relates to the studies which contribute data to the meta‐analysis for the pre‐specified outcomes. We used methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook</i> (<a href="./references#CD012078-bbs2-0157" title="HigginsJP , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>) and used <a href="./references#CD012078-bbs2-0155" title="GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster University, 2015 (developed by Evidence Prime, Inc.). Available from gradepro.org.">GRADEpro</a> software. We justified all decisions to down‐ or up‐grade the quality of studies using footnotes, and made comments to aid readers' understanding of the review where necessary. We considered whether there is any additional outcome information that was not able to be incorporated into meta‐analysis, and noted this in the comments and stated if it supports or contradicts the information from the meta‐analysis. </p> </section> <section id="CD012078-sec-0039"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We carried out the following subgroup analyses.</p> <p> <ol id="CD012078-list-0012"> <li> <p>Line of treatment (second line versus third line and beyond).</p> </li> <li> <p>Geographical region (East and South‐East Asia versus the rest of the world).</p> </li> <li> <p>Extent of the disease (locally advanced versus metastatic).</p> </li> <li> <p>Type of biological therapy (non‐immunotherapy versus immunotherapy).</p> </li> </ol> </p> <p>Geographical region rather than ethnicity was chosen as this additionally accounts for the regional difference in the preferred first‐line systemic therapy for gastric and OGJ cancer, and also to maximise the data attainment. </p> <p>The following outcomes were used in subgroup analysis:</p> <p> <ol id="CD012078-list-0013"> <li> <p>OS; and</p> </li> <li> <p>PFS.</p> </li> </ol> </p> <p>We used the formal statistical test, Chi² test, with significance set at 10%, to test for subgroup interactions. </p> <p>We aimed to compare the following treatment groups for the subgroup analysis.</p> <p> <ol id="CD012078-list-0014"> <li> <p>Chemotherapy versus placebo, BSC or no treatment.</p> </li> <li> <p>Biological therapy versus placebo, BSC or no treatment.</p> </li> <li> <p>Chemotherapy combined with biological therapy versus placebo, BSC or no treatment.</p> </li> <li> <p>Chemotherapy versus biological therapy.</p> </li> <li> <p>Chemotherapy combined with biological therapy versus chemotherapy.</p> </li> <li> <p>Chemotherapy combined with biological therapy versus biological therapy.</p> </li> </ol> </p> </section> <section id="CD012078-sec-0040"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analysis to assess the effect of risk of bias and heterogeneity in the included studies. We repeated the OS and PFS analysis with the following conditions. </p> <p> <ol id="CD012078-list-0015"> <li> <p>Use of a fixed‐effect model.</p> </li> <li> <p>Exclusion of studies with high risk or unclear risk of bias for randomisation, blinding or attrition. </p> </li> <li> <p>Exclusion of studies with incomplete reporting of primary outcome (HR for OS and/or PFS estimated from the test or acquired directly from investigators). </p> </li> <li> <p>Exclusion of studies evaluating HER2‐targeted therapy in biomarker selected participants.</p> </li> </ol> </p> <p>If any additional clinical or methodological variations suitable for sensitivity analysis arose during the review process, we considered this. </p> </section> <section id="CD012078-sec-0041"> <h4 class="title">Reaching conclusions</h4> <p>We based our conclusions only on findings from the quantitative or narrative synthesis of included studies for this review. We avoided making specific recommendations for practice and our implications for research gave the reader a clear sense of where the focus of any future research in the area should be and what the remaining uncertainties are. </p> <p>We conducted the review according to the published protocol and reported any deviations from it in the '<a href="#CD012078-sec-0135">Differences between protocol and review</a>' section of the systematic review. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012078-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012078-sec-0042"></div> <section id="CD012078-sec-0043"> <h3 class="title">Description of studies</h3> <p>We categorised the relevant studies into four categories and their characteristics were summarised see <a href="./references#CD012078-sec-0137" title="">Characteristics of included studies</a>, <a href="./references#CD012078-sec-0138" title="">Characteristics of excluded studies</a>, <a href="./references#CD012078-sec-0139" title="">Characteristics of studies awaiting classification</a> and <a href="./references#CD012078-sec-0140" title="">Characteristics of ongoing studies</a>. </p> <section id="CD012078-sec-0044"> <h4 class="title">Results of the search</h4> <p>Through the electronic search in October 2020, we identified 9099 unique records; 3024 from EMBASE, 375 from CENTRAL, 1934 from MEDLINE, 3294 from WHO ICTRP and 472 from ClinicalTrials.gov. Handsearching found no relevant abstracts from conference proceedings. Of 9093 records left after removing duplicates, 8999 records were considered not suitable for further assessment; 8509 records were excluded after screening title and abstract and 442 records were excluded as they were related records for single trials. Tweenty‐nine studies are ongoing and nineteen studies are awaiting classification as there were no publication on results available (n = 7) or their abstracts provided insufficient information for screening in the absence of full‐text articles (n = 12). One study (<a href="./references#CD012078-bbs2-0113" title="ZhaoX , GuoW , ChenZ , ZhangX , ZhuX , ZhangW , et al. Comparison of efficacy and safety of second-line palliative chemotherapy with paclitaxel plus raltitrexed and paclitaxel alone in patients with metastatic gastric adenocarcinoma: A randomized phase II trial. Journal of Clinical Oncology2019;37(15_suppl):4054. [DOI: 10.1200/JCO.2019.37.15_suppl.4054]">Zhao 2019</a>) identified in the top‐up search performed immediately prior to publication is not yet fully incorporated into the review and is added to studies awaiting classifications; it will be incorporated into the review at the next update. Ninety‐four published abstracts or full‐text articles were assessed in detail and seventy‐six of them were considered to have failed screening based on non‐RCT (n = 9), included participants with oesophageal cancer other than oesophago‐gastric junction (OGJ) adenocarcinoma (n = 4), included participants who received intervention as first‐line systemic therapy (n = 32), equal or more than 10%, or unknown proportion of participants received non‐fluoropyrimidine and platinum‐containing chemotherapy as the first‐line (n = 29), participants had stable disease on first‐line fluoropyrimidine and platinum‐containing chemotherapy (n = 1) and eligibility for inclusion could not be assessed on the published full‐text article (n = 1). Details of search results are shown in the PRISMA flow diagram (<a href="#CD012078-fig-0001">Figure 1</a>). </p> </section> <section id="CD012078-sec-0045"> <h4 class="title">Included studies</h4> <p>Fourteen studies (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>; <a href="./references#CD012078-bbs2-0002" title="HironakaS , UedaS , YasuiH , NishinaT , TsudaM , TsumuraT , et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology2013;31(35):4438-44. [PMID: 24190112]">Hironaka 2013</a>; <a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a>; <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>; <a href="./references#CD012078-bbs2-0007" title="LingS , BoL . Efficacy and safety of second-line chemotherapy with EOX and FOLFIRI in advanced gastric cancer. Journal of Xi'an Jiaotong University (Medical Sciences)2018;39(4):546-50. [DOI: 10.7652/jdyxb201804020]">Ling 2018</a>; <a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>; <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>; <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a>; <a href="./references#CD012078-bbs2-0012" title="ShitaraK , ÖzgüroğluM , BangYJ , BartolomeoMD , MandalàM , RyuMH , et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet2018;392(10142):123-33. [PMID: 29880231]">Shitara 2018</a>; <a href="./references#CD012078-bbs2-0013" title="ShitaraK , DoiT , DvorkinM , MansoorW , ArkenauHT , ProkharauA , et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2018;19(11):1437-48. [PMID: 30355453]">Shitara 2018b</a>; <a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a>; <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>; <a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a>; <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>) were considered to have satisfied our selection criteria and included into this review. Three studies (<a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>; <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>; <a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>) did not provide sufficient information for screening whether more than 90% of participants from these studies received and progressed on fluoropyrimidine and platinum‐containing chemotherapy, however, whether these two agents were administered concurrently was not clear in the texts. Although no response was obtained from study authors, these studies were considered highly relevant and included in the review. A total of 17 studies with 5110 participants were considered in this review. </p> <p><b>Study design</b> </p> <p>Eight studies had double‐blind placebo‐controlled design (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>; <a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>; <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>; <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>; <a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>; <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a>; <a href="./references#CD012078-bbs2-0013" title="ShitaraK , DoiT , DvorkinM , MansoorW , ArkenauHT , ProkharauA , et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2018;19(11):1437-48. [PMID: 30355453]">Shitara 2018b</a>; <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>), while another six studies had open‐label design (<a href="./references#CD012078-bbs2-0002" title="HironakaS , UedaS , YasuiH , NishinaT , TsudaM , TsumuraT , et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology2013;31(35):4438-44. [PMID: 24190112]">Hironaka 2013</a>; <a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>; <a href="./references#CD012078-bbs2-0012" title="ShitaraK , ÖzgüroğluM , BangYJ , BartolomeoMD , MandalàM , RyuMH , et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet2018;392(10142):123-33. [PMID: 29880231]">Shitara 2018</a>; <a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a>; <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>; <a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a>). Three studies (<a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a>; <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>; <a href="./references#CD012078-bbs2-0007" title="LingS , BoL . Efficacy and safety of second-line chemotherapy with EOX and FOLFIRI in advanced gastric cancer. Journal of Xi'an Jiaotong University (Medical Sciences)2018;39(4):546-50. [DOI: 10.7652/jdyxb201804020]">Ling 2018</a>) did not mention blinding status, however, were most likely open‐label trials. Seven studies (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>; <a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>; <a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>; <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a>; <a href="./references#CD012078-bbs2-0012" title="ShitaraK , ÖzgüroğluM , BangYJ , BartolomeoMD , MandalàM , RyuMH , et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet2018;392(10142):123-33. [PMID: 29880231]">Shitara 2018</a>; <a href="./references#CD012078-bbs2-0013" title="ShitaraK , DoiT , DvorkinM , MansoorW , ArkenauHT , ProkharauA , et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2018;19(11):1437-48. [PMID: 30355453]">Shitara 2018b</a>; <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>) were multinational, eight studies (<a href="./references#CD012078-bbs2-0002" title="HironakaS , UedaS , YasuiH , NishinaT , TsudaM , TsumuraT , et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology2013;31(35):4438-44. [PMID: 24190112]">Hironaka 2013</a>; <a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a>; <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>; <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>; <a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>; <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>; <a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a>; <a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a>) were multi‐centre trials in a single country, and two studies (<a href="./references#CD012078-bbs2-0007" title="LingS , BoL . Efficacy and safety of second-line chemotherapy with EOX and FOLFIRI in advanced gastric cancer. Journal of Xi'an Jiaotong University (Medical Sciences)2018;39(4):546-50. [DOI: 10.7652/jdyxb201804020]">Ling 2018</a>; <a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a>) were single‐centre trials. Nine studies (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>; <a href="./references#CD012078-bbs2-0002" title="HironakaS , UedaS , YasuiH , NishinaT , TsudaM , TsumuraT , et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology2013;31(35):4438-44. [PMID: 24190112]">Hironaka 2013</a>; <a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>; <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>; <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a>; <a href="./references#CD012078-bbs2-0012" title="ShitaraK , ÖzgüroğluM , BangYJ , BartolomeoMD , MandalàM , RyuMH , et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet2018;392(10142):123-33. [PMID: 29880231]">Shitara 2018</a>; <a href="./references#CD012078-bbs2-0013" title="ShitaraK , DoiT , DvorkinM , MansoorW , ArkenauHT , ProkharauA , et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2018;19(11):1437-48. [PMID: 30355453]">Shitara 2018b</a>; <a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a>; <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>) were phase 3, six studies (<a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a>; <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>; <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>; <a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>; <a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>; <a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a>) were phase 2, and one study (<a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>) was phase 2/3. One study (<a href="./references#CD012078-bbs2-0007" title="LingS , BoL . Efficacy and safety of second-line chemotherapy with EOX and FOLFIRI in advanced gastric cancer. Journal of Xi'an Jiaotong University (Medical Sciences)2018;39(4):546-50. [DOI: 10.7652/jdyxb201804020]">Ling 2018</a>) did not describe the phase. </p> <p><b>Participants</b> </p> <p>Reported median age of participants varied from 52 to 65 years with the youngest and oldest participant being 19 and 85 years old, respectively. All the studies when data were available, had more male than female participants with the proportion of male participants ranging from 65.4% to 80.8%. In total, 3379 out of 4721 participants in this review were estimated to be males with two studies (<a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>; <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>) not providing any information on the gender of participants. The number of participants with ECOG PS 2 was low in the majority of included studies; seven studies (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>; <a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>; <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>; <a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>; <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a>; <a href="./references#CD012078-bbs2-0013" title="ShitaraK , DoiT , DvorkinM , MansoorW , ArkenauHT , ProkharauA , et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2018;19(11):1437-48. [PMID: 30355453]">Shitara 2018b</a>; <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>) only enrolled participants with ECOG PS 0‐1 and in five studies (<a href="./references#CD012078-bbs2-0002" title="HironakaS , UedaS , YasuiH , NishinaT , TsudaM , TsumuraT , et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology2013;31(35):4438-44. [PMID: 24190112]">Hironaka 2013</a>; <a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a>; <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>; <a href="./references#CD012078-bbs2-0012" title="ShitaraK , ÖzgüroğluM , BangYJ , BartolomeoMD , MandalàM , RyuMH , et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet2018;392(10142):123-33. [PMID: 29880231]">Shitara 2018</a>; <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>), the proportion of participants with ECOG PS 2 was less than 6.0%. In three studies (<a href="./references#CD012078-bbs2-0007" title="LingS , BoL . Efficacy and safety of second-line chemotherapy with EOX and FOLFIRI in advanced gastric cancer. Journal of Xi'an Jiaotong University (Medical Sciences)2018;39(4):546-50. [DOI: 10.7652/jdyxb201804020]">Ling 2018</a>; <a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a>: <a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a>) more than 10% of the study population had ECOG PS 2 with the highest being 24.3%. </p> <p>Four studies (<a href="./references#CD012078-bbs2-0002" title="HironakaS , UedaS , YasuiH , NishinaT , TsudaM , TsumuraT , et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology2013;31(35):4438-44. [PMID: 24190112]">Hironaka 2013</a>; <a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a>; <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>; <a href="./references#CD012078-bbs2-0007" title="LingS , BoL . Efficacy and safety of second-line chemotherapy with EOX and FOLFIRI in advanced gastric cancer. Journal of Xi'an Jiaotong University (Medical Sciences)2018;39(4):546-50. [DOI: 10.7652/jdyxb201804020]">Ling 2018</a>) included participants with only gastric cancer. For nine studies (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>; <a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>; <a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>; <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a>; <a href="./references#CD012078-bbs2-0012" title="ShitaraK , ÖzgüroğluM , BangYJ , BartolomeoMD , MandalàM , RyuMH , et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet2018;392(10142):123-33. [PMID: 29880231]">Shitara 2018</a>; <a href="./references#CD012078-bbs2-0013" title="ShitaraK , DoiT , DvorkinM , MansoorW , ArkenauHT , ProkharauA , et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2018;19(11):1437-48. [PMID: 30355453]">Shitara 2018b</a>; <a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a>; <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>; <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>), which reported the number of participants with gastric and OGJ adenocarcinoma, 57.5% to 97.0% of the study participants had gastric cancer. The remaining four studies (<a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>; <a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>; <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>; <a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a>) enrolled participants with both gastric and OGJ adenocarcinoma, however, the number of participants with each condition was not provided. </p> <p>Five studies (<a href="./references#CD012078-bbs2-0002" title="HironakaS , UedaS , YasuiH , NishinaT , TsudaM , TsumuraT , et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology2013;31(35):4438-44. [PMID: 24190112]">Hironaka 2013</a>; <a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a>; <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>; <a href="./references#CD012078-bbs2-0007" title="LingS , BoL . Efficacy and safety of second-line chemotherapy with EOX and FOLFIRI in advanced gastric cancer. Journal of Xi'an Jiaotong University (Medical Sciences)2018;39(4):546-50. [DOI: 10.7652/jdyxb201804020]">Ling 2018</a>; <a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a>) included participants with metastatic or recurrent disease, while the other 12 studies (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>; <a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>; <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>; <a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>; <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>; <a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>; <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a>; <a href="./references#CD012078-bbs2-0012" title="ShitaraK , ÖzgüroğluM , BangYJ , BartolomeoMD , MandalàM , RyuMH , et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet2018;392(10142):123-33. [PMID: 29880231]">Shitara 2018</a>; <a href="./references#CD012078-bbs2-0013" title="ShitaraK , DoiT , DvorkinM , MansoorW , ArkenauHT , ProkharauA , et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2018;19(11):1437-48. [PMID: 30355453]">Shitara 2018b</a>; <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>; <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>; <a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a>) included participants with locally advanced unresectable disease and those with metastatic or recurrent disease. When known, the proportion of participants with metastatic disease ranged between 57.0% to 100.0%. Participants with recurrent disease were evaluated by seven studies (<a href="./references#CD012078-bbs2-0002" title="HironakaS , UedaS , YasuiH , NishinaT , TsudaM , TsumuraT , et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology2013;31(35):4438-44. [PMID: 24190112]">Hironaka 2013</a>; <a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>; <a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a>; <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>; <a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>; <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>; <a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>) . </p> <p>Nine studies (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>; <a href="./references#CD012078-bbs2-0002" title="HironakaS , UedaS , YasuiH , NishinaT , TsudaM , TsumuraT , et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology2013;31(35):4438-44. [PMID: 24190112]">Hironaka 2013</a>; <a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>; <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>; <a href="./references#CD012078-bbs2-0012" title="ShitaraK , ÖzgüroğluM , BangYJ , BartolomeoMD , MandalàM , RyuMH , et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet2018;392(10142):123-33. [PMID: 29880231]">Shitara 2018</a>; <a href="./references#CD012078-bbs2-0013" title="ShitaraK , DoiT , DvorkinM , MansoorW , ArkenauHT , ProkharauA , et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2018;19(11):1437-48. [PMID: 30355453]">Shitara 2018b</a>; <a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a>; <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>; <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>) reported the number of participants who had previous gastrectomy or resection of primary tumours and the proportion such participants varied between 30.0% to 76.6%. <a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a> reported the proportion of participants who had received palliative operation to be 46.2%, however, it did not describe the type of surgery performed. </p> <p>Study treatment was administered as second‐line systemic therapy in 12 studies (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>; <a href="./references#CD012078-bbs2-0002" title="HironakaS , UedaS , YasuiH , NishinaT , TsudaM , TsumuraT , et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology2013;31(35):4438-44. [PMID: 24190112]">Hironaka 2013</a>; <a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a>; <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>; <a href="./references#CD012078-bbs2-0007" title="LingS , BoL . Efficacy and safety of second-line chemotherapy with EOX and FOLFIRI in advanced gastric cancer. Journal of Xi'an Jiaotong University (Medical Sciences)2018;39(4):546-50. [DOI: 10.7652/jdyxb201804020]">Ling 2018</a>; <a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>; <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a>; <a href="./references#CD012078-bbs2-0012" title="ShitaraK , ÖzgüroğluM , BangYJ , BartolomeoMD , MandalàM , RyuMH , et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet2018;392(10142):123-33. [PMID: 29880231]">Shitara 2018</a>; <a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a>; <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>; <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>; <a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a>) with 3522 participants, second‐ or third‐line in one study (<a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>) with 147 participants, second‐ to fourth‐line in one study (<a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>) with 300 participants, and third‐line and beyond in three studies (<a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>; <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>; <a href="./references#CD012078-bbs2-0013" title="ShitaraK , DoiT , DvorkinM , MansoorW , ArkenauHT , ProkharauA , et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2018;19(11):1437-48. [PMID: 30355453]">Shitara 2018b</a>) with 1141 participants. Six studies (<a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>; <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a>; <a href="./references#CD012078-bbs2-0012" title="ShitaraK , ÖzgüroğluM , BangYJ , BartolomeoMD , MandalàM , RyuMH , et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet2018;392(10142):123-33. [PMID: 29880231]">Shitara 2018</a>; <a href="./references#CD012078-bbs2-0013" title="ShitaraK , DoiT , DvorkinM , MansoorW , ArkenauHT , ProkharauA , et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2018;19(11):1437-48. [PMID: 30355453]">Shitara 2018b</a>; <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>; <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>) were multinational trials with participating centres located worldwide, nine studies (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>; <a href="./references#CD012078-bbs2-0002" title="HironakaS , UedaS , YasuiH , NishinaT , TsudaM , TsumuraT , et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology2013;31(35):4438-44. [PMID: 24190112]">Hironaka 2013</a>; <a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>; <a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a>; <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>; <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>; <a href="./references#CD012078-bbs2-0007" title="LingS , BoL . Efficacy and safety of second-line chemotherapy with EOX and FOLFIRI in advanced gastric cancer. Journal of Xi'an Jiaotong University (Medical Sciences)2018;39(4):546-50. [DOI: 10.7652/jdyxb201804020]">Ling 2018</a>; <a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>; <a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a>) recruited participants from Asian countries and two studies from Germany (<a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>; <a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a>). In total, 2327 participants from 13 studies (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>; <a href="./references#CD012078-bbs2-0002" title="HironakaS , UedaS , YasuiH , NishinaT , TsudaM , TsumuraT , et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology2013;31(35):4438-44. [PMID: 24190112]">Hironaka 2013</a>; <a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>; <a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a>; <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>; <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>; <a href="./references#CD012078-bbs2-0007" title="LingS , BoL . Efficacy and safety of second-line chemotherapy with EOX and FOLFIRI in advanced gastric cancer. Journal of Xi'an Jiaotong University (Medical Sciences)2018;39(4):546-50. [DOI: 10.7652/jdyxb201804020]">Ling 2018</a>; <a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>; <a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>; <a href="./references#CD012078-bbs2-0012" title="ShitaraK , ÖzgüroğluM , BangYJ , BartolomeoMD , MandalàM , RyuMH , et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet2018;392(10142):123-33. [PMID: 29880231]">Shitara 2018</a>; <a href="./references#CD012078-bbs2-0013" title="ShitaraK , DoiT , DvorkinM , MansoorW , ArkenauHT , ProkharauA , et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2018;19(11):1437-48. [PMID: 30355453]">Shitara 2018b</a>; <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>; <a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a>) were enrolled from Asian countries with additional 157 participants in one study (<a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>) being enrolled from countries in the Asia‐Pacific region. The number participants enrolled from Asian countries was unknown for one study (<a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a>), which was a multinational trial. </p> <p>Three studies selected participants based on biomarker expression. Only participants with HER2 positivity were enrolled in two studies (<a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>; <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>). In the third study (<a href="./references#CD012078-bbs2-0012" title="ShitaraK , ÖzgüroğluM , BangYJ , BartolomeoMD , MandalàM , RyuMH , et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet2018;392(10142):123-33. [PMID: 29880231]">Shitara 2018</a>), the study's predefined primary outcomes were overall survival (OS) and progression‐free survival (PFS) in PD‐L1 combined positive score ≥ 1 participants and the enrolment was restricted to participants with PD‐L1 combined positive score of ≥ 1 after 489 out of 592 participants were enrolled. </p> <p><b>Interventions</b> </p> <p>Taxanes were the most commonly investigated single‐agent chemotherapy: paclitaxel was examined in six studies (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>; <a href="./references#CD012078-bbs2-0002" title="HironakaS , UedaS , YasuiH , NishinaT , TsudaM , TsumuraT , et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology2013;31(35):4438-44. [PMID: 24190112]">Hironaka 2013</a>; <a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>; <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>; <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a>; <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>), docetaxel in three studies (<a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a>; <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>; <a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a>) and either paclitaxel or docetaxel in one study (<a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>). Irinotecan was assessed in two studies (<a href="./references#CD012078-bbs2-0002" title="HironakaS , UedaS , YasuiH , NishinaT , TsudaM , TsumuraT , et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology2013;31(35):4438-44. [PMID: 24190112]">Hironaka 2013</a>; <a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a>) and Trifluridine/tipiracil in one study (<a href="./references#CD012078-bbs2-0013" title="ShitaraK , DoiT , DvorkinM , MansoorW , ArkenauHT , ProkharauA , et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2018;19(11):1437-48. [PMID: 30355453]">Shitara 2018b</a>). Combination chemotherapy was compared with either single‐agent chemotherapy or another combination chemotherapy in five studies: docetaxel‐oxaliplatin (<a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a>), docetaxel‐cisplatin (<a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>), docetaxel‐S1 (<a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>), EOX (<a href="./references#CD012078-bbs2-0007" title="LingS , BoL . Efficacy and safety of second-line chemotherapy with EOX and FOLFIRI in advanced gastric cancer. Journal of Xi'an Jiaotong University (Medical Sciences)2018;39(4):546-50. [DOI: 10.7652/jdyxb201804020]">Ling 2018</a>) and FOLFIRI (<a href="./references#CD012078-bbs2-0007" title="LingS , BoL . Efficacy and safety of second-line chemotherapy with EOX and FOLFIRI in advanced gastric cancer. Journal of Xi'an Jiaotong University (Medical Sciences)2018;39(4):546-50. [DOI: 10.7652/jdyxb201804020]">Ling 2018</a>). Five studies examined single‐agent biological therapy: nivolumab (<a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>), apatinib (<a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>), regorafenib (<a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>), pembrolizumab (<a href="./references#CD012078-bbs2-0012" title="ShitaraK , ÖzgüroğluM , BangYJ , BartolomeoMD , MandalàM , RyuMH , et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet2018;392(10142):123-33. [PMID: 29880231]">Shitara 2018</a>) and trastuzumab emtansine (<a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>). Alternatively, biological therapy was examined as an addition to taxane chemotherapy:olaparib‐paclitaxel (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>), trastuzumab‐paclitaxel (<a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>), everolimus‐paclitaxel (<a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>), napabucasin‐paclitaxel (<a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a>), ramucirumab‐paclitaxel (<a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>) and sunitinib‐docetaxel (<a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a>). </p> <p><b>Outcome measures</b> </p> <p>Outcomes on efficacy: overall survival (OS), progression‐free survival (PFS) and tumour response rate (TRR). </p> <p>World Health Organization (WHO) criteria were used for efficacy assessment in one study (<a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a>) and the method was not described in two studies published as conference abstracts (<a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>; <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>). WHO criteria have been previously shown to be comparable to Response Evaluation Criteria in Solid Tumours (RECIST) criteria in evaluating the response of colorectal carcinoma (<a href="./references#CD012078-bbs2-0149" title="ChoiJH , AhnMJ , RhimHC , KimJW , LeeGH , LeeYY , et al. Comparison of WHO and RECIST criteria for response in metastatic colorectal carcinoma. Cancer Research and treatment2005;37(5):290-3. [PMID: 19956529]">Choi 2005</a>). In the remaining studies RECIST or immune‐related Response Evaluation Criteria in Solid Tumours (irRECIST) was used to assess for radiological disease progression. OS and PFS were measured in all the studies included in this review, except in <a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a> where time to progression (TTP) was reported in place of PFS. Three studies (<a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>; <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>; <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a>) did not specify if efficacy analysis was performed on the intention‐to‐treat population. As these studies specified radiologically measurable or evaluable disease as one of their inclusion criteria, we assumed efficacy analysis was performed on the intention‐to‐treat population. One study (<a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a>) reported PFS and TRR on participants in the irinotecan arm and not the best supportive care (BSC) arm. Two studies (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>; <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>) reported hazard ratios (HRs) for survival outcomes with 97.5% confidence intervals (CIs and P values; 95% CIs were estimated under the assumption for Gaussian distribution. Three studies (<a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a>; <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>; <a href="./references#CD012078-bbs2-0007" title="LingS , BoL . Efficacy and safety of second-line chemotherapy with EOX and FOLFIRI in advanced gastric cancer. Journal of Xi'an Jiaotong University (Medical Sciences)2018;39(4):546-50. [DOI: 10.7652/jdyxb201804020]">Ling 2018</a>) reported survival outcomes without referring to HRs and they were estimated from the published Kaplan‐Meire curves for two of the studies (<a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a>; <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>). Kaplan‐Meier curves from <a href="./references#CD012078-bbs2-0007" title="LingS , BoL . Efficacy and safety of second-line chemotherapy with EOX and FOLFIRI in advanced gastric cancer. Journal of Xi'an Jiaotong University (Medical Sciences)2018;39(4):546-50. [DOI: 10.7652/jdyxb201804020]">Ling 2018</a> indicated median overall survival (mOS) and median progression‐free survival (mPFS), which differed from those described in its text, raising a question on the accuracy of these Kaplan‐Meier curves and the estimated HRs from them. TRR was assessed on subpopulation of randomised participants, those with measurable disease at baseline in three studies (<a href="./references#CD012078-bbs2-0002" title="HironakaS , UedaS , YasuiH , NishinaT , TsudaM , TsumuraT , et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology2013;31(35):4438-44. [PMID: 24190112]">Hironaka 2013</a>; <a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>; <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>). One study (<a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>) did not report TRR and was excluded from meta‐analysis for this outcome. 4806, 4766 and 4328 participants were considered to have been included in OS, PFS and TRR analyses, respectively. </p> <p>Outcomes on adverse events: serious adverse events (SAEs) and adverse events (AEs).</p> <p>Apart from three studies (<a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>; <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>; <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a>), which did not specify the assessment method for safety, National Cancer Institute <b>:</b> Common Terminology Criteria for Adverse Events (NCI CTCAE) version 2.0‐4.03 was used for measuring AEs and SAEs. Minimal descriptions were provided on AEs for three studies (<a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>; <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>; <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a>).Two studies (<a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>; <a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a>) only reported data on SAEs alone with the second study only measuring AEs in the irinotecan arm and not the BSC arm. For the remaining studies, comprehensive results on AEs were available. </p> <p><b>Outcomes on quality of life (QoL)</b> </p> <p>Seven studies listed patient‐reported QoL as their outcomes and assessed QoL using one or combinations of three questionnaires: European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 (QLQ‐C30) in all the studies (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>; <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>; <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>; <a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>; <a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a>; <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>; <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>), EORTC gastric module (QLQ‐STO22) in four studies (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>; <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>; <a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>; <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>), and the EuroQol five dimensions health status questionnaire (EQ‐5D) in two studies (<a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>; <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>). Two studies (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>; <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>) resulted in separate publications focusing on the QoL outcomes. QoL outcomes of another study (<a href="./references#CD012078-bbs2-0013" title="ShitaraK , DoiT , DvorkinM , MansoorW , ArkenauHT , ProkharauA , et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2018;19(11):1437-48. [PMID: 30355453]">Shitara 2018b</a>) were similarly going to be published separately, however, this was not available at the time of preparing this review. </p> </section> <section id="CD012078-sec-0046"> <h4 class="title">Excluded studies</h4> <p>The two commonest reasons for studies being excluded after the assessment of abstracts or full‐text articles were enrolment of participants who received intervention as first‐line systemic therapy (n = 32) and equal or more than 10%, or unknown proportion of participants having received non‐fluoropyrimidine and platinum‐containing chemotherapy as first‐line therapy (n = 29). Study authors were contacted via email when insufficient data were available for screening, however, only a few responses were received and in those occasions study data were owned by sponsors and could not be released. </p> </section> </section> <section id="CD012078-sec-0047"> <h3 class="title">Risk of bias in included studies</h3> <p>Potential source of bias in included studies are described in <a href="./references#CD012078-sec-0137" title="">Characteristics of included studies</a> and summarised in 'Risk of bias' summary table (<a href="#CD012078-fig-0002">Figure 2</a>). </p> <section id="CD012078-sec-0048"> <h4 class="title">Allocation</h4> <p>Randomisation method was not described for four studies: one full‐text article (<a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a>) and three conference abstracts (<a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>; <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>; <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a>). In an additional four studies (<a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>; <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>; <a href="./references#CD012078-bbs2-0007" title="LingS , BoL . Efficacy and safety of second-line chemotherapy with EOX and FOLFIRI in advanced gastric cancer. Journal of Xi'an Jiaotong University (Medical Sciences)2018;39(4):546-50. [DOI: 10.7652/jdyxb201804020]">Ling 2018</a>; <a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a>), authors only reported random sequence method or allocation concealment method, but not both. </p> </section> <section id="CD012078-sec-0049"> <h4 class="title">Blinding</h4> <p>Eight studies (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>; <a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>; <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>; <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>; <a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>; <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a>; <a href="./references#CD012078-bbs2-0013" title="ShitaraK , DoiT , DvorkinM , MansoorW , ArkenauHT , ProkharauA , et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2018;19(11):1437-48. [PMID: 30355453]">Shitara 2018b</a>; <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>) had double‐blind placebo‐controlled design and were considered to be at low risk of performance and detection bias, except for <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a> where the data safety monitoring board recommended unblinding after an interim analysis suggested meeting the primary endpoint at final analyses was unlikely. In three of the six open‐label studies included in the review (<a href="./references#CD012078-bbs2-0002" title="HironakaS , UedaS , YasuiH , NishinaT , TsudaM , TsumuraT , et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology2013;31(35):4438-44. [PMID: 24190112]">Hironaka 2013</a>; <a href="./references#CD012078-bbs2-0012" title="ShitaraK , ÖzgüroğluM , BangYJ , BartolomeoMD , MandalàM , RyuMH , et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet2018;392(10142):123-33. [PMID: 29880231]">Shitara 2018</a>; <a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a>) response assessment was performed centrally by masked reviewers, therefore these studies were thought to be at high risk of performance bias, but not detection bias. Two open‐label studies (<a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a>; <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>) were considered to be at high risk of both performance and detection bias. No blinding status for outcome assessment was provided for the remaining one study (<a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>). </p> </section> <section id="CD012078-sec-0050"> <h4 class="title">Imbalance in baseline characteristics (confounding)</h4> <p>Twelve studies (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>; <a href="./references#CD012078-bbs2-0002" title="HironakaS , UedaS , YasuiH , NishinaT , TsudaM , TsumuraT , et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology2013;31(35):4438-44. [PMID: 24190112]">Hironaka 2013</a>; <a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>; <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>; <a href="./references#CD012078-bbs2-0007" title="LingS , BoL . Efficacy and safety of second-line chemotherapy with EOX and FOLFIRI in advanced gastric cancer. Journal of Xi'an Jiaotong University (Medical Sciences)2018;39(4):546-50. [DOI: 10.7652/jdyxb201804020]">Ling 2018</a>; <a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>; <a href="./references#CD012078-bbs2-0012" title="ShitaraK , ÖzgüroğluM , BangYJ , BartolomeoMD , MandalàM , RyuMH , et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet2018;392(10142):123-33. [PMID: 29880231]">Shitara 2018</a>; <a href="./references#CD012078-bbs2-0013" title="ShitaraK , DoiT , DvorkinM , MansoorW , ArkenauHT , ProkharauA , et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2018;19(11):1437-48. [PMID: 30355453]">Shitara 2018b</a>; <a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a>; <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>; <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>; <a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a>) were assessed to be at low risk of confounding based on the description of stratification at randomisation and well‐balanced patient and disease characteristics at baseline. In two studies (<a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a>; <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>) the risk of confounding was unclear due to some imbalances in patient and disease characteristics at baseline. Detailed study description was not available for <a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>, <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>, and <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a>, which were published as conference abstracts, to adequately assess their risk of confounding. </p> </section> <section id="CD012078-sec-0051"> <h4 class="title">Efficacy and safety outcomes</h4> <p>All the studies performed the survival analysis on the intention‐to‐treat population and assessed to be at low risk of attrition bias, except for the three conference abstracts (<a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>; <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>; <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a>) where details of analysis performed was unknown. Five studies (<a href="./references#CD012078-bbs2-0002" title="HironakaS , UedaS , YasuiH , NishinaT , TsudaM , TsumuraT , et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology2013;31(35):4438-44. [PMID: 24190112]">Hironaka 2013</a>; <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>; <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>; <a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>; <a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a>) modified their intention‐to‐treat population by removing participants who were found to be ineligible for the study after randomisation, withdrew the consent and/or did not receive any study treatment, however, in these studies the intention‐to‐treat population still constituted more than 95% of the total randomised population and considered to be at low risk of attrition bias. </p> </section> <section id="CD012078-sec-0052"> <h4 class="title">Quality of life (QoL) outcomes</h4> <p>QoL endpoints were measured in seven studies. 84.2% of participants completed QoL questionnaires at least one post‐baseline time point in <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>, and this study was assessed to be low risk of attrition bias. For <a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a> and <a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>, they were rated 65.9% and 62.6%, respectively and these studies were considered to be at high risk of attrition bias. For <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>, more than 60% of participants completed baseline QoL questionnaires and for <a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a> the completion rate of the QoL questionnaire was said to be "poor". Therefore, these studies were similarly considered to be at high risk of attrition bias. For the remaining two studies (<a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>; <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>), detailed results including the number of participants completing the relevant questionnaires were not provided. For <a href="./references#CD012078-bbs2-0013" title="ShitaraK , DoiT , DvorkinM , MansoorW , ArkenauHT , ProkharauA , et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2018;19(11):1437-48. [PMID: 30355453]">Shitara 2018b</a>, in which QoL outcome is yet to be published, and for the studies which did not measure QoL outcome, their attrition bias risk was categorised as low in 'Risk of bias' summary table (<a href="#CD012078-fig-0002">Figure 2</a>). </p> </section> <section id="CD012078-sec-0053"> <h4 class="title">Selective reporting</h4> <p>One study (<a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a>) reported OS for both treatment arms, but not PFS, TRR and AE outcomes, which were provided for the active treatment arm alone and not the BSC arm. In the same study, QoL was not reported due to poor completion rate of EORTC QLQ‐C30 questionnaire by the participants, which authors explained limited any meaningful analysis. Detailed results on AEs were not given for the two conference abstracts (<a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>; <a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>), however, all the predefined efficacy outcomes were reported in these studies. The other 14 studies in the review provided results for both AAEs and SAEs, except for <a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a> and <a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a>, which only provided the result for SAEs. Four studies (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>; <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>; <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>; <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>) provided variable amount of results on QoL in a descriptive manner. In two studies (<a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>; <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>), separate articles focusing on QoL outcomes alone were published. </p> <p>At least a brief summary of their protocols was available through relevant clinical trial registries for all the studies except for three studies (<a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a>; <a href="./references#CD012078-bbs2-0007" title="LingS , BoL . Efficacy and safety of second-line chemotherapy with EOX and FOLFIRI in advanced gastric cancer. Journal of Xi'an Jiaotong University (Medical Sciences)2018;39(4):546-50. [DOI: 10.7652/jdyxb201804020]">Ling 2018</a>; <a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a>). All the efficacy outcomes relevant to this review (predefined in the case of studies with protocols available) were reported in all the studies apart from <a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a>. Considering the order of importance of different outcomes based on the purpose of this review to be efficacy outcomes &gt; safety outcomes &gt; QoL outcomes, one study (<a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a>) was assessed to be at high risk of reporting bias, three studies (<a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>; <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>; <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a>) to be unclear and the rest of studies to be at low risk of reporting bias. </p> </section> <section id="CD012078-sec-0054"> <h4 class="title">Other potential sources of bias</h4> <p>Three studies (<a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a>; <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>; <a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a>) were terminated prematurely due to poor accrual, making these studies at high risk of recruitment bias. Enrolment was restricted to a biomarker‐selected population after 82.6% of the study participants had enrolled in <a href="./references#CD012078-bbs2-0012" title="ShitaraK , ÖzgüroğluM , BangYJ , BartolomeoMD , MandalàM , RyuMH , et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet2018;392(10142):123-33. [PMID: 29880231]">Shitara 2018</a>, however, this did not affect the study's primary outcome results and hence this study was considered to be still low risk of recruitment bias. Other sources of bias could not be adequately assessed in three studies (<a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>; <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>; <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a>) published as conference abstracts. </p> </section> </section> <section id="CD012078-sec-0055"> <h3 class="title" id="CD012078-sec-0055">Effects of interventions</h3> <p>See: <a href="./full#CD012078-tbl-0001"><b>Summary of findings 1</b> Chemotherapy versus placebo, best supportive care (BSC) or no treatment</a>; <a href="./full#CD012078-tbl-0002"><b>Summary of findings 2</b> Biological therapy versus placebo, best supportive care (BSC) or no treatment</a>; <a href="./full#CD012078-tbl-0003"><b>Summary of findings 3</b> Chemotherapy versus biological therapy</a>; <a href="./full#CD012078-tbl-0004"><b>Summary of findings 4</b> Chemmotherapy combined with biological therapy versus chemotherapy</a>; <a href="./full#CD012078-tbl-0005"><b>Summary of findings 5</b> Chemotherapy versus chemotherapy</a> </p> <p>We extracted summary data from all 17 included studies. No studies were identified for the following four pre‐specified comparisons. </p> <p> <ol id="CD012078-list-0016"> <li> <p>Chemotherapy combined with biological therapy versus placebo, best supportive care (BSC) or no treatment. </p> </li> <li> <p>Chemotherapy combined with biological therapy versus biological therapy.</p> </li> <li> <p>Biological therapy versus biological therapy.</p> </li> <li> <p>Chemotherapy combined with biological therapy versus chemotherapy combined with biological therapy </p> </li> </ol> </p> <section id="CD012078-sec-0056"> <h4 class="title">Chemotherapy versus placebo, best supportive care (BSC) or no treatment</h4> <p>Two studies (<a href="./references#CD012078-bbs2-0013" title="ShitaraK , DoiT , DvorkinM , MansoorW , ArkenauHT , ProkharauA , et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2018;19(11):1437-48. [PMID: 30355453]">Shitara 2018b</a>; <a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a>) involving 547 participants compared chemotherapy versus placebo or BSC with 358 and 189 participants in each arm, respectively. <a href="./references#CD012078-bbs2-0013" title="ShitaraK , DoiT , DvorkinM , MansoorW , ArkenauHT , ProkharauA , et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2018;19(11):1437-48. [PMID: 30355453]">Shitara 2018b</a> examined the efficacy of trifluridine/tipiracil against placebo as third‐line and beyond treatment in metastatic gastric and oesophago‐gastric junction (OGJ) adenocarcinoma, while <a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a> examined that of irinotecan against BSC as second‐line treatment in metastatic gastric and OGJ adenocarcinoma. </p> <section id="CD012078-sec-0057"> <h5 class="title">Overall survival (OS)</h5> <p>Two studies (<a href="./references#CD012078-bbs2-0013" title="ShitaraK , DoiT , DvorkinM , MansoorW , ArkenauHT , ProkharauA , et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2018;19(11):1437-48. [PMID: 30355453]">Shitara 2018b</a>; <a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a>) involving 547 participants contributed data to this meta‐analysis. Median OS (mOS), weighed for study size was 5.6 months in the chemotherapy arm and 3.5 months in the placebo or BSC arm. The pooled hazard ratio (HR) was 0.66 (95% confidence interval (CI) 0.52 to 0.83), indicating OS benefit of chemotherapy over placebo or BSC (<a href="./references#CD012078-fig-0003" title="">Analysis 1.1</a>). Heterogeneity between the two studies was low (I<sup>2</sup> = 7%, P = 0.30) and sensitivity analysis using fixed‐effect model resulted in similar HR (HR = 0.66, 95% CI 0.52 to 0.83). The certainty of evidence was moderate due to imprecision. The 95% CI for the pooled HR included null effect and appreciable benefit from chemotherapy. <a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a> was associated with high risk of detection and reporting biases, however, they were considered unlikely to have impacted the OS outcome. </p> </section> <section id="CD012078-sec-0058"> <h5 class="title">Progression‐free survival (PFS)</h5> <p><a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a> reported PFS only for the irinotecan‐treated participants and their median PFS (mPFS) was 2.5 months. Hence, <a href="./references#CD012078-bbs2-0013" title="ShitaraK , DoiT , DvorkinM , MansoorW , ArkenauHT , ProkharauA , et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2018;19(11):1437-48. [PMID: 30355453]">Shitara 2018b</a> alone was included in the quantitative analysis and mPFS was 2.0 months in the trifluridine/tipiracil arm and 1.8 months in the placebo arm with HR of 0.57 (95% CI 0.47 to 0.69) in favour of chemotherapy (<a href="./references#CD012078-fig-0004" title="">Analysis 1.2</a>). The certainty of evidence was high. </p> </section> <section id="CD012078-sec-0059"> <h5 class="title">Serious adverse events (SAEs)</h5> <p>SAEs were reported by both studies, however, only for the irinotecan‐treated participants by <a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a>. The most common SAE associated with irinotecan was diarrhoea (26%), and neutropenic fever affected 16% of participants receiving irinotecan. No treatment‐related death was observed. In <a href="./references#CD012078-bbs2-0013" title="ShitaraK , DoiT , DvorkinM , MansoorW , ArkenauHT , ProkharauA , et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2018;19(11):1437-48. [PMID: 30355453]">Shitara 2018b</a>, the most frequently reported SAEs were neutropenia (34.0%) and anaemia (19.1%) in the trifluridine/tipiracil arm and abdominal pain (8.9%) and general deterioration of physical health (8.9%) in the placebo arm. Grade ≥ 3 febrile neutropenia occurred in 1.8% of participants receiving trifluridine/tipiracil. The cause of treatment‐related death was cardiopulmonary arrest (n = 1) in the trifluridine/tipiracil arm and toxic hepatitis (n = 1) in the placebo arm. </p> <p>The quantitative analysis considered 503 participants from <a href="./references#CD012078-bbs2-0013" title="ShitaraK , DoiT , DvorkinM , MansoorW , ArkenauHT , ProkharauA , et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2018;19(11):1437-48. [PMID: 30355453]">Shitara 2018b</a> and SAEs affected 79.7% and 57.78% of those receiving trifluridine/tipiracil and placebo, respectively. Risk ratio (RR) was 1.38 (95% CI 1.20 to 1.59), indicating higher occurrence of SAEs in the trifluridine/tipiracil arm (<a href="./references#CD012078-fig-0005" title="">Analysis 1.3</a>). Heterogeneity assessment and sensitivity analysis were not performed. The certainty of evidence was moderate due to imprecision. The 95% CI for the RR included null effect and appreciable harm from chemotherapy. </p> </section> <section id="CD012078-sec-0060"> <h5 class="title">Tumour response rate (TRR)</h5> <p><a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a> reported TRR only for the irinotecan‐treated participants and this was 0%. The quantitative analysis as a result only considered 435 participants from <a href="./references#CD012078-bbs2-0013" title="ShitaraK , DoiT , DvorkinM , MansoorW , ArkenauHT , ProkharauA , et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2018;19(11):1437-48. [PMID: 30355453]">Shitara 2018b</a>. TRR was 4.5% and 2.1% for participants receiving trifluridine/tipiracil and placebo, respectively. RR was 2.17 (95% CI 0.63 to 7.48), indicating insufficient evidence for TRR benefit of trifluridine/tipiracil (<a href="./references#CD012078-fig-0006" title="">Analysis 1.4</a>). The certainty of evidence was low due to imprecision with the small number of events analysed and the wide 95% CI for the RR. </p> </section> <section id="CD012078-sec-0061"> <h5 class="title">Any adverse events (AAE)</h5> <p>AAE outcome was provided by one study (<a href="./references#CD012078-bbs2-0013" title="ShitaraK , DoiT , DvorkinM , MansoorW , ArkenauHT , ProkharauA , et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2018;19(11):1437-48. [PMID: 30355453]">Shitara 2018b</a>) for 503 participants. AAEs reported in more than 30% of participants in both trifluridine/tipiracil and placebo arms were nausea, anaemia and decreased appetite. Neutropenia additionally affected 52.5% of participants in the trifluridine/tipiracil arm. AAEs affected 97.3% and 93.5% of participants receiving trifluridine/tipiracil and placebo, respectively. RR was 1.04 (95% CI 1.00 to 1.09), indicating equivalent occurrence of AAEs between the two arms (<a href="./references#CD012078-fig-0007" title="">Analysis 1.5</a>). The certainty of evidence was high. </p> </section> <section id="CD012078-sec-0062"> <h5 class="title">Quality of life (QoL)</h5> <p>QoL measured using EORTC QLQ‐C30 questionnaire was one of the predefined endpoints in <a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a>, however, due to the poor return of the forms, the study authors decided meaningful analysis was not plausible and no result was reported. </p> </section> </section> <section id="CD012078-sec-0063"> <h4 class="title">Biological therapy versus placebo, best supportive care (BSC) or no treatment</h4> <p>Three studies (<a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>; <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>; <a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>) involving 781 participants compared biological therapy versus placebo in locally advanced, metastatic or recurrent gastric and OGJ adenocarcinoma. Biological therapy and placebo were administered to 520 (190 in the VEGFR‐targeted therapy arm and 330 in the immunotherapy arm) and 261 participants, respectively. Biological therapy examined were PD‐1 inhibitor, nivolumab (<a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>) and two tyrosine kinase inhibitors, apatinib (<a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>) and regorafenib (<a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>). While apatinib selectively targets VEGFR2, regorafenib is a multi‐target tyrosine kinase inhibitor including VEGFR2. All the studies were placebo‐controlled studies. In one study (<a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>), participants received study treatment as second‐ or third‐line systemic treatment, while in the remaining two studies (<a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>; <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>), study treatment was provided in the third‐line setting. </p> <section id="CD012078-sec-0064"> <h5 class="title">Overall survival (OS)</h5> <p>Three studies ( <a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>; <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>; <a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a> ) involving 781 participants contributed data to this meta‐analysis. mOS weighed fro study size was 5.2 months in the biological therapy arm and 3.9 months in the placebo arm. The pooled HR was 0.55 (95% CI 0.41 to 0.73), indicating OS benefit of biological therapy over placebo (<a href="./references#CD012078-fig-0011" title="">Analysis 2.1</a>). Heterogeneity between studies was moderate (I<sup>2</sup> = 55%, P = 0.08) and sensitivity analysis using fixed‐effect model narrowed the 95% CI (HR = 0.59, 95% CI 0.50 to 0.70). With exclusion of <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>, which was associated with unclear risk of selection bias, the result remained in favour of biological therapy (HR = 0.66, 95% CI 0.55 to 0.79). The certainty of evidence was high. </p> </section> <section id="CD012078-sec-0065"> <h5 class="title">Progression‐free survival (PFS)</h5> <p>Three studies (<a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>; <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>; <a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>) involving 781 participants contributed data to this meta‐analysis. mPFS weighed fro study size was 2.1 months in the biological therapy arm and 1.3 months in the placebo arm. As with the OS analysis, we found PFS benefit of biological therapy with the pooled HR of 0.33 (95% CI 0.19 to 0.57) (<a href="./references#CD012078-fig-0012" title="">Analysis 2.2</a>). Heterogeneity between studies was high (I<sup>2</sup> = 87%, P &lt; 0.0001). The 95% CI narrowed on sensitivity analysis using fixed‐effect model (HR = 0.47, 95% CI 0.40 to 0.55). With exclusion of <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>, which was associated with unclear risk of selection bias, the 95% CI widened, although the result still indicated the PFS benefit of biological therapy (HR = 0.50, 95% CI 0.34 to 0.75). The certainty of evidence was moderate due to heterogeneity between studies and the 95% CIs of some studies did not overlap. </p> </section> <section id="CD012078-sec-0066"> <h5 class="title">Serious adverse events (SAEs)</h5> <p>The result on SAEs was available for all three studies. In <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>, one death was possibly related to SAEs from apatinib. The most common SAEs associated with apatinib were hypertension and hand‐foot syndrome, being observed in 8.5% to 10.9% and 4.3% to 13.0% of participants receiving apatinib, respectively. In <a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>, treatment‐related deaths were reported in 1.5% of participants receiving nivolumab. These events included acute hepatitis (n = 1), cardiac arrest (n = 1), death of unknown cause (n = 1), exertional dyspnoea (n = 1), and pneumonia (n = 1). The most common SAE associated with nivolumab was anaemia (11.5%). In <a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>, treatment‐related death occurred in 2.1% of participants receiving regorafenib, which included one case of hepatic failure and one case of unresolved Grade 3 abdominal pain. The most common SAEs associated with regorafenib was hypertension occurring in 10.3% of participants in the regorafenib arm. </p> <p>Two studies (<a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>; <a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>) involving 638 participants reported the number of participants with any SAEs. 47.3% of participants receiving biological therapy experienced any SAEs compared to 42.2% of participants receiving placebo. The pooled RR was 1.14 (95% CI 0.95 to 1.37) and there was insufficient evidence to decide whether biological therapy increases the incidence of SAEs (<a href="./references#CD012078-fig-0013" title="">Analysis 2.3</a>). The observed heterogeneity between the two studies was low (I<sup>2</sup> = 3%, P = 0.31). Sensitivity analysis using fixed‐effect model did not change the result (HR = 1.13, 95% CI 0.94 to 1.36). The certainty of evidence was low due to imprecision; the total number of events in the analysis was small and the 95% CI for the pooled RR included null effect and appreciable harm from biological therapy. </p> </section> <section id="CD012078-sec-0067"> <h5 class="title">Tumour response rate (TRR)</h5> <p>Three studies (<a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>; <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>; <a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>) involving 687 participants contributed data to this meta‐analysis. The pooled TRR was 9.2% in the biological therapy arm and 0.4% in the placebo arm. When studies examining VEGFR‐targeted therapy and immunotherapy were separated, TRR was 6.3% and 11.2%, respectively. The pooled RR was 5.12 (95% CI 1.23 to 21.27), in favour of biological therapy (<a href="./references#CD012078-fig-0014" title="">Analysis 2.4</a>). The observed heterogeneity was low (I² = 13%, P = 0.33). The certainty of evidence was low due to imprecision; the number of events analysed was small and the 95% CI for the pooled RR was very wide. </p> </section> <section id="CD012078-sec-0068"> <h5 class="title">Any adverse events (AAEs)</h5> <p>AAE outcome was available for two studies (<a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>; <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>). In <a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>, AAEs reported in 15% or more of participants in the nivolumab arm were abdominal pain, decreased appetite, nausea, diarrhoea and pruritis. In <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>, the most common AAEs were hypertension, hand‐foot syndrome, elevated aminotransferases and leucopenia. They were experienced by 39.1% to 40.4%, 25.5% to 45.7%, 19.2% to 41.3% and 39.1% to 48.9% of participants in the apatinib arms, respectively. </p> <p>One study (<a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>) involving 491 participants reported the number of participants with AAEs. The occurrence of AAEs was 90.9% for participants receiving nivolumab compared to 83.9% for those receiving placebo with RR of 1.08 (95% CI 1.00 to 1.17) (<a href="./references#CD012078-fig-0015" title="">Analysis 2.5</a>). Nivolumab was not associated with increased AAEs. The certainty of evidence was high. </p> </section> <section id="CD012078-sec-0069"> <h5 class="title">Quality of life (QoL)</h5> <p>Two studies reported on QoL. In <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>, EORTC QLQ‐C30 was used and the descriptive result was provided. The number of participants completing the questionnaire was not reported. The significant change in QoL over the course of treatment was only found for insomnia, where after two cycles of treatment, insomnia significantly improved in participants receiving apatinib compared to those receiving placebo (P = 0.002). There was a trend for improved cognitive function in the apatinib arm compared to the placebo arm after two cycles of treatment (P = 0.067). <a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a> assessed QoL associated with regorafenib and placebo treatment using EORTC QLQ‐C30, QLQ‐STO22, EQ‐5D and the patient disease and treatment assessment (PTDATA) form. 92.5% of the randomised participants completed the baseline QoL assessment with 40.8% of placebo‐ and 32.3% of regorafenib‐receiving participants providing no post‐baseline information. At Week four, there was more reporting of diarrhoea by participants receiving regorafenib (regorafenib‐to‐placebo difference of 14.0%, CI 2 to 24, P = 0.019). Pain score at Week 8 between the two treatment arms differed by 10 in favour of regorafenib treatment, however, this was not statistically significant. There was a lower incidence of cough (P = 0.004) and higher incidence of sore mouth or throat (P = 0.05) in the regorafenib arm. The overall certainty of evidence was low due to attrition bias and imprecision related to the small number of participants analysed. </p> </section> </section> <section id="CD012078-sec-0070"> <h4 class="title">Chemotherapy versus biological therapy</h4> <p>One study (<a href="./references#CD012078-bbs2-0012" title="ShitaraK , ÖzgüroğluM , BangYJ , BartolomeoMD , MandalàM , RyuMH , et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet2018;392(10142):123-33. [PMID: 29880231]">Shitara 2018</a>) involving 592 participants compared chemotherapy versus any biological therapy in participants with metastatic or locally advanced unresectable gastric and OGJ adenocarcinoma as second‐line therapy. 296 participants were in each arm. Biological therapy examined was PD‐1 inhibitor, pembrolizumab and this was compared to paclitaxel. The study selected participants based on biomarker expression; PD‐L1 combined positive score (CPS) ≥ 1. The study initially enrolled participants independent of their PD‐L1 CPS, which was later restricted to those with PD‐L1 CPS ≥ 1 and its predefined primary endpoints were OS and PFS in participants with PD‐L1 CPS ≥ 1. We, therefore, analysed participants with PD‐L1 CPS ≥ 1 for our efficacy outcomes and their overall population for safety outcomes. </p> <section id="CD012078-sec-0071"> <h5 class="title">Overall survival (OS)</h5> <p>One study (<a href="./references#CD012078-bbs2-0012" title="ShitaraK , ÖzgüroğluM , BangYJ , BartolomeoMD , MandalàM , RyuMH , et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet2018;392(10142):123-33. [PMID: 29880231]">Shitara 2018</a>) involving 395 participants contributed data to the analysis. mOS for the PD‐L1 CPS ≥ 1 population was 9.1 months in the pembrolizumab arm and 8.3 months in the paclitaxel arm. The HR was 0.82 (95% CI 0.66 to 1.02), indicating insufficient evidence for OS benefit of pembrolizumab over paclitaxel (<a href="./references#CD012078-fig-0020" title="">Analysis 3.1</a>). For the overall population (n = 592), mOS was 6.7 months in the pembrolizumab arm and 8.3 months in the paclitaxel arm with HR of 0·94 (95% CI 0·79 to 1·12). The certainty of evidence was moderate due to imprecision; the 95% CI for the HR included both null effect and appreciable benefit from biological therapy. </p> </section> <section id="CD012078-sec-0072"> <h5 class="title">Progression‐free survival (PFS)</h5> <p>One study (<a href="./references#CD012078-bbs2-0012" title="ShitaraK , ÖzgüroğluM , BangYJ , BartolomeoMD , MandalàM , RyuMH , et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet2018;392(10142):123-33. [PMID: 29880231]">Shitara 2018</a>) involving 395 participants contributed data to the analysis. mPFS for the PD‐L1 CPS ≥ 1 population was 1.5 months for the pembrolizumab arm and 4.1 months for the paclitaxel arm. The HR was 1.27 (95% CI 1.03 to 1.57) in favour of paclitaxel (<a href="./references#CD012078-fig-0021" title="">Analysis 3.2</a>). PFS analysis on the overall population resulted in HR of 1·49 (95% CI 1·25 to 1·77) and mPFS for each arm remained unchanged. The certainty of evidence was moderate due to imprecision; the 95% CI for the HR included both null effect and appreciable harm from pembrolizumab. </p> </section> <section id="CD012078-sec-0073"> <h5 class="title">Serious adverse events (SAEs)</h5> <p>One study (<a href="./references#CD012078-bbs2-0012" title="ShitaraK , ÖzgüroğluM , BangYJ , BartolomeoMD , MandalàM , RyuMH , et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet2018;392(10142):123-33. [PMID: 29880231]">Shitara 2018</a>) involving 570 participants contributed data to this analysis. Treatment‐related death occurred in 1.0% of participants in the pembrolizumab arm (one case of colitis, interstitial lung disease, and unspecified death each) and &lt; 1% in the paclitaxel arm (one case of pulmonary embolism). The most common treatment‐related SAEs were anaemia (2.4%) and fatigue (2.4%) in the pembrolizumab arm and neutropenia (7.2%) and fatigue (4.7%) in the paclitaxel arm. Immune‐mediated SAEs due to pembrolizumab were rare; hepatitis (1.4%), hypophysitis (&lt; 1%) and pneumonitis (&lt; 1%). </p> <p>Participants receiving pembrolizumab (14.3%) experienced SAEs compared to 34.8% of those receiving paclitaxel. RR was 0.41 (95% CI 0.30 to 0.57) in favour of pembrolizumab (<a href="./references#CD012078-fig-0022" title="">Analysis 3.3</a>). The certainty of evidence was low due to risk of bias and imprecision; the study was associated with risk of performance bias and the number of events included in the analysis was small. </p> </section> <section id="CD012078-sec-0074"> <h5 class="title">Tumour response rate (TRR)</h5> <p>One study (<a href="./references#CD012078-bbs2-0012" title="ShitaraK , ÖzgüroğluM , BangYJ , BartolomeoMD , MandalàM , RyuMH , et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet2018;392(10142):123-33. [PMID: 29880231]">Shitara 2018</a>) involving 395 participants contributed data to this analysis. TRR for the PD‐L1 CPS ≥ 1 population was 15.8% in the pembrolizumab arm and 13.6% in the paclitaxel arm with RR of 1.17 (95% CI 0.72 to 1.88), implying insufficient evidence for TRR benefit from pembrolizumab or paclitaxel (<a href="./references#CD012078-fig-0023" title="">Analysis 3.4</a>). The certainty of evidence was low due to imprecision; the number of events included in the analysis was small and the 95% CI for the RR included both null effect and appreciable benefit of biological therapy. </p> </section> <section id="CD012078-sec-0075"> <h5 class="title">Any adverse events (AAEs)</h5> <p>One study (<a href="./references#CD012078-bbs2-0012" title="ShitaraK , ÖzgüroğluM , BangYJ , BartolomeoMD , MandalàM , RyuMH , et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet2018;392(10142):123-33. [PMID: 29880231]">Shitara 2018</a>) involving 570 participants contributed data to this analysis. AAEs affecting more than 10% of participants were fatigue (11.9%) in the pembrolizumab arm and alopecia (40.2%), fatigue (23.2%), nausea (18.1%), decreased appetite (15.6%), diarrhoea (13.8%), anaemia (14.1%) and peripheral neuropathy (14.5%) in the paclitaxel arm. Immune mediated AAEs were observed in 18.4% of participants receiving pembrolizumab and 7.6% of those receiving paclitaxel in this study. The incidence of AAEs was 52.7% for pembrolizumab‐treated participants and 84.1% for paclitaxel‐treated participants. RR was 0.63 (95% CI 0.56 to 0.71) in favour of pembrolizumab (<a href="./references#CD012078-fig-0024" title="">Analysis 3.5</a>). The certainty of evidence was moderate due to risk of performance bias. </p> </section> </section> <section id="CD012078-sec-0076"> <h4 class="title">Chemotherapy combined with biological therapy versus chemotherapy</h4> <p>Seven studies (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>; <a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>; <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>; <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a>; <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>; <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>; <a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a>) involving 2743 participants compared chemotherapy combined with biological therapy versus chemotherapy in participants with locally advanced, metastatic or recurrent gastric and OGJ adenocarcinoma as second‐line therapy. One thousand, four hundred and twenty‐eight and 1315 participants received chemotherapy combined with biological therapy and chemotherapy alone, respectively. The type of biological therapy used varied between studies; poly ADP ribose polymerase (PARP) inhibitor, olaparib (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>), monoclonal antibody against HER2, trastuzumab (<a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>), mTOR kinase inhibitor, everolimus (<a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>), cancer stem cell inhibitor, napabucasin (<a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a>), monoclonal antibody against VEGFR2, ramucirumab (<a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>) and multi‐targeted tyrosine kinase inhibitor, sunitinib (<a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a>). In one study (<a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>), trastuzumab‐emtansine, which is trastuzumab conjugated with a cytotoxic agent DM1 was administered in the chemotherapy combined with biological therapy arm. Taxanes were used in the chemotherapy arm for all the studies. Three studies (<a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>; <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>; <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a>) were conference abstracts, while others were full‐text articles. In <a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a> and <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>, participants were enrolled based on HER2 positivity. <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a> reported the total number of participants randomised, but not the number of participants in each treatment arm and whether efficacy analysis was performed on the intention‐to‐treat population was not known. The number of participants, hence, in each treatment arm was estimated based on the described 1:1 randomisation and the study was only included in the meta‐analysis for efficacy outcomes. </p> <section id="CD012078-sec-0077"> <h5 class="title">Overall survival (OS)</h5> <p>Seven studies (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>; <a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>; <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>; <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a>; <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>; <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>; <a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a>) involving 2743 participants contributed data to this meta‐analysis. mOS weighed for study size was 8.1 months in the chemotherapy combined with biological therapy arm and 7.2 months in the chemotherapy arm. In two studies (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>; <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>), 95% CIs associated with HR for OS outcome were not provided; <a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a> reported the HR with 97.5% CIs and <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a> with a P value; 95% CIs were estimated under the assumption for Gaussian distribution. </p> <p>The pooled HR was 0.93 (95% CI 0.83 to 1.04), indicating equivalent OS benefit between the two arms (<a href="./references#CD012078-fig-0026" title="">Analysis 4.1</a>). The observed heterogeneity was moderate (I<sup>2</sup> = 36%, P = 0.15). Sensitivity analysis using fixed‐effect model made little difference to the result (HR = 0.92, 95% CI 0.84 to 1.00). The result changed little with exclusion of three studies (<a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>; <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>; <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a>) published as conference abstracts with unclear risk of bias (HR = 0.88, 95% CI 0.75 to 1.04), and exclusion of <a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a> and <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a> for which 95% CIs were estimated (HR = 0.97, 95% CI 0.84 to 1.13). Removal of <a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a> and <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>, which investigated paclitaxel‐trastuzumab and trastuzumab emtansine, respectively in the HER2‐positive population, made the small OS benefit become apparent (HR = 0.89, 95% CI 0.80 to 0.99). The certainty of evidence was moderate due to <a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a> , <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a> and <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a> being associated with unclear risk of selection, attrition and reporting bias as well as confounders. </p> </section> <section id="CD012078-sec-0078"> <h5 class="title">Progression‐free survival (PFS)</h5> <p>Seven studies (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>; <a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>; <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>; <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a>; <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>; <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>; <a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a>) involving 2743 participants contributed data to this meta‐analysis. <a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a> reported TTP defined as the interval between the date of the first study treatment and the date of documented disease progression in place of PFS. As more than 90% of participants in both docetaxel‐sunitinib and docetaxel arms experienced disease progression in the study, we accepted this TTP outcome for the PFS analysis. mPFS weighed for study size was 3.9 months in the chemotherapy combined with biological therapy arm and 3.1 months in the chemotherapy arm. As with OS, no 95% CIs were provided by <a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a> and <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a> for their HR and they were estimated. </p> <p>The pooled HR was 0.87 (95% CI 0.74 to 1.02), indicating insufficient evidence for PFS benefit of chemotherapy combined with biological therapy (<a href="./references#CD012078-fig-0027" title="">Analysis 4.2</a>). The observed heterogeneity was high (I<sup>2</sup> = 71%, P = 0.002). On sensitivity analysis using fixed‐effect model, PFS benefit of combined chemotherapy and biological therapy became apparent (HR = 0.85, 95% CI 0.79 to 0.93). Exclusion of three studies (<a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>; <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>; <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a>) published as conference abstracts with unclear risk of bias widened the 95% CI (HR = 0.82, 95% CI 0.63 to 1.07). When two studies (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>; <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>) with unpublished 95% CIs for their HRs as well as <a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a>, which reported TTP instead of PFS, were removed, the 95% CI widened further (HR = 0.89, 95% CI 0.68 to 1.18). Exclusion of <a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a> and <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>, which investigated paclitaxel‐trastuzumab and trastuzumab emtansine, respectively in the HER2‐positive population made PFS benefit of combined chemotherapy and biological therapy became apparent (HR =0.82, 95% CI 0.68 to 0.98). The certainty of evidence was very low due to risk of detection bias in <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a> as well as unclear risk of bias in several domains for <a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a> , <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a> and <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a> as described for the OS outcome. Inconsistency and imprecision were additionally detected; the 95% CIs of some studies did not overlap and the 95% CI for the pooled HR included PFS benefit of chemotherapy combined with biological therapy as well as null effect. </p> </section> <section id="CD012078-sec-0079"> <h5 class="title">Serious adverse events (SAEs)</h5> <p>Four studies (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>; <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>; <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>; <a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a>) involving 1618 participants contributed data to this meta‐analysis. In <a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>, two treatment‐related deaths occurred; liver injury (n = 1) in the olaparib‐paclitaxel arm and cardiac failure (n = 1) in the placebo‐paclitaxel arm. The most common SAE was neutropenia in both arms; 29.8% in the olaparib‐paclitaxel arm and 22.8% in the placebo‐ paclitaxel arm. In <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>, treatment‐related deaths were reported in 4% of participants in both arms; gastric haemorrhage (n = 1), upper gastrointestinal haemorrhage (n = 1), atypical pneumonia (n = 1), septic shock (n = 1), aspiration pneumonia (n = 1), pulmonary alveolar haemorrhage (n = 1) and pneumonia (n = 2) in the trastuzumab emtansine arm and unexplained cause of death (n = 1), respiratory failure (n = 1) and pneumonia (n = 2) in the taxane arm. The most common SAEs in participants receiving trastuzumab emtansine were anaemia (26.3%) and thrombocytopenia (11.2%), while in participants treated with taxanes they were neutropenia (38.7%) and anaemia (18.0%). In <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>, 2% of participants from ramucirumab‐paclitaxel and placebo‐paclitaxel arms experienced treatment‐related death; details of underlying AEs were septic shock, malabsorption, gastrointestinal haemorrhage, death of unknown origin, pulmonary embolism and sepsis in the ramucirumab‐paclitaxel arm and acute renal failure, cardiac failure, febrile neutropenia, septic shock, pulmonary embolism and cerebral haemorrhage in the placebo‐paclitaxel arm. The most common SAE was again neutropenia; 40.7% in the ramucirumab‐paclitaxel arm and 18.8% in the placebo‐paclitaxel arm. In <a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a>, neutropenia was frequent in both the docetaxel‐sunitinib and docetaxel arms, and 26.8% and 16.3% of participants in each arm experienced febrile neutropenia, respectively. <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a>, reported 69.2% and 59.7% of participants receiving napabucasin‐paclitaxel and placebo‐paclitaxel, respectively experienced SAEs. As the study did not provide the number of participants analysed, it was not included in the meta‐analysis. </p> <p>The total incidence of SAEs were 72.6% in the chemotherapy combined with biological therapy arm, compared to 61.3% in the chemotherapy alone arm. The pooled RR was 1.17 (95% CI 0.95 to 1.44) and there was insufficient evidence to decide whether addition of biological therapy to chemotherapy increases occurrence of SAEs (<a href="./references#CD012078-fig-0028" title="">Analysis 4.3</a>). The heterogeneity between the studies was high (I<sup>2</sup> = 86%, P &lt; 0.0001). Sensitivy analyses using fixed‐effect model caused the chemotherapy combined with biological therapy arm to be associated with more SAEs (RR = 1.20, 95% CI 1.12 to 1.29). Similarly, exclusion of <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a> and <a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a>, which were associated with performance bias, resulted in the pooled RR to be in favour of chemotherapy (RR = 1.29, 95% CI 1.19 to 1.39). The certainty of evidence was very low due to risk of bias, inconsistency and imprecision. <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a> and <a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a> are both open‐label studies with risk of performance bias. The 95% CIs of some studies did not overlap and the 95% CI associated with the pooled RR included both null effect and appreciable harm of chemotherapy combined with biological therapy. </p> </section> <section id="CD012078-sec-0080"> <h5 class="title">Tumour response rate (TRR)</h5> <p>Six studies (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>; <a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>; <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a>; <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>; <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>; <a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a>) involving 2404 participants contributed data to this meta‐analysis. <a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a> and <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a> only reported TRR without the exact number of participants who had complete and partial responses and no reference was made if the analysis was performed on the intention‐to‐treat population. Hence, the number of events was estimated from the number of participants randomised. </p> <p>We observed the pooled RR of 1.35 (95% CI 0.99 to 1.85), indicating insufficient evidence for TRR benefit of adding biological therapy to chemotherapy (<a href="./references#CD012078-fig-0029" title="">Analysis 4.4</a>). The heterogeneity observed was high (I<sup>2</sup> = 66%, P = 0.01). The certainty of evidence was very low due to risk of detection bias in <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>, inconsistency with 95% CIs of some studies not overlapping and imprecision with the 95% CI for the pooled RR including both null effect and appreciable benefit from chemotherapy combined with biological therapy. </p> </section> <section id="CD012078-sec-0081"> <h5 class="title">Any adverse events (AAEs)</h5> <p>Five studies (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>; <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a>; <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>; <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>; <a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a>) reported the result on AAEs. In <a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>, the most common AEs in the olaparib‐paclitaxel arm were neutropenia (46.9%), alopecia (42.7%) and anaemia (38.5%), and in the placebo‐paclitaxel group, they were alopecia (44.8%) and neutropenia (41.7%). In <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>, the most common AAEs were alopecia (51.4%), neutropenia (50.4%), fatigue (47.7%) and peripheral neuropathy (36.9%) in the taxane arm and anaemia (35.8%) and fatigue (30.3%) in the trastuzumab emtansine arm. Haemorrhoage was experienced by 11.7% of participants receiving taxane and 28.1% of those receiving trastuzumab emtansine. In <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>, the most common AAEs were neutropenia (54.4%), fatigue (56.9%) and neuropathy (45.9%), in the ramucirumab‐paclitaxel arm and fatigue (43.8%) in the placebo‐paclitaxel arm. In <a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a>, the most common AAEs was anaemia in both docetaxel‐sunitinib and docetaxel arm (91.1% versus 93.9%). Addition of sunitinib to docetaxel increased incidence of stomatitis (51.8%), diarrhoea (35.7%) and hand‐foot syndrome (53.6%). </p> <p>Three studies (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>,<a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>; <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>) involving 1513 participants contributed data to the meta‐analysis. The rate of AAEs were 98.6% in the chemotherapy combined with biological therapy arm and 97.7% in the chemotherapy alone arm. The pooled RR was 1.01 (95% CI 1.00 to 1.03), indicating equivalent occurrence of AAEs between the two arms (<a href="./references#CD012078-fig-0030" title="">Analysis 4.5</a>). We observed low heterogeneity between the studies (I<sup>2</sup> = 0%, P = 0.78). The certainty of evidence was moderate due to risk of performance and detection bias in <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>. </p> </section> <section id="CD012078-sec-0082"> <h5 class="title">Quality of life (QoL)</h5> <p>QoL data were reported by three studies (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>; <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>; <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>). <a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a> reported time to deterioration of EORTC QLQ‐C30 global health status. For overall population, median time to deterioration of global health status was 3.4 months in the olaparib‐paclitaxel arm and 2.4 months in the placebo‐paclitaxel arm with HR of 0.82 (95% CI 0.64 to 1.05). <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a> measured QoL using EORTC QLQ‐C30, QLQ‐STO22 and EQ‐5D and described it to be similar between the treatment arms. <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a> assessed QoL using EORTC QLQ‐C30 and EQ‐5D‐3L. HR for global health status measured using QLQ‐C30 was 0.93 (95% CI 0.73 to 1.18). A consistently higher proportion of participants in the ramucirumab‐paclitaxel arm experienced stable or improved QoL parameters at each assessment, compared with those in the placebo‐paclitaxel arm. The compliance of questionnaires were similar across the two treatment arms throughout the study; 97.6% and 97.9% at baseline and 70.0% and 69.2% at Week 36. </p> <p>Meta‐analysis on time to deterioration of EORTC QLQ‐C30 global health status was performed on data from 1154 participants in the two studies (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>; <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>). The pooled HR was 0.88 (95% CI 0.74 to 1.04) and whether chemotherapy combined with biological therapy improves QoL experienced could not be decided (<a href="./references#CD012078-fig-0031" title="">Analysis 4.6</a>). Heterogeneity assessed was very low (I² = 0%, P = 0.47). The certainty of evidence was low due to risk of attrition bias in both studies and the 95% CI for the pooled HR including both null effect and appreciable benefit from chemotherapy combined with biological therapy. </p> </section> </section> <section id="CD012078-sec-0083"> <h4 class="title">Chemotherapy versus chemotherapy</h4> <p>Four studies (<a href="./references#CD012078-bbs2-0002" title="HironakaS , UedaS , YasuiH , NishinaT , TsudaM , TsumuraT , et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology2013;31(35):4438-44. [PMID: 24190112]">Hironaka 2013</a>; <a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a>; <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>; <a href="./references#CD012078-bbs2-0007" title="LingS , BoL . Efficacy and safety of second-line chemotherapy with EOX and FOLFIRI in advanced gastric cancer. Journal of Xi'an Jiaotong University (Medical Sciences)2018;39(4):546-50. [DOI: 10.7652/jdyxb201804020]">Ling 2018</a>) involving 447 participants compared chemotherapy to another chemotherapy in participants with advanced or recurrent gastric adenocarcinoma as second‐line treatment. Chemotehrpay regimens examined varied widely between studies. One study (<a href="./references#CD012078-bbs2-0002" title="HironakaS , UedaS , YasuiH , NishinaT , TsudaM , TsumuraT , et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology2013;31(35):4438-44. [PMID: 24190112]">Hironaka 2013</a>) compared non‐taxane monotherapy (irinotecan) versus taxane monotherapy with 108 participants in the irinotecan arm and 111 in the paclitaxel arm. Two studies (<a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a> ; <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a> ) compared taxane‐containing doublet therapy (docetaxel‐oxaliplatin, docetaxel‐cisplatin and docetaxel‐S1) versus taxane monotherapy with 71 participants in the taxane‐containing doublet therapy arm and 50 in the taxane monotherapy arm. One study (<a href="./references#CD012078-bbs2-0007" title="LingS , BoL . Efficacy and safety of second-line chemotherapy with EOX and FOLFIRI in advanced gastric cancer. Journal of Xi'an Jiaotong University (Medical Sciences)2018;39(4):546-50. [DOI: 10.7652/jdyxb201804020]">Ling 2018</a>) compared non‐taxane containing doublet therapy (FOLFIRI) to triplet therapy (capecitabine‐epirubicin‐oxaliplatin) with 51 participants in the FOLFIRI arm and 56 in the EOX arm. To enable meaningful analysis, efficacy outcomes are discussed under following three categories: non‐taxane monotherapy versus taxane monotherapy, taxane‐containing doublet chemotherapy versus taxane monotherapy, and non‐taxane containing chemotherapy versus another non‐taxane containing chemotherapy. </p> <section id="CD012078-sec-0084"> <h5 class="title">Overall survival (OS)</h5> <p>Four studies (<a href="./references#CD012078-bbs2-0002" title="HironakaS , UedaS , YasuiH , NishinaT , TsudaM , TsumuraT , et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology2013;31(35):4438-44. [PMID: 24190112]">Hironaka 2013</a>; <a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a>; <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>; <a href="./references#CD012078-bbs2-0007" title="LingS , BoL . Efficacy and safety of second-line chemotherapy with EOX and FOLFIRI in advanced gastric cancer. Journal of Xi'an Jiaotong University (Medical Sciences)2018;39(4):546-50. [DOI: 10.7652/jdyxb201804020]">Ling 2018</a>) involving 447 participants reported OS outcomes. For two of the studies (<a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a> ; <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>) OS outcomes were provided without HRs and they were estimated from the published Kaplan‐Meier curves using a previously described method (<a href="./references#CD012078-bbs2-0171" title="TierneyJF , StewardLA , GhersiD , BudettS , SydesMR . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8(16):https://doi.org/10.1186/1745-6215-8-16. [PMID: 17555582]">Tierney 2007</a>). <a href="./references#CD012078-bbs2-0007" title="LingS , BoL . Efficacy and safety of second-line chemotherapy with EOX and FOLFIRI in advanced gastric cancer. Journal of Xi'an Jiaotong University (Medical Sciences)2018;39(4):546-50. [DOI: 10.7652/jdyxb201804020]">Ling 2018</a> similarly reported OS outcome without HR, however, the mOS in the text did not correspond with the mOS obtained from the published Kaplan‐Meier curve, raising a question on the accuracy of this Kaplan‐Meier curve and the estimated HR. This study, therefore, was not considered for the quantitative analysis. </p> <section id="CD012078-sec-0085"> <h6 class="title">Non‐taxane monotherapy versus taxane monotherapy</h6> <p>One study (<a href="./references#CD012078-bbs2-0002" title="HironakaS , UedaS , YasuiH , NishinaT , TsudaM , TsumuraT , et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology2013;31(35):4438-44. [PMID: 24190112]">Hironaka 2013</a>) involving 219 participants contributed data to this analysis. Reported mOS was 8.4 months in the irinotecan arm and 9.5 months in the paclitaxel arm. HR was 1.13 (95% CI 0.86 to 1.48), indicating insufficient evidence for OS benefit of paclitaxel over irinotecan (<a href="./references#CD012078-fig-0035" title="">Analysis 5.1</a>). The certainty of evidence was low due to imprecision secondary to the limited number of participants analysed and the 95% CI for the HR including both null effect and appreciable harm from irinotecan. The study was at risk of performance bias, but this is unlikely to have affected the outcome. </p> <p><b>Taxane‐containing doublet therapy vs taxane monotherapy</b> </p> <p>Two studies (<a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a>; <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>) involving 121 participants contributed data to this meta‐analysis. mOS weighed for study size was 7.0 months in the taxane‐containing doublet arm and 8.8 months in the taxane monotherapy arm. The pooled HR was 1.05 (95% CI 0.72 to 1.54), indicating insufficient evidence for OS benefit of taxane‐containing doublet therapy or taxane monotherapy (<a href="./references#CD012078-fig-0036" title="">Analysis 5.2</a>). There was moderate heterogeneity between studies (I<sup>2</sup> = 44%, P = 0.17). Sensitivity analysis using fixed‐effect mode resulted in similar HR (HR = 1.07, 95% CI 0.81 to 1.42). Exclusion of <a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a>, which was associated with unclear risk of selection bias, caused the HR to widen (HR = 1.11, 95% CI 0.61 to 2.00). The certainty of evidence was low due to imprecision; the number of participants analysed was small and the 95% CI for the pooled HR included both appreciable benefit and harm from taxane‐containing doublet therapy. </p> <p><b>Non‐taxane containing chemotherapy vs another non‐taxane containing chemotherapy</b> </p> <p><a href="./references#CD012078-bbs2-0007" title="LingS , BoL . Efficacy and safety of second-line chemotherapy with EOX and FOLFIRI in advanced gastric cancer. Journal of Xi'an Jiaotong University (Medical Sciences)2018;39(4):546-50. [DOI: 10.7652/jdyxb201804020]">Ling 2018</a> involving 107 participants compared the efficacy of FOLFIRI and EOX chemotherapy and observed equivalent OS outcome from the two regimens; reported mOS was 18.5 and 19.3 months, respectively (P = 0.170). </p> </section> </section> <section id="CD012078-sec-0086"> <h5 class="title">Progression‐free survival (PFS)</h5> <p>Four studies (<a href="./references#CD012078-bbs2-0002" title="HironakaS , UedaS , YasuiH , NishinaT , TsudaM , TsumuraT , et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology2013;31(35):4438-44. [PMID: 24190112]">Hironaka 2013</a>; <a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a>; <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>; <a href="./references#CD012078-bbs2-0007" title="LingS , BoL . Efficacy and safety of second-line chemotherapy with EOX and FOLFIRI in advanced gastric cancer. Journal of Xi'an Jiaotong University (Medical Sciences)2018;39(4):546-50. [DOI: 10.7652/jdyxb201804020]">Ling 2018</a>) involving 447 participants reported PFS outcomes. For the same reasons described in the OS section, HRs associated with PFS outcomes were estimated from the published Kaplan‐Meier curves for <a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a> and <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>, and <a href="./references#CD012078-bbs2-0007" title="LingS , BoL . Efficacy and safety of second-line chemotherapy with EOX and FOLFIRI in advanced gastric cancer. Journal of Xi'an Jiaotong University (Medical Sciences)2018;39(4):546-50. [DOI: 10.7652/jdyxb201804020]">Ling 2018</a> was not considered for the quantitative analysis. </p> <p><b>Non‐taxane monotherapy versus taxane monotherapy</b> </p> <p>One study (<a href="./references#CD012078-bbs2-0002" title="HironakaS , UedaS , YasuiH , NishinaT , TsudaM , TsumuraT , et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology2013;31(35):4438-44. [PMID: 24190112]">Hironaka 2013</a>) involving 219 participants contributed data to this analysis. mPFS was 2.3 months in the irinotecan arm and 3.6 months in the paclitaxel arm. We could not decide between irinotecan and paclitaxel in terms of effects on PFS (HR = 1.14, 95% CI 0.88 to 1.48) (<a href="./references#CD012078-fig-0037" title="">Analysis 5.3</a>). The certainty of evidence was low due to imprecision secondary to the limited number of participants analysed and the 95% CI for the HR including both null effect and the appreciable harm from irinotecan. </p> <p><b>Taxane‐containing doublet therapy versus taxane monotherapy</b> </p> <p>Two studies (<a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a>; <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>) involving 121 participants contributed data to this meta‐analysis. mPFS weighed for study size was 3.4 months in the taxane‐containing doublet therapy arm and 1.6 months in the taxane monotherapy arm. The pooled HR was 0.75 (95% CI 0.5 to 1.09), indicating insufficient evidence for PFS benefit of taxane‐containing doublet therapy over taxane monotherapy (<a href="./references#CD012078-fig-0038" title="">Analysis 5.4</a>). Hetereogeniety between studies was moderate (I<sup>2</sup> = 59%, P = 0.09). Sensitivity analysis using fixed‐effect mode resulted in the HR to become in favour of taxane containing doublet therapy (HR = 95% CI 0.59 to 0.95). Exclusion of <a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a>, which was associated with unclear risk of selection bias resulted in the 95% CI to widen (HR = 0.86 95% CI 0.54 to 1.38). The certainty of evidence was low due to imprecision; the number of events analysed was small and the 95% CI for the HR included both null effect and appreciable benefit from taxane‐containing doublet therapy. </p> <p><b>Non‐taxane containing chemotherapy versus another non‐taxane containing chemotherapy</b> </p> <p><a href="./references#CD012078-bbs2-0007" title="LingS , BoL . Efficacy and safety of second-line chemotherapy with EOX and FOLFIRI in advanced gastric cancer. Journal of Xi'an Jiaotong University (Medical Sciences)2018;39(4):546-50. [DOI: 10.7652/jdyxb201804020]">Ling 2018</a> involving 107 participants compared the efficacy of FOLFIRI and EOX and observed equivalent PFS outcome from the two regimens; the reported mPFS was 8.1 and 7.4 months, respectively (P = 0.460). </p> </section> <section id="CD012078-sec-0087"> <h5 class="title">Serious adverse events (SAEs)</h5> <p>All four studies measured SAEs, however, none of them reported the total number of participants with any SAEs. Meta‐analysis was not possible for this outcome. </p> <p>In <a href="./references#CD012078-bbs2-0002" title="HironakaS , UedaS , YasuiH , NishinaT , TsudaM , TsumuraT , et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology2013;31(35):4438-44. [PMID: 24190112]">Hironaka 2013</a>, treatment‐related death was observed in two patients (1.8%) in the irinotecan arm with causes being serious pneumonia (n = 1) and gastric perforation (n = 1). The most common Grade 3‐4 AEs were neutropenia and anaemia in both arms; 28.7% and 21.3% in the paclitaxel arm and 39.1% and 30.0% in the irinotecan arm. In <a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a>, the most common SAEs were neutropenia (32.0%) in the docetaxel‐oxaliplatin arm with 20.0% of participants in this arm developing febrile neutropenia. There was one possible treatment‐related death in <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a> in the docetaxel‐cisplatin arm (peritonitis without neutropenia) and for the docetaxel‐S1 arm (pneumonia with neutropenia). The most common Grade 3‐4 SAEs in this study was neutropenia with febrile neutropenia affecting 8.3%, 4.3% and 8.7% of participants in the docetaxel‐cisplatin, docetaxel‐S1 and docetaxel arms, respectively. In <a href="./references#CD012078-bbs2-0007" title="LingS , BoL . Efficacy and safety of second-line chemotherapy with EOX and FOLFIRI in advanced gastric cancer. Journal of Xi'an Jiaotong University (Medical Sciences)2018;39(4):546-50. [DOI: 10.7652/jdyxb201804020]">Ling 2018</a>, neutropenia was again the most common SAE, being observed in 33.3% and 7.1% of participants receiving FOLFIRI and EOX, respectively. The certainty of evidence was considered to be high as none of risk of bias recognised for the included studies was thought to have significantly impacted the reporting of SAEs. </p> </section> <section id="CD012078-sec-0088"> <h5 class="title">Tumour response rate</h5> <p>Four studies (<a href="./references#CD012078-bbs2-0002" title="HironakaS , UedaS , YasuiH , NishinaT , TsudaM , TsumuraT , et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology2013;31(35):4438-44. [PMID: 24190112]">Hironaka 2013</a>; <a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a>; <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>; <a href="./references#CD012078-bbs2-0007" title="LingS , BoL . Efficacy and safety of second-line chemotherapy with EOX and FOLFIRI in advanced gastric cancer. Journal of Xi'an Jiaotong University (Medical Sciences)2018;39(4):546-50. [DOI: 10.7652/jdyxb201804020]">Ling 2018</a>) involving 407 participants reported TRR data. </p> <section id="CD012078-sec-0089"> <h6 class="title">Non‐taxane monotherapy vs taxane monotherapy</h6> <p>One study (<a href="./references#CD012078-bbs2-0002" title="HironakaS , UedaS , YasuiH , NishinaT , TsudaM , TsumuraT , et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology2013;31(35):4438-44. [PMID: 24190112]">Hironaka 2013</a>) involving 179 participants with more than one measurable lesions at baseline contributed data to this analysis. TRR was 13.6% in the irinotecan arm and 20.9% in the paclitaxel arm. RR was 0.65 (95% CI 0.34 to 1.26), implying insufficient evidence for TRR benefit of paclitaxel or irinotecan (<a href="./references#CD012078-fig-0039" title="">Analysis 5.5</a>). The certainty of evidence was low due to imprecision; the number events analysed was small and the 95% CI for the RR included both appreciable benefit and harm from paclitaxel. </p> </section> <section id="CD012078-sec-0090"> <h6 class="title">Taxane‐containing doublet therapy versus taxane monotherapy</h6> <p>Two studies (<a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a>; <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>) involving 121 participants contributed data to this meta‐analysis. We observed TRR of 12.7% in the taxane‐containing doublet therapy arm and 10.0% in the taxane monotherapy arm. The pooled RR was 1.47 (95% CI 0.56 to 3.89) and whether taxane‐containing doublet therapy increases or decreases TRR could not be decided (<a href="./references#CD012078-fig-0040" title="">Analysis 5.6</a>). Heterogeneity observed between the two studies was low (I² = 0%, P = 0.92). The certainty of evidence was very low due to risk of bias and imprecision. There was unclear risk of selection and detection bias as well as confounders in both studies. The number of events analysed was small and the 95% CI for the pooled RR included both appreciable benefit and harm from taxane‐containing doublet chemotherapy. </p> </section> <section id="CD012078-sec-0091"> <h6 class="title">Non‐taxane containing chemotherapy versus another non‐taxane containing chemotherapy</h6> <p>One study (<a href="./references#CD012078-bbs2-0007" title="LingS , BoL . Efficacy and safety of second-line chemotherapy with EOX and FOLFIRI in advanced gastric cancer. Journal of Xi'an Jiaotong University (Medical Sciences)2018;39(4):546-50. [DOI: 10.7652/jdyxb201804020]">Ling 2018</a>) involving 107 participants contributed data to this analysis. TRR was 25.5% in the FOLFIRI arm and 28.6 % in the EOX arm. RR was 0.89 (95% CI 0.48 to 1.67), indicating insufficient evidence for TRR benefit of both arms (<a href="./references#CD012078-fig-0041" title="">Analysis 5.7</a>). The certainty of evidence was low due to imprecision; the number of events analysed was small and the 95% CI for the RR included both appreciable benefit and harm from FOLFIRI. </p> </section> </section> <section id="CD012078-sec-0092"> <h5 class="title">Any adverse events (AAEs)</h5> <p>None of the four studies which compared chemotherapy to another chemotherapy reported the total number of participants with AAEs to allow meta‐analysis on this outcome. </p> <p>In <a href="./references#CD012078-bbs2-0002" title="HironakaS , UedaS , YasuiH , NishinaT , TsudaM , TsumuraT , et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology2013;31(35):4438-44. [PMID: 24190112]">Hironaka 2013</a>, neutropenia and anaemia were the most commonly observed AAEs and observed in 70.0% and 78.7%, 76.4% and 63.9% of participants in the irinotecan and paclitaxel arms, respectively. Febrile neutropenia occurred more frequently in the irinotecan‐treated participants, affecting 9.1% of them compared to 2.8% in the paclitaxel arm. Sensory neuropathy occurred in 57.4% of participants receiving paclitaxel. In <a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a>, the most common AAE was neutropenia in both arms; it affected 40.0% and 14.8% of participants in the docetaxel‐oxaliplatin and the docetaxel arm, respectively. In <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>, anaemia and anorexia affected the majority of participants regardless of their treatment arm. Peripheral neuropathy was another frequently observed AEs, occurring in 41.7%, 52.2% and 43.5% of participants receiving docetaxel‐cisplatin, docetaxel‐S1 and docetaxel, respectively. Diarrhoea occurred more frequently in docetaxel and docetaxel‐S1 arms (47.8%) than docetaxel‐cisplatin arm (25.0%). In <a href="./references#CD012078-bbs2-0007" title="LingS , BoL . Efficacy and safety of second-line chemotherapy with EOX and FOLFIRI in advanced gastric cancer. Journal of Xi'an Jiaotong University (Medical Sciences)2018;39(4):546-50. [DOI: 10.7652/jdyxb201804020]">Ling 2018</a>, neutropenia, anaemia, thrombocytopenia and diarrhoea were much more common in the FOLFIRI arm occurring in 66.7%,66.7% and 88.2%, and 25.5% of participants in the FOLFIRI arm. The certainty of evidence was moderate due to the risk of performance bias in <a href="./references#CD012078-bbs2-0002" title="HironakaS , UedaS , YasuiH , NishinaT , TsudaM , TsumuraT , et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology2013;31(35):4438-44. [PMID: 24190112]">Hironaka 2013</a>. </p> </section> <section id="CD012078-sec-0093"> <h5 class="title">Quality of life</h5> <p>Quality of life was reported by one study (<a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>) using EORTC QLQ‐C30 and gastric modules QLQ‐STO22. More than 60% of the participants in each arm completed the baseline QoL questionnaire and at least one post‐treatment questionnaire, and QoL compliance was similar in the three arms. Although there was no significant difference in the global QoL scores between the three arms, the combination arms had poorer QoL scores compared to the docetaxel alone arm in several domains including physical functioning, fatigue and appetite loss. The certainty of evidence was very low due to the risk of attrition bias and very small number of participants analysed from one study. </p> </section> </section> <section id="CD012078-sec-0094"> <h4 class="title">Subgroup analysis by line of treatment (second‐line versus third‐line and beyond)</h4> <p>Of the 17 studies included in this review,12 studies (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>; <a href="./references#CD012078-bbs2-0002" title="HironakaS , UedaS , YasuiH , NishinaT , TsudaM , TsumuraT , et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology2013;31(35):4438-44. [PMID: 24190112]">Hironaka 2013</a>; <a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a>; <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>; <a href="./references#CD012078-bbs2-0007" title="LingS , BoL . Efficacy and safety of second-line chemotherapy with EOX and FOLFIRI in advanced gastric cancer. Journal of Xi'an Jiaotong University (Medical Sciences)2018;39(4):546-50. [DOI: 10.7652/jdyxb201804020]">Ling 2018</a>; <a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>; <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a>; <a href="./references#CD012078-bbs2-0012" title="ShitaraK , ÖzgüroğluM , BangYJ , BartolomeoMD , MandalàM , RyuMH , et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet2018;392(10142):123-33. [PMID: 29880231]">Shitara 2018</a>; <a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a>; <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>; <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>; <a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a>) investigated study treatments in the second‐line setting, one study (<a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>) in the second‐ or third‐line setting, one study (<a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>) in the second‐ to fourth‐line setting and three studies (<a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>; <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>; <a href="./references#CD012078-bbs2-0013" title="ShitaraK , DoiT , DvorkinM , MansoorW , ArkenauHT , ProkharauA , et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2018;19(11):1437-48. [PMID: 30355453]">Shitara 2018b</a>) in the third‐line and beyond setting. Subgroup analysis by line of treatment was only possible for chemotherapy versus placebo, BSC or no treatment on OS, and biological therapy versus placebo, BSC or no treatment on PFS. </p> <section id="CD012078-sec-0095"> <h5 class="title">Chemotherapy versus placebo, best supportive care (BSC) or no treatment: overall survival (OS) </h5> <p>Two studies (<a href="./references#CD012078-bbs2-0013" title="ShitaraK , DoiT , DvorkinM , MansoorW , ArkenauHT , ProkharauA , et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2018;19(11):1437-48. [PMID: 30355453]">Shitara 2018b</a>; <a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a>) involving 547 participants contributed data to this subgroup analysis; 40 and 507 participants received second‐ and third‐line treatment, respectively. Chemotherapy provided OS benefit regardless of line of treatment over placebo, BSC or no treatment; HR was 0.48 (95% CI 0.25 to 0.92) in second‐line and 0.69 (95% CI 0.56 to 0.85) in third‐line (<a href="./references#CD012078-fig-0008" title="">Analysis 1.6</a>). Test for subgroup difference did not reach statistical significance (I² = 7.3%, P = 0.30). </p> </section> <section id="CD012078-sec-0096"> <h5 class="title">Biological therapy versus placebo, best supportive care (BSC) or no treatment: progression‐free survival (PFS) (VEGFR‐targeted therapy) </h5> <p>Two studies (<a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>; <a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>) involving 288 participants contributed data to this subgroup analysis; 62 and 226 participants were in the second‐ and third‐line setting, respectively. PFS benefit was achieved by biological therapy regardless of line of treatment with the observed benefit being larger for the third‐line setting. HR in the second‐line setting was 0.49 (95% CI 0.28 to 0.86) and that in the third‐line setting was 0.24 (95% CI 0.17 to 0.34) (<a href="./references#CD012078-fig-0016" title="">Analysis 2.6</a>). Test for subgroup difference reached statistical significance (I² = 78.5%, P = 0.03), while the 95% CIs for the two subgroups overlapped. </p> </section> </section> <section id="CD012078-sec-0097"> <h4 class="title">Subgroup analysis by geographical region (East and South‐East Asia versus rest of the world) </h4> <p>Of the 17 studies included in this review, nine studies (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>; <a href="./references#CD012078-bbs2-0002" title="HironakaS , UedaS , YasuiH , NishinaT , TsudaM , TsumuraT , et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology2013;31(35):4438-44. [PMID: 24190112]">Hironaka 2013</a>; <a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>; <a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a>; <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>; <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>; <a href="./references#CD012078-bbs2-0007" title="LingS , BoL . Efficacy and safety of second-line chemotherapy with EOX and FOLFIRI in advanced gastric cancer. Journal of Xi'an Jiaotong University (Medical Sciences)2018;39(4):546-50. [DOI: 10.7652/jdyxb201804020]">Ling 2018</a>; <a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>; <a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a>) were conducted in East and South‐East Asia, two studies (<a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>; <a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a>) in Europe and six studies (<a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>; <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a>; <a href="./references#CD012078-bbs2-0012" title="ShitaraK , ÖzgüroğluM , BangYJ , BartolomeoMD , MandalàM , RyuMH , et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet2018;392(10142):123-33. [PMID: 29880231]">Shitara 2018</a>; <a href="./references#CD012078-bbs2-0013" title="ShitaraK , DoiT , DvorkinM , MansoorW , ArkenauHT , ProkharauA , et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2018;19(11):1437-48. [PMID: 30355453]">Shitara 2018b</a>; <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>; <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>) worldwide. Subgroup analysis by geographical region was only possible for chemotherapy versus placebo, BSC or no treatment on OS and PFS, biological therapy versus placebo, BSC or no treatment on PFS, and chemotherapy combined with biological therapy versus chemotherapy on OS and PFS. </p> <section id="CD012078-sec-0098"> <h5 class="title">Chemotherapy versus placebo, best supportive care (BSC) or no treatment: overall survival (OS) and progression‐free survival (PFS) </h5> <p>Two studies (<a href="./references#CD012078-bbs2-0013" title="ShitaraK , DoiT , DvorkinM , MansoorW , ArkenauHT , ProkharauA , et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2018;19(11):1437-48. [PMID: 30355453]">Shitara 2018b</a>; <a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a>) involving 547 participants contributed data to this subgroup analysis for OS; 73 participants were treated in East and South‐East Asia and 474 in the rest of the world. OS benefit of chemotherapy was observed only for participants from the rest of the world (HR = 0.65, 95% CI 0.52 to 0.80) and was unclear for those from East and South‐East Asia (HR = 0.77, 95% CI 0.46 to 1.29) (<a href="./references#CD012078-fig-0009" title="">Analysis 1.7</a>). The test for subgroup difference did not reach statistical significance (I² = 0.0%, P = 0.37). </p> <p>One study (<a href="./references#CD012078-bbs2-0013" title="ShitaraK , DoiT , DvorkinM , MansoorW , ArkenauHT , ProkharauA , et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2018;19(11):1437-48. [PMID: 30355453]">Shitara 2018b</a>) involving 507 participants contributed data to this subgroup analysis for PFS; 73 participants were from East and South‐East Asia and 434 from the rest of the world. PFS benefit was demonstrated for participants from both East and South‐East Asia and the rest of the world. HR was 0.33 (95% CI 0.19 to 0.57) for East and South‐East Asia and 0.61 (95% CI 0.49 to 0.76) for the rest of the world (<a href="./references#CD012078-fig-0010" title="">Analysis 1.8</a>). The test for subgroup difference was significant (I² = 75.5%, P = 0.04) and the observed PFS benefit was larger for participants from East and South‐East Asia with overlapping 95% CIs for the two subgroups. </p> </section> <section id="CD012078-sec-0099"> <h5 class="title">Biological therapy versus placebo, best supportive care (BSC) or no treatment: progression‐free survival ({FS) (VEGFR‐targeted therapy) </h5> <p>Two studies (<a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>; <a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>) involving 288 participants contributed data to this subgroup analysis; 195 participants were treated in East and South‐East Asia and 93 in the rest of the world. HR for participants from East and South‐East Asia was 0.17 (95% 0.12 to 0.24), indicating PFS benefit of VEGFR‐targeted therapy over placebo (<a href="./references#CD012078-fig-0017" title="">Analysis 2.7</a>). PFS benefit was also observed for participants from the rest of the world (HR = 0.61, 95% CI 0.39 to 0.95). The test for subgroup difference reached statistical significance (I² = 94.7%, P = 0.0001), with the observed PFS benefit larger for participants from East and South‐East Asia. </p> </section> <section id="CD012078-sec-0100"> <h5 class="title">Chemotherapy versus biological therapy: overall survival (OS)</h5> <p>One study (<a href="./references#CD012078-bbs2-0012" title="ShitaraK , ÖzgüroğluM , BangYJ , BartolomeoMD , MandalàM , RyuMH , et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet2018;392(10142):123-33. [PMID: 29880231]">Shitara 2018</a>) involving 395 participants contributed data to this subgroup analysis; 104 participants were from East and South‐East Asia and 291 from the rest of the world. The data indicated insufficient evidence for OS benefit of pembrolizumab or paclitaxel for participants from East and South‐East Asia (HR = 0.90, 95% CI 0.59 to 1.37) (<a href="./references#CD012078-fig-0025" title="">Analysis 3.6</a>). OS benefit of pembrolizumab in participants from the rest of the world was similarly unclear (HR = 0.81, 95% 0.61 to 1.08). The test for subgroup difference did not reach statistical significance (I² = 0.0%, P = 0.69). </p> </section> <section id="CD012078-sec-0101"> <h5 class="title">Chemotherapy combined with biological therapy versus chemotherapy: overall survival (OS) and progression‐free survival (PFS) </h5> <p>Six studies (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>; <a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>; <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>;<a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>; <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>; <a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a>) involving 2030 participants contributed data to the subgroup analysis for OS; 1099 participants were treated in East and South‐East Asia and 931 in the rest of the world. HR for participants from East and South‐East Asia was 0.95 (95% CI 0.78 to 1.16), indicating the lack of OS benefit of chemotherapy combined with biological therapy, unlike participants from the rest of the world who were shown to have OS benefit (HR = 0.84, 95% CI 0.73 to 0.97) (<a href="./references#CD012078-fig-0032" title="">Analysis 4.7</a>). The test for subgroup difference did not reach statistical significance (I² = 0.7%, P = 0.32). </p> <p>Five studies (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>; <a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>; <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>; <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>; <a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a>) involving 1684 participants also contributed data to the subgroup analysis for PFS; 942 participants were from East and South‐East Asia and 742 were from the rest of the world. HR for participants from East and South‐East Asia was 0.79 (95% CI 0.68 to 0.92), indicating PFS benefit of chemotherapy combined with biological therapy (<a href="./references#CD012078-fig-0033" title="">Analysis 4.8</a>). Participants from the rest of the world similarly received PFS benefit from chemotherapy combined with biological therapy (HR = 0.74, 95% CI 0.57 to 0.95). The test for subgroup difference did not reach statistical significance (I² = 0.0%, P = 0.67). </p> </section> </section> <section id="CD012078-sec-0102"> <h4 class="title">Subgroup analysis by extent of disease (locally advanced versus metastatic disease)</h4> <p>Of the 17 studies included in this review, 12 studies (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>; <a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>; <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>; <a href="./references#CD012078-bbs2-0007" title="LingS , BoL . Efficacy and safety of second-line chemotherapy with EOX and FOLFIRI in advanced gastric cancer. Journal of Xi'an Jiaotong University (Medical Sciences)2018;39(4):546-50. [DOI: 10.7652/jdyxb201804020]">Ling 2018</a>; <a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>; <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>; <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a>; <a href="./references#CD012078-bbs2-0012" title="ShitaraK , ÖzgüroğluM , BangYJ , BartolomeoMD , MandalàM , RyuMH , et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet2018;392(10142):123-33. [PMID: 29880231]">Shitara 2018</a>; <a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a>; <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>; <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>; <a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a>) enrolled participants with either locally advanced and metastatic disease with some additionally including recurrent disease. The remaining five studies (<a href="./references#CD012078-bbs2-0002" title="HironakaS , UedaS , YasuiH , NishinaT , TsudaM , TsumuraT , et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology2013;31(35):4438-44. [PMID: 24190112]">Hironaka 2013</a>; <a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a>; <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>; <a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>; <a href="./references#CD012078-bbs2-0013" title="ShitaraK , DoiT , DvorkinM , MansoorW , ArkenauHT , ProkharauA , et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2018;19(11):1437-48. [PMID: 30355453]">Shitara 2018b</a>) enrolled metastatic and recurrent disease. Subgroup analysis was only possible for chemotherapy combined with biological therapy versus chemotherapy. </p> <section id="CD012078-sec-0103"> <h5 class="title">Chemotherapy combined with biological therapy versus chemotherapy: overall survival (OS) </h5> <p>Two studies (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>; <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>) involving 859 participants contributed data to this subgroup analysis. Only 14 participants with locally advanced disease were included and the remaining 845 participants had metastatic disease. HR for participants with locally advanced disease was 1.56 (95% CI 0.31 to 7.85) and whether chemotherapy combined with biological therapy improves or worsens OS could not be decided (<a href="./references#CD012078-fig-0034" title="">Analysis 4.9</a>). There was similarly insufficient evidence to decide between chemotherapy combined with biological therapy and chemotherapy alone in terms of effects on OS for participants with metastatic disease (HR = 0.93, 95% CI 0.64 to 1.35). The test for subgroup difference did not reach statistical significance (I² = 0.0%, P = 0.54). </p> </section> </section> <section id="CD012078-sec-0104"> <h4 class="title">Subgroup analysis by type of biological therapy (non‐immunotherapy versus immunotherapy)</h4> <p>As immunotherapy is associated with clinical response patterns not observed with other biological therapy including its durable response, an unplanned subgroup analysis was performed based on the types of biological therapy. Of the 17 studies included in this review, 11 studies (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>; <a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>; <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>; <a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>; <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>; <a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>; <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a>; <a href="./references#CD012078-bbs2-0012" title="ShitaraK , ÖzgüroğluM , BangYJ , BartolomeoMD , MandalàM , RyuMH , et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet2018;392(10142):123-33. [PMID: 29880231]">Shitara 2018</a>; <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>; <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>; <a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a>) examined biological therapy and two of them (<a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>; <a href="./references#CD012078-bbs2-0012" title="ShitaraK , ÖzgüroğluM , BangYJ , BartolomeoMD , MandalàM , RyuMH , et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet2018;392(10142):123-33. [PMID: 29880231]">Shitara 2018</a>) assessed immunotherapy. Subgroup analysis was only possible for biological therapy versus placebo, BSC or no treatment. </p> <section id="CD012078-sec-0105"> <h5 class="title">Biological therapy versus placebo, best supportive care (BSC) or no treatment: overall survival (OS) and progression‐free survival (PFS) </h5> <p>Three studies (<a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>; <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>; <a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>) involving 781 participants contributed data to this subgroup analysis for OS; 288 participants were assessed in the two studies (<a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>; <a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>) examining VEGFR‐targeted therapy and 493 participants were assessed in one study (<a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>) examining immunotherapy. The mOS, weighed for study size was 5.2 months in the VEGFR‐targeted therapy arm and 3.5 months in the placebo arm for <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a> and <a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>, and 5.3 months in the immunotherapy arm and 4.4 months in the placebo arm for <a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>. OS benefit was observed for both VEGFR‐targeted therapy (HR = 0.50, 95% CI 0.31 to 0.79) and immunotherapy (HR = 0.63, 95% 0.51 to 0.78) (<a href="./references#CD012078-fig-0018" title="">Analysis 2.8</a>). The test for subgroup difference did not reach statistical significance (I² = 0.0%, P = 0.37). </p> <p>Three studies (<a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>; <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>; <a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>) involving 781 participants contributed data to this subgroup analysis for PFS. 288 participants were assessed in the two studies (<a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>; <a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>) examining VEGFR‐targeted therapy and 493 participants were assessed in one study (<a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>) examining immunotherapy. mPFS, weighed for study size was 3.5 months in the VEGFR‐targeted therapy arm and 1.1 months in the placebo arm for <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a> and <a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>, and 1.6 months in the immunotherapy arm and 1.5 months in the placebo arm for <a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>. As with OS subgroup analysis, PFS benefit was observed for both VEGFR‐targeted therapy (HR = 0.26, 95% CI 0.15 to 0.45) and immunotherapy (HR = 0.60, 95% CI 0.49 to 0.73) (<a href="./references#CD012078-fig-0019" title="">Analysis 2.9</a>). The test for subgroup difference reached statistical significance (I² = 87.4%, P &lt; 0.005) with the observed PFS benefit larger for participants receiving VEGFR‐targeted therapy. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012078-sec-0106" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012078-sec-0106"></div> <p>This review and meta‐analysis included only parallel‐group randomised studies. The majority of studies reported adequate randomisation and allocation concealment. Six studies were open‐label, however, in some of them the tumour response rate (TRR) was assessed centrally by blinded reviewers or investigators were kept blinded from the data until the analysis was complete. Treatment arms in individual studies were generally well‐balanced for patient and disease characteristics and at low risk of reporting bias. Attrition bias was a problem in all the studies reporting quality of life (QoL) outcomes. </p> <section id="CD012078-sec-0107"> <h3 class="title" id="CD012078-sec-0107">Summary of main results</h3> <section id="CD012078-sec-0108"> <h4 class="title">Chemotherapy versus placebo, best supportive care (BSC) or no treatment</h4> <p>The meta‐analysis was only possible for overall survival (OS) outcome. Chemotherapy (irinotecan and trifluridine/tipiracil) provided probable OS benefit over placebo and BSC with prolongation of median overall survival (mOS). Chemotherapy (trifluridine/tipiracil) prolonged progression‐free survival (PFS) slightly while there was insufficient evidence to decide whether it increases TRR. Subgroup analysis by line of treatment indicated OS benefit of chemotherapy in both the second‐ and third‐line settings. OS benefit of chemotherapy was only observed in the rest of the world and there was insufficient evidence in East and South‐East Asia. PFS benefit was seen regardless of geographical region with the magnitude of benefit being larger in East and South‐East Asia. OS benefit of chemotherapy was accompanied by the probable higher incidence of serious adverse events (SAEs). The rate of Grade ≥ 3 febrile neutropenia was 1.8% in participants receiving trifluridine/tipiracil. The most common SAE associated with irinotecan was diarrhoea and Grade ≥ 3 febrile neutropenia occurred in 16% of irinotecan‐receiving participants. There was no difference in the rate of any adverse events (AAEs) between the two arms. </p> <p>Chemotherapy probably improves OS in patients with metastatic gastric and <b>:</b> oesophago‐gastric junction (OGJ) adenocarcinoma in both the second‐ and third‐line settings and may be considered in those with good performance status. Trifluridine/tipiracil may be preferred over irinotecan given the lower rate of Grade ≥ 3 febrile neutropenia. </p> </section> <section id="CD012078-sec-0109"> <h4 class="title">Biological therapy versus placebo, best supportive care (BSC) or no treatment</h4> <p>The meta‐analysis showed biological therapy provided OS and probably slight PFS benefits over placebo with possibly improved TRR. Subgroup analysis by the types of biological therapy showed no difference for OS benefit, however, PFS benefit was larger from vascular endothelial growth factor receptor (VEGFR)‐targeted therapy compared to immunotherapy while TRR was larger for immunotherapy. Subgroup analysis by line of treatment indicated PFS benefit of VEGFR‐targeted therapy applies to both the second‐ and third‐line settings with the magnitude of benefit being larger in the third‐line setting. PFS benefit of VEGFR‐target therapy was observed regardless of geographical region with larger benefit being demonstrated in East and South‐East Asia. There was insufficient evidence to decide between biological therapy and placebo in terms of effects on SAEs. SAEs affected 67.0% of participants receiving regorafenib and 41.5% of those receiving nivolumab. The occurrence of AAEs was equivalent between the immunotherapy and placebo arms. Narrative analysis of the two studies reporting QoL outcome suggested overall similar QoL experienced by participants treated with VEGFR‐targeted therapy and placebo. </p> <p>Apatinib, regorafenib and nivolumab are all reasonable biological therapy options with OS and probably slight PFS benefits over placebo. Toxicity of nivolumab deferred from that of apatinib and regorafenib due to its action of mechanism. Based on the lower incidence of SAEs associated with nivolumab, this agent may be preferred for frailer patients with advanced gastric and OGJ adenocarcinoma, who are still keen to explore salvage systemic therapy. </p> </section> <section id="CD012078-sec-0110"> <h4 class="title">Chemotherapy versus biological therapy</h4> <p>There was insufficient evidence to indicate OS benefit of pembrolizumab over paclitaxel for participants with PD‐L1 PCS ≥ 1 gastric and OGJ adenocarcinoma. Paclitaxel probably improved PFS in this population and there was insufficient evidence to decide between the two arms in terms of effects on TRR. In the subgroup analysis by geographical region, there was insufficient evidence for OS benefit of pembrolizumab in East and South‐East Asia or the rest of the world. SAEs affected 34.8% of participants in the paclitaxel arm and the rate was more than twice of that observed in the pembrolizumab arm. AAEs were similarly observed more frequently in the paclitaxel arm. </p> <p>Pembrolizumab is a reasonable alternative to paclitaxel for patients with PD‐L1 CPS ≥ 1 status, especially if toxicity of chemotherapy is a problem. It may provide an additional therapeutic option upon development of resistance to taxane chemotherapy in this population of patients. </p> </section> <section id="CD012078-sec-0111"> <h4 class="title">Chemotherapy combined with biological therapy versus chemotherapy</h4> <p>Biological therapy assessed in this comparison included six agents all from different therapeutic groups. OS outcome was probably equivalent between combined chemotherapy and biological therapy, and chemotherapy alone with uncertainty to whether combined chemotherapy and biological therapy improves PFS or TRR. Exclusion of studies evaluating HER2‐targeted therapy resulted in slight OS and PFS benefits of combined chemotherapy and biological therapy. Subgroup analysis by geographical region demonstrated small OS benefit of chemotherapy combined with biological therapy only in the rest of the world and not in East and South‐East Asia, although the test for subgroup difference did not reach statistical significance. The subgroup analysis by geographical region showed PFS benefit of combined chemotherapy and biological therapy for all regions. There was insufficient evidence to decide between chemotherapy combined with biological therapy and chemotherapy alone in terms of effects on OS for participants with both locally advanced and metastatic disease. SAEs affected 72.6% and 61.3% of participants in the chemotherapy combined with biological therapy and chemotherapy alone arms, respectively and it was uncertain whether combined biological therapy increases occurrence of SAEs. There was insufficient evidence to decide whether time to deterioration of EORTC QLQ‐C30 global health status improves with combined chemotherapy and biological therapy. </p> <p>Combining chemotherapy and biological therapy probably achieves equivalent OS benefit to chemotherapy alone, except it may slightly improve OS and PFS outcomes when the therapy works through mechanisms other than those involving HER2 receptors. Combined chemotherapy and biological therapy is associated with common occurrence of SAEs, making this type of treatment less favoured as salvage therapy for patients with advanced gastric and OGJ adenocarcinoma. </p> </section> <section id="CD012078-sec-0112"> <h4 class="title">Chemotherapy versus chemotherapy</h4> <p>Chemtoehrapy regimens assessed included irinotecan, taxane monotherapy, docetaxel‐containing doublet chemotherapy and non‐taxane containing poly‐chemotherapy. We could not decide between irinotecan and paclitaxel in terms of effects on OS or PFS and reported mOS and median progression‐free survival (mPFS) were not far apart. There was insufficient evidence to indicate OS and PFS benefits of addition of another chemotherapy to docetaxel. There was similarly insufficient evidence to decide between FOLFIRI and EOX in terms of effects on TRR. Treatment‐related deaths occurred in 1.8% of irinotecan‐receiving participants and 4.2% to 4.3% of participants receiving docetaxel‐containing doublet chemotherapy. Grade ≥ 3 neutropenia was common occurrence among participants receiving both mono‐and poly‐chemotherapy except for docetaxel‐S1 and EOX treatment and docetaxel‐oxaliplatin was associated with 20.0% risk of febrile neutropenia. No difference was observed for the global QoL between the docetaxel‐cisplatin, docetaxel‐S1 and docetaxel arms, however, worse QoL was reported for participants receiving the doublet chemotherapy for several symptom categories. </p> <p>There is no evidence of a difference between irinotecan and paclitaxel in terms of effects on OS and PFS outcomes, however, irinotecan is associated with more treatment‐related deaths. Poly‐chemotherapy increased toxicity, particularly treatment‐related death and Grade ≥ 3 neutropenia without obvious improvement in efficacy outcomes. </p> </section> </section> <section id="CD012078-sec-0113"> <h3 class="title" id="CD012078-sec-0113">Overall completeness and applicability of evidence</h3> <p>Seventeen studies were chosen based on the pre‐specified selection criteria for this review. Thirteen studies, which were 12conference abstracts and one full‐text article, could not be included in the review as an insufficient amount of information was available for adequate eligibility assessment. Authors of these studies were contacted via email, however, we received either no reply or were advised study data were owned by independent organisations, commonly pharmaceutical companies, who could not release them. Additional 29 studies were identified to be relevant to this review, but are ongoing. </p> <p>The median age of participants in the studies included in this review varied between 52 and 65 years old and it was thought to be in line with typical gastric cancer patients. 71.6% of participants in the review were estimated to be males and this proportion was consistent with the available literature (<a href="./references#CD012078-bbs2-0143" title="AjaniJA , LeeJ , SanoT , JanjigianYY , FanD , SongS . Gastric adenocarcinoma. Nature Reviews Disease Primers2017;1(3):17036. [PMID: 28569272]">Ajani 2017</a>). The majority of the participants in the review was ECOG PS ≤ 1 and excluding <a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a> and <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>, studies, which did not describe well the characteristics of patients, participants with ECOG PS 2 comprised only 1.0% of the review population. This was felt to be lower than typical gastric cancer patients in our clinical practice. When known, the proportion of participants with metastatic disease in studies included in the review ranged 89.5% to 100% and this rate was consistent with our clinical practice. The only exception was <a href="./references#CD012078-bbs2-0007" title="LingS , BoL . Efficacy and safety of second-line chemotherapy with EOX and FOLFIRI in advanced gastric cancer. Journal of Xi'an Jiaotong University (Medical Sciences)2018;39(4):546-50. [DOI: 10.7652/jdyxb201804020]">Ling 2018</a> where only 57.0% of participants had metastatic gastric cancer. </p> <p>No studies were found under the following comparisons; chemotherapy combined with biological therapy versus placebo, BSC or no treatment, chemotherapy combined with biological therapy versus biological therapy, biological therapy versus another biological therapy, and chemotherapy combined with biological therapy versus another chemotherapy combined with biological therapy. Neither quantitative or narrative analysis was performed for these comparisons. </p> <p>For many of the preplanned outcomes there was only one study providing the data and more than half the meta‐analyses performed in this review contained data from only two or three studies, frequently examining heterogenous regimens, making the generalisation of the result difficult. For comparisons between chemotherapy versus another chemotherapy, we were unable to combine the data from all applicable studies for efficacy outcomes due to the difference in the regimens examined. </p> <p>Three studies (<a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>; <a href="./references#CD012078-bbs2-0012" title="ShitaraK , ÖzgüroğluM , BangYJ , BartolomeoMD , MandalàM , RyuMH , et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet2018;392(10142):123-33. [PMID: 29880231]">Shitara 2018</a>; <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>) selected the study population based on tumour biomarker expression. Response to trastuzumab has been previously linked to HER2 positivity (<a href="./references#CD012078-bbs2-0145" title="BangYJ , Van CutsemE , FeyereislovaA , ChungHC , ShenL , SawakiA , et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet2010;376(9742):687-97. [PMID: 20728210]">Bang 2010</a>). The association of response to nivolumab and PD‐L1 expression has been more recently reported by <a href="./references#CD012078-bbs2-0158" title="JanjigianYY , OttPA , CalvoE , KimJW , AsciertoPA , SharmaP , et al. Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study. Journal of Clinical Oncology2017;35(15_suppl):4014.">Janjigian 2017</a> with an increase in the response to nivolumab with or without ipilimumab in patients with gastric, oesophageal and OGJ cancer showing PD‐L1 ≥ 1%. Efficacy analysis for the comparison of chemotherapy versus biological therapy was hence performed on the participants with PD‐L1 CPS ≥ 1% from <a href="./references#CD012078-bbs2-0012" title="ShitaraK , ÖzgüroğluM , BangYJ , BartolomeoMD , MandalàM , RyuMH , et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet2018;392(10142):123-33. [PMID: 29880231]">Shitara 2018</a>. It is not possible to apply the findings from these three studies to the general population with advanced gastric and OGJ adenocarcinoma. </p> <p>Five studies (<a href="./references#CD012078-bbs2-0003" title="KangYK , BokuN , SatohT , RyuMH , ChaoY , KatoK , et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017;390(10111):2461-71. [PMID: 28993052]">Kang 2017</a>; <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>; <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>; <a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>; <a href="./references#CD012078-bbs2-0013" title="ShitaraK , DoiT , DvorkinM , MansoorW , ArkenauHT , ProkharauA , et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2018;19(11):1437-48. [PMID: 30355453]">Shitara 2018b</a>) included participants who had failed two or more lines of systemic treatment and their proportion was 19.9% for studies providing the number of patients in various lines of treatment. Two subgroup analyses performed indicated survival outcome to be not affected by line of treatment, however, for the regimens which were only examined in the second‐line setting, if their reported efficacy applies to patients in the third‐line and beyond setting is unclear. </p> <p>Of the seven studies (<a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a>; <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>; <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>; <a href="./references#CD012078-bbs2-0010" title="MartinAJ , GibbsE , SjoquistK , PavlakisN , SimesJ , PriceT , et al. Health‑related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer2018;21((3)):473-80. [PMID: 28815316]PavlakisN , SjoquistKM , MartinAJ , TsobanisE , YipS , KangYK , et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. Journal of Clinical Oncology2016;34(23):2728-35. [PMID: 27325864]">Pavlakis 2016</a>; <a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a>; <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>; <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>), which intended to measure QoL, two studies provided no or minimal results; <a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a> did not report QoL outcome as attainment of participants was too poor to achieve meaningful analysis and <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a> only described QoL outcome to be similar between the two treatment arms without detailed data. For the remaining studies, despite EORTC QLQ‐C30 being used for QoL assessment by all of them, there was inconsistency in their analysis methods, making it difficult to collectively evaluate the findings for the purpose of this review. The only meta‐analysis performed for QoL outcome was an unplanned analysis on time to deterioration of global health status measured using EORTC QLQ‐C30, which was reported by <a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a> and <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>. The survival benefit of systemic therapy for advanced gastric and OGJ cancer in the salvage setting is not large and the largest OS benefit, calculated as the difference in mOS weighed for study size between the treatment arms was 2.1 months for the comparison between chemotherapy versus placebo, BSC or no treatment. Considering the cost to healthcare systems and the potential psychological stress treatment may impose on patients, sustainment of QoL is an important goal for both clinicians and patients embarking on salvage systemic therapy and this outcome should be evaluated in more clinical trials. </p> </section> <section id="CD012078-sec-0114"> <h3 class="title" id="CD012078-sec-0114">Quality of the evidence</h3> <p>The majority of studies included in this review were at low risk of randomisation and allocation bias. Six studies (<a href="./references#CD012078-bbs2-0002" title="HironakaS , UedaS , YasuiH , NishinaT , TsudaM , TsumuraT , et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology2013;31(35):4438-44. [PMID: 24190112]">Hironaka 2013</a>; <a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>; <a href="./references#CD012078-bbs2-0012" title="ShitaraK , ÖzgüroğluM , BangYJ , BartolomeoMD , MandalàM , RyuMH , et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet2018;392(10142):123-33. [PMID: 29880231]">Shitara 2018</a>; <a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a>; <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>; <a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a>) were open‐label with no blinding of study treatment to participants. Although it is unlikely that the knowledge of study treatment by participants altered the OS, PFS, SAE and TRR outcomes, it is suspected to have affected AAE outcome due to performance bias. In two studies (<a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a>; <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>), outcome assessment was not blinded. <a href="./references#CD012078-bbs2-0014" title="Thuss-PatiencePC , KretzschmarA , BichevD , DeistT , HinkeA , BreithauptK , et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer2011;47(15):2306-14. [PMID: 21742485]">Thuss‐Patience 2011</a> only reported OS outcome and hence, it is unlikely to have been affected by detection bias. In <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>, however, all the outcomes other than OS were at risk of detection bias. Atteninment bias affected the majority of studies reporting QoL outcome. For the three studies published as conference abstracts (<a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>; <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a>; <a href="./references#CD012078-bbs2-0013" title="ShitaraK , DoiT , DvorkinM , MansoorW , ArkenauHT , ProkharauA , et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology2018;19(11):1437-48. [PMID: 30355453]">Shitara 2018b</a>) and three other studies (<a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a>; <a href="./references#CD012078-bbs2-0006" title="LiJ , QinS , XuJ , GuoW , XiongJ , BaiY , et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology2013;31(26):3219-25. [PMID: 23918952]">Li 2013</a>; <a href="./references#CD012078-bbs2-0007" title="LingS , BoL . Efficacy and safety of second-line chemotherapy with EOX and FOLFIRI in advanced gastric cancer. Journal of Xi'an Jiaotong University (Medical Sciences)2018;39(4):546-50. [DOI: 10.7652/jdyxb201804020]">Ling 2018</a>), risk of bias for several domains was unclear. <a href="./references#CD012078-bbs2-0007" title="LingS , BoL . Efficacy and safety of second-line chemotherapy with EOX and FOLFIRI in advanced gastric cancer. Journal of Xi'an Jiaotong University (Medical Sciences)2018;39(4):546-50. [DOI: 10.7652/jdyxb201804020]">Ling 2018</a>, the only study published in a non‐English language in this review, was not associated with increased study bias compared to the rest of studies published in English, however, inconsistency in the survival outcomes detected between the text and the published Kaplan‐Meier curves was a concern for the certainty of data presented. </p> <p>Because of the small number of participants considered and the low occurrence of events, certainty of evidence was downgraded for imprecision in some of the meta‐analyses performed in this review. This was particularly the case with the TRR analyses. For none of the comparisons examined in this review, except for that between chemotherapy combined with biological therapy versus chemotherapy, more than 300 events of tumour response, which are generally considered adequate to prevent imprecision, were achieved. The majority of the analyses on the primary outcomes had sufficient number of events. Heterogeneity which was assessed by the Chi² test and the I² statistic was frequently detected and was partly due to the diversity in the regimens used across studies. For those meta‐analyses which were not associated with heterogeneity, imprecision due to a wide 95% CI associated with hazard ratio (HR) or risk ratio (RR) was often observed. Overall, the certainty of evidence for analyses on OS and SAEs, the two outcomes commonly considered most important in the clinical practice were of moderate to high, with the exception of that on SAE outcome for biological therapy versus placebo, chemotherapy versus biological therapy, and chemotherapy combined with biological therapy versus chemotherapy as well as OS outcome for chemotherapy versus another chemotherapy. </p> </section> <section id="CD012078-sec-0115"> <h3 class="title" id="CD012078-sec-0115">Potential biases in the review process</h3> <p>Publication bias was a concern throughout this review process as studies which did not identify the treatment to be effective may not have been published. To minimise publication bias, our literature search included unpublished or ongoing trials and no restriction on language was applied. </p> </section> <section id="CD012078-sec-0116"> <h3 class="title" id="CD012078-sec-0116">Agreements and disagreements with other studies or reviews</h3> <p>Two reviews on related topics have been published in recent times. <a href="./references#CD012078-bbs2-0154" title="GaldyS , CellaCA , SpadaF , MurgioniS , FrezzaAM , RavendaSP , et al. Systemic therapy beyond first-line in advanced gastric cancer: an overview of the main randomized clinical trials. Critical Reviews in Oncology/Hematology2016;99:1-12. [PMID: 26697987]">Glady 2016</a> published a narrative review of randomised controlled trials (RCTs) examining systemic therapy for advanced gastric cancer in second‐ and third‐line settings. The major difference from our review was that we specified included patients to have experienced disease progression on the first‐line fluoropyrimidine and platinum‐containing chemotherapy. Additionally, some patients considered in <a href="./references#CD012078-bbs2-0154" title="GaldyS , CellaCA , SpadaF , MurgioniS , FrezzaAM , RavendaSP , et al. Systemic therapy beyond first-line in advanced gastric cancer: an overview of the main randomized clinical trials. Critical Reviews in Oncology/Hematology2016;99:1-12. [PMID: 26697987]">Glady 2016</a> had oesophageal cancer other than OGJ adenocarcinoma. Consequently, it contained more randomised studies. AEs and QoL associated with systemic therapy were not considered. As demonstrated by our review, it reported survival benefit of mono‐chemotherapy and biological therapy with VEGFR‐targeted therapy over placebo or BSC and authors concluded BSC should not be accepted as gold standard in management of advanced gastric cancer beyond the first‐line treatment. <a href="./references#CD012078-bbs2-0154" title="GaldyS , CellaCA , SpadaF , MurgioniS , FrezzaAM , RavendaSP , et al. Systemic therapy beyond first-line in advanced gastric cancer: an overview of the main randomized clinical trials. Critical Reviews in Oncology/Hematology2016;99:1-12. [PMID: 26697987]">Glady 2016</a> reviewed three RCTs for the comparison of chemotherapy combined with biological therapy versus chemotherapy alone and reported variable survival benefit depending on the choice of biological agents. In our review, meta‐analysis for the same comparison demonstrated small OS and PFS benefit of combining chemotherapy with biological therapy only when studies examining HER2‐targeted therapy were excluded. This type of treatment was additionally associated with increased SAEs compared to chemotherapy alone. </p> <p><a href="./references#CD012078-bbs2-0170" title="ter VeerE , Haj MohammadN , vanValkenhoefG , NgaiLL , MaliRM , vanOijenMG , et al. Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature. Cancer Metastasis Review2016;35(3):439-56. [PMID: 27417221]">ter Veer 2016</a> reviewed phase 2 and 3 RCTs of systemic therapy in advanced oesophago‐gastric cancer again in the salvage setting. Unlike our review, which focused on gastric and OGJ adenocarcinoma alone, patients with non‐OGJ oesophageal adenocarcinoma were included in this review. Difference in risk factors, gene expression and tumour biology have been previously suggested between OGJ adenocarcinoma arising from distal oesophagus and gastric cardia (<a href="./references#CD012078-bbs2-0162" title="MarsmanWA , TytgatGN , ten KateFJ , vanLanschotJJ . Differences and similarities of adenocarcinomas of the esophagus and esophagogastric junction. Journal of Surgical Oncology2005;92(3):160-8. [PMID: 16299781]">Marsman 2005</a>). Differential efficacy of chemotherapy was suggested in <a href="./references#CD012078-bbs2-0147" title="ChauI , NormanAR , CunninghamD , OatesJ , HawkinsR , IvesonT , et al. The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials. Annals of Oncology2009;20(5):885-91. [PMID: 19164454]">Chau 2009</a>. Overall, their findings were consistent with results of this review. <a href="./references#CD012078-bbs2-0170" title="ter VeerE , Haj MohammadN , vanValkenhoefG , NgaiLL , MaliRM , vanOijenMG , et al. Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature. Cancer Metastasis Review2016;35(3):439-56. [PMID: 27417221]">ter Veer 2016</a> reported OS benefit of chemotherapy and equivalent OS and PFS outcomes from taxane‐ and irinotecan‐based chemotherapy. The nature of survival benefit from biological therapy over placebo or BSC depended on the agent investigated with apatinib showing both OS and PFS benefit. The review also reported no difference in the OS outcome when taxane‐ or irinotecan‐containing doublet chemotherapy was compared to taxane or irinotecan monotherapy. We observed unclear TRR benefit when platinum or S1 was added to taxane with increased incidence of serious infective complications including febrile neutropenia. Unlike our review, which showed OS and PFS benefit of addition of biological therapy to chemotherapy in the meta‐analysis evaluating five non‐trastuzumab‐based biological agents all from different groups, <a href="./references#CD012078-bbs2-0170" title="ter VeerE , Haj MohammadN , vanValkenhoefG , NgaiLL , MaliRM , vanOijenMG , et al. Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature. Cancer Metastasis Review2016;35(3):439-56. [PMID: 27417221]">ter Veer 2016</a> found ramucirumab and olaparib to be the only biological therapy with survival benefit when combined with chemotherapy. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012078-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012078-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/full#CD012078-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-FIG-02" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012078-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/full#CD012078-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Chemotherapy versus placebo, BSC or no treatment, Outcome 1: Overall survival" data-id="CD012078-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Chemotherapy versus placebo, BSC or no treatment, Outcome 1: Overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Chemotherapy versus placebo, BSC or no treatment, Outcome 2: Progression‐free survival" data-id="CD012078-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Chemotherapy versus placebo, BSC or no treatment, Outcome 2: Progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Chemotherapy versus placebo, BSC or no treatment, Outcome 3: Serious adverse events" data-id="CD012078-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Chemotherapy versus placebo, BSC or no treatment, Outcome 3: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Chemotherapy versus placebo, BSC or no treatment, Outcome 4: Tumour response rate" data-id="CD012078-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Chemotherapy versus placebo, BSC or no treatment, Outcome 4: Tumour response rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Chemotherapy versus placebo, BSC or no treatment, Outcome 5: Any adverse events" data-id="CD012078-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Chemotherapy versus placebo, BSC or no treatment, Outcome 5: Any adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Chemotherapy versus placebo, BSC or no treatment, Outcome 6: Subgroup analysis by line of treatment: overall survival" data-id="CD012078-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Chemotherapy versus placebo, BSC or no treatment, Outcome 6: Subgroup analysis by line of treatment: overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Chemotherapy versus placebo, BSC or no treatment, Outcome 7: Subgroup analysis by geographical region: overall survival" data-id="CD012078-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Chemotherapy versus placebo, BSC or no treatment, Outcome 7: Subgroup analysis by geographical region: overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Chemotherapy versus placebo, BSC or no treatment, Outcome 8: Subgroup analysis by geographical region: progression‐free survival" data-id="CD012078-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Chemotherapy versus placebo, BSC or no treatment, Outcome 8: Subgroup analysis by geographical region: progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Biological therapy versus placebo, BSC or no treatment, Outcome 1: Overall survival" data-id="CD012078-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Biological therapy versus placebo, BSC or no treatment, Outcome 1: Overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Biological therapy versus placebo, BSC or no treatment, Outcome 2: Progression‐free survival" data-id="CD012078-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Biological therapy versus placebo, BSC or no treatment, Outcome 2: Progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Biological therapy versus placebo, BSC or no treatment, Outcome 3: Serious adverse events" data-id="CD012078-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Biological therapy versus placebo, BSC or no treatment, Outcome 3: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Biological therapy versus placebo, BSC or no treatment, Outcome 4: Tumour response rate" data-id="CD012078-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Biological therapy versus placebo, BSC or no treatment, Outcome 4: Tumour response rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Biological therapy versus placebo, BSC or no treatment, Outcome 5: Any adverse events" data-id="CD012078-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Biological therapy versus placebo, BSC or no treatment, Outcome 5: Any adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Biological therapy versus placebo, BSC or no treatment, Outcome 6: Subgroup analysis by line of treatment: progression‐free survival" data-id="CD012078-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Biological therapy versus placebo, BSC or no treatment, Outcome 6: Subgroup analysis by line of treatment: progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Biological therapy versus placebo, BSC or no treatment, Outcome 7: Subgroup analysis by geographical region: progression‐free survival (VEGFR‐targeted therapy)" data-id="CD012078-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Biological therapy versus placebo, BSC or no treatment, Outcome 7: Subgroup analysis by geographical region: progression‐free survival (VEGFR‐targeted therapy) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Biological therapy versus placebo, BSC or no treatment, Outcome 8: Subgroup analysis by types of biological therapy: overall survival" data-id="CD012078-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Biological therapy versus placebo, BSC or no treatment, Outcome 8: Subgroup analysis by types of biological therapy: overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Biological therapy versus placebo, BSC or no treatment, Outcome 9: Subgroup analysis by types of biological therapy: progression‐free survival" data-id="CD012078-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Biological therapy versus placebo, BSC or no treatment, Outcome 9: Subgroup analysis by types of biological therapy: progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Chemotherapy versus biological therapy, Outcome 1: Overall survival" data-id="CD012078-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Chemotherapy versus biological therapy, Outcome 1: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Chemotherapy versus biological therapy, Outcome 2: Progression‐free survival" data-id="CD012078-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Chemotherapy versus biological therapy, Outcome 2: Progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Chemotherapy versus biological therapy, Outcome 3: Serious adverse events" data-id="CD012078-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Chemotherapy versus biological therapy, Outcome 3: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Chemotherapy versus biological therapy, Outcome 4: Tumour response rate" data-id="CD012078-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Chemotherapy versus biological therapy, Outcome 4: Tumour response rate</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Chemotherapy versus biological therapy, Outcome 5: Any adverse events" data-id="CD012078-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Chemotherapy versus biological therapy, Outcome 5: Any adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Chemotherapy versus biological therapy, Outcome 6: Subgroup analysis by geographical region: overall survival" data-id="CD012078-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Chemotherapy versus biological therapy, Outcome 6: Subgroup analysis by geographical region: overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Chemotherapy combined with biological therapy versus chemotherapy, Outcome 1: Overall survival" data-id="CD012078-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Chemotherapy combined with biological therapy versus chemotherapy, Outcome 1: Overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Chemotherapy combined with biological therapy versus chemotherapy, Outcome 2: Progression‐free survival" data-id="CD012078-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Chemotherapy combined with biological therapy versus chemotherapy, Outcome 2: Progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Chemotherapy combined with biological therapy versus chemotherapy, Outcome 3: Serious adverse events" data-id="CD012078-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Chemotherapy combined with biological therapy versus chemotherapy, Outcome 3: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Chemotherapy combined with biological therapy versus chemotherapy, Outcome 4: Tumour response rate" data-id="CD012078-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Chemotherapy combined with biological therapy versus chemotherapy, Outcome 4: Tumour response rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Chemotherapy combined with biological therapy versus chemotherapy, Outcome 5: Any adverse events" data-id="CD012078-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Chemotherapy combined with biological therapy versus chemotherapy, Outcome 5: Any adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Chemotherapy combined with biological therapy versus chemotherapy, Outcome 6: QoL" data-id="CD012078-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Chemotherapy combined with biological therapy versus chemotherapy, Outcome 6: QoL </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Chemotherapy combined with biological therapy versus chemotherapy, Outcome 7: Subgroup analysis by geographical region: overall survival" data-id="CD012078-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: Chemotherapy combined with biological therapy versus chemotherapy, Outcome 7: Subgroup analysis by geographical region: overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-004.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Chemotherapy combined with biological therapy versus chemotherapy, Outcome 8: Subgroup analysis by geographical region: progression‐free survival" data-id="CD012078-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-004.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-004.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4: Chemotherapy combined with biological therapy versus chemotherapy, Outcome 8: Subgroup analysis by geographical region: progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-004.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-004.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Chemotherapy combined with biological therapy versus chemotherapy, Outcome 9: Subgroup analysis by extent of disease: overall survival" data-id="CD012078-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-004.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-004.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4: Chemotherapy combined with biological therapy versus chemotherapy, Outcome 9: Subgroup analysis by extent of disease: overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-004.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Chemotherapy versus chemotherapy, Outcome 1: Overall survival (non‐taxane monotherapy vs taxane monotherapy)" data-id="CD012078-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Chemotherapy versus chemotherapy, Outcome 1: Overall survival (non‐taxane monotherapy vs taxane monotherapy) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Chemotherapy versus chemotherapy, Outcome 2: Overall survival (taxane‐containing doublet therapy vs taxane monotherapy)" data-id="CD012078-fig-0036" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Chemotherapy versus chemotherapy, Outcome 2: Overall survival (taxane‐containing doublet therapy vs taxane monotherapy) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Chemotherapy versus chemotherapy, Outcome 3: Progression‐free survival (non‐taxane monotherapy vs taxane monotherapy)" data-id="CD012078-fig-0037" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Chemotherapy versus chemotherapy, Outcome 3: Progression‐free survival (non‐taxane monotherapy vs taxane monotherapy) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Chemotherapy versus chemotherapy, Outcome 4: Progression‐free survival (taxane‐containing doublet therapy vs taxane monotherapy)" data-id="CD012078-fig-0038" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Chemotherapy versus chemotherapy, Outcome 4: Progression‐free survival (taxane‐containing doublet therapy vs taxane monotherapy) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Chemotherapy versus chemotherapy, Outcome 5: Tumour response rate (non‐taxane monotherapy vs taxane monotherapy)" data-id="CD012078-fig-0039" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Chemotherapy versus chemotherapy, Outcome 5: Tumour response rate (non‐taxane monotherapy vs taxane monotherapy) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Chemotherapy versus chemotherapy, Outcome 6: Tumour response rate (taxane‐containing doublet therapy vs taxane monotherapy)" data-id="CD012078-fig-0040" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: Chemotherapy versus chemotherapy, Outcome 6: Tumour response rate (taxane‐containing doublet therapy vs taxane monotherapy) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012078-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/urn:x-wiley:14651858:media:CD012078:CD012078-CMP-005.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Chemotherapy versus chemotherapy, Outcome 7: Tumour response rate (non‐taxane containing therapy vs another non‐taxane containing therapy)" data-id="CD012078-fig-0041" src="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-005.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_t/tCD012078-CMP-005.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5: Chemotherapy versus chemotherapy, Outcome 7: Tumour response rate (non‐taxane containing therapy vs another non‐taxane containing therapy) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/media/CDSR/CD012078/image_n/nCD012078-CMP-005.07.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012078-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Chemotherapy versus placebo, best supportive care (BSC) or no treatment</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Chemotherapy compared to placebo, BSC or no treatment for advanced gastric and oesophago‐gastric junction adenocarcinoma</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> advanced gastric and oesophago‐gastric junction adenocarcinoma<br/><b>Setting:</b> second‐line and beyond<br/><b>Intervention:</b> chemotherapy<br/><b>Comparison:</b> placebo, BSC or no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with chemotherapy</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo, BSC or no treatment</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>mOS weighed for study size</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.66<br/>(0.52 to 0.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>547<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2 studies compared chemotherapy (irinotecan and trifluridine/tipiracil) to placebo or BSC. Heterogeneity was low (I<sup>2</sup> = 7%, P = 0.30). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5.6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3.5 months</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression‐free survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>mPFS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.57<br/>(0.47 to 0.69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>507<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared trifluridine/tipiracil to placebo.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2.0 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.8 months</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.38<br/>(1.20 to 1.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>503<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared trifluridine/tipiracil to placebo.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>797 per 1,000</p> <p>(693 to 918)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>577 per 1,000</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tumour response rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.17<br/>(0.63 to 7.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>435<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared trifluridine/tipiracil to placebo.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>97 per 1,000<br/>(28 to 335) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1,000</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.04<br/>(1.00 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>503<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared trifluridine/tipiracil to placebo.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>972 per 1,000<br/>(935 to 1,000) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>935 per 1,000</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval ;<b>HR:</b> hazard ratio; <b>mOS:</b> median overall survival; <b>mPFS:</b> median progression‐free survival; <b>RCT:</b> randomised controlled trial; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level for imprecision; 95% CI for the HR included null effect and appreciable benefit from chemotherapy. </p> <p><sup>2</sup> Downgraded by one level for imprecision; 95% CI for the RR included null effect and appreciable harm from chemotherapy. </p> <p><sup>3</sup> Downgraded by two levels for imprecision; the number of events analysed was small and 95% CI included both appreciable benefit and harm from chemotherapy. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Chemotherapy versus placebo, best supportive care (BSC) or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/full#CD012078-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012078-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Biological therapy versus placebo, best supportive care (BSC) or no treatment</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Biological therapy compared to placebo, BSC or no treatment for advanced gastric and oesophago‐gastric junction adenocarcinoma</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> advanced gastric and oesophago‐gastric junction adenocarcinoma<br/><b>Setting:</b> second‐ and third‐line<br/><b>Intervention:</b> biological therapy<br/><b>Comparison:</b> placebo, BSC or no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with biological therapy</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo, BSC or no treatment</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>mOS weighed for study size</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.55<br/>(0.41 to 0.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>781<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared nivolumab to placebo and 2 studies compared VEGFR‐targeted agents (apatinib and regorafenib) to placebo. Heterogeneity was moderate (I<sup>2</sup> = 55%, P = 0.08). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5.2 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3.9 months</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression‐free survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>mPFS weighed for study size</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.33<br/>(0.19 to 0.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>781<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared nivolumab to placebo and 2 studies compared VEGFR‐targeted agents (apatinib and regorafenib) to placebo. Heterogeneity was high (I<sup>2</sup> = 87%, P &lt; 0.0001). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2.1 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.3 months</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.14<br/>(0.95 to 1.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>638<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared nivolumab to placebo and the other study compared regorafenib to placebo. Heterogeneity was low (I<sup>2</sup> = 3%, P = 0.31). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>481 per 1,000<br/>(401 to 578) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>422 per 1,000</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tumour response rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 5.12 (1.23 to 21.27)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>687<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared nivolumab to placebo and 2 studies compared VEGFR‐targeted agents (apatinib and regorafenib) to placebo. Heterogeneity was low (I² = 13%, P = 0.33). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>470 per 1,000<br/>(113 to 1,000) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>92 per 1,000</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.08<br/>(1.00 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>491<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared nivolumab to placebo.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>906 per 1,000<br/>(839 to 981) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>839 per 1,000</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life (QoL</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>)Similar QoL was experienced by participants treated with biological therapy and placebo, except for improved insomnia and pain associated with apatinib and regorafenib treatment, respectively. More participants receiving regorafenib experienced diarrhoea, and sore throat and mouth. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>283<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>4 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>QoL was assessed in 2 studies comparing VEGFR‐targeted agents (apatinib and regorafenib) to placebo, using EORTC QLQ‐C30 +/‐ QLQ‐STO22 and EQ‐5D. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>HR:</b> hazard ratio; <b>mOS:</b> median overall survival; <b>mPFS:</b> median progression‐free survival; <b>RCT:</b> randomised controlled trial; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level for inconsistency; heterogeneity between studies was high. </p> <p><sup>2</sup> Downgraded by two levels for imprecision; the number of events analysed was small and 95% CI included both null effect and appreciable harm from biological therapy. </p> <p><sup>3</sup> Downgraded by two levels for imprecision; the number of events analysed was small and 95% CI was very wide. </p> <p><sup>4</sup> Downgraded by one level for attrition bias; less participants in the placebo arm completed QoL questionnaires post baseline. </p> <p><sup>5</sup> Downgraded by one level for imprecision; the number of events analysed was small. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Biological therapy versus placebo, best supportive care (BSC) or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/full#CD012078-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012078-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Chemotherapy versus biological therapy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Chemotherapy compared to biological therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> advanced gastric and oesophago‐gastric junction adenocarcinoma<br/><b>Setting:</b> second‐line<br/><b>Intervention:</b> biological therapy<br/><b>Comparison:</b> chemotherapy </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with biological therapy</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Chemotherapy</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>mOS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.82<br/>(0.66 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>395<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared pembrolizumab to paclitaxel in PD‐L1 CPS ≥ 1 population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9.1 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8.3 months</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression‐free survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>mPFS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.27<br/>(1.03 to 1.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>395<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared pembrolizumab to paclitaxel in PD‐L1 CPS ≥ 1 population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.5 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4.1 months</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.41<br/>(0.30 to 0.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>570<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared pembrolizumab to paclitaxel.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>143 per 1,000<br/>(104 to 198) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>348 per 1,000</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tumour response rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.17<br/>(0.72 to 1.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>395<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared pembrolizumab to paclitaxel in PD‐L1 CPS ≥ 1 population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>159 per 1,000</p> <p>(98 to 255)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>136 per 1,000</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.63<br/>(0.56 to 0.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>570<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared pembrolizumab to paclitaxel.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>530 per 1,000</p> <p>(471 to 597)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>841 per 1,000</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>HR:</b> hazard ratio; <b>mOS:</b> median overall survival; <b>mPFS:</b> median progression‐free survival; <b>RCT:</b> randomised controlled trial;<b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level for imprecision; 95% CI included both null effect and appreciable benefit from biological therapy. </p> <p><sup>2</sup> Downgraded by one level for imprecision; 95% CI included both null effect and appreciable harm from biological therapy. </p> <p><sup>3</sup> Downgraded by one level for imprecision; the total number of events analysed was small. </p> <p><sup>4</sup> Downgraded by one level for risk of performance bias in <a href="./references#CD012078-bbs2-0012" title="ShitaraK , ÖzgüroğluM , BangYJ , BartolomeoMD , MandalàM , RyuMH , et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet2018;392(10142):123-33. [PMID: 29880231]">Shitara 2018</a>. </p> <p><sup>5</sup> Downgraded by two levels for imprecision; the number of events analysed was small and 95% CI included both appreciable benefit and harm from biological therapy. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Chemotherapy versus biological therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/full#CD012078-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012078-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Chemmotherapy combined with biological therapy versus chemotherapy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Chemmotherapy compared to chemotherapy combined with biological therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> advanced gastric and oesophago‐gastric junction adenocarcinoma<br/><b>Setting:</b> second‐ to fourth‐line<br/><b>Intervention:</b> chemotherapy combined with biological therapy<br/><b>Comparison:</b> chemotherapy </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with chemotherapy combined with biological therapy</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with chemotherapy</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>mOS weighed for study size</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.93<br/>(0.83 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2743<br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study each examined PARP inhibitor (olaparib), anti‐HER2 antibody (trastuzumab), cancer stem cell inhibitor (napabucasin), mTOR inhibitor (everolimus), anti‐VEGFR2 antibody (ramucirumab) and multi‐tyrosine kinase inhibitor (sunitinib) together with chemotherapy. The other study examined anti‐HER2 antibody conjugated with chemotherapy (trastuzumab‐emtansine). The control arm was taxane in all studies. Heterogeneity was moderate (I<sup>2</sup> = 36%, P = 0.15). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8.1 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7.2 months</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression‐free survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>mPFS weighed for study size</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.87<br/>(0.74 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2743<br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study each examined PARP inhibitor (olaparib), anti‐HER2 antibody (trastuzumab), cancer stem cell inhibitor (napabucasin), mTOR inhibitor (everolimus), anti‐VEGFR2 antibody (ramucirumab) and multi‐tyrosine kinase inhibitor (sunitinib) together with chemotherapy. The other study examined anti‐HER2 antibody conjugated with chemotherapy (trastuzumab‐emtansine). The control arm was taxane in all studies. Heterogeneity was high (I<sup>2</sup> = 71%, P = 0.002). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3.9 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3.1 months</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.17<br/>(0.95 to 1.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1618<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>3 5 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study each examined PARP inhibitor (olaparib), anti‐VEGFR2 antibody (ramucirumab) and multi‐tyrosine kinase inhibitor (sunitinib) together with chemotherapy. The other study examined anti‐HER2 antibody conjugated with chemotherapy (trastuzumab‐emtansine). The control arm was taxane in all studies. Heterogeneity was high (I<sup>2</sup> = 86%, P &lt; 0.0001). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>735 per 1,000</p> <p>(686 to 791)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>613 per 1,000</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tumour response rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.35<br/>(0.99 to 1.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2404<br/>(6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study each examined PARP inhibitor (olaparib), anti‐HER2 antibody (trastuzumab), cancer stem cell inhibitor (napabucasin), anti‐VEGFR2 antibody (ramucirumab) and multi‐tyrosine kinase inhibitor (sunitinib) together with chemotherapy. The other study examined anti‐HER2 antibody conjugated with chemotherapy (trastuzumab‐emtansine). The control arm was taxane in all studies. Heterogeneity was high (I<sup>2</sup> = 66%, P = 0.01). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>294 per 1,000</p> <p>(216 to 403)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>218 per 1,000</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/>(1.00 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1513<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study each examined PARP inhibitor (olaparib) and anti‐VEGFR2 antibody (ramucirumab). The other study examined anti‐HER2 antibody conjugated with chemotherapy (trastuzumab‐emtansine). The control arm was taxane in all studies. Heterogeneity was low (I<sup>2</sup> = 0%, P = 0.78). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>987 per 1,000</p> <p>(977 to 1000)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>977 per 1,000</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Quality of life (QoL)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Median time to deterioration of EORTC QLQ‐C30 global health status for olaparib‐paclitaxel vs placebo‐paclitaxel </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.88<br/>(0.74 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1154<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>4 8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>QoL was assessed by 2 out of 7 studies using EORTC QLQ‐C30 plus QLQ‐SOT22 or EQ‐5D‐3L. 1 study each investigated PARP inhibitor (olaparib) and anti‐VEGFR2 antibody (ramucirumab). The control arm was taxane in both studies. Meta‐analysis was performed for time to deterioration of EORTC QLQ‐C30 global health status. Heterogeneity was very low (I² = 0%, P = 0.47). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3.4 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2.4 months</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>HR:</b> hazard ratio; <b>mOS:</b> median overall survival; <b>mPFS:</b> median progression‐free survival; <b>RCT:</b> randomised controlled trial; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level for unclear risk of selection, attrition and reporting bias and confounders in <a href="./references#CD012078-bbs2-0008" title="MakiyamaA , SagaraK , KawadaJ , KashiwadaT , HosokawaA , HorieY , et al. T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Journal of Clinical Oncology2018;36(15_suppl):4011. [DOI: 10.1200/JCO.2017.35.4_suppl.TPS218 ]">Makiyama 2018</a>, <a href="./references#CD012078-bbs2-0009" title="PauligkC , LorenzenS , GoetzeT , RieraJK , HegewischSB , SeraphinJ , et al. A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Annals of Oncology2017;28(suppl_5):mdx369.054. [DOI: org/10.1093/annonc/mdx369.054]">Pauligk 2017</a> and <a href="./references#CD012078-bbs2-0011" title="ShahMA , ShitaraK , LordickF , BangYJ , TebbuttNC , MetgesJP , et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology2018;36(15_suppl):4010. [DOI: 10.1200/JCO.2018.36.15_suppl.4010]">Shah 2018</a>. </p> <p><sup>2</sup> Downgraded by one level for risk of detection bias in <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>. </p> <p><sup>3</sup> Downgraded by one level for inconsistency; 95% CIs of some studies did not overlap. </p> <p><sup>4</sup> Downgraded by one level for imprecision; 95% CI included both null effect and appreciable benefit from chemotherapy combined with biological therapy. </p> <p><sup>5</sup> Downgraded by one level for imprecision; 95% CI included both null effect and appreciable harm from chemotherapy combined with biological therapy. </p> <p><sup>6</sup> Downgraded by one level for risk of performance bias in <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a> and <a href="./references#CD012078-bbs2-0017" title="YiJH , LeeJ , LeeJ , ParkSH , ParkJO , YimDS , et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. British Journal of Cancer2012;106(9):1469-74. [PMID: 22460270]">Yi 2012</a>. </p> <p><sup>7</sup> Downgraded by one level for risk of performance and detection bias in <a href="./references#CD012078-bbs2-0015" title="Thuss-PatiencePC , ShahMA , OhtsuA , Van CutsemE , AjaniJA , CastroH , et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology2017;18(5):640-53. [PMID: 28343975]">Thuss‐Patience 2017</a>. </p> <p><sup>8</sup> Downgraded by one level for attrition bias in <a href="./references#CD012078-bbs2-0001" title="BangYJ , XuRH , ChinK , LeeKW , ParkSH , RhaSY , et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology2017;18(12):1637-51. [PMID: 29103871 ]">Bang 2017</a> and <a href="./references#CD012078-bbs2-0016" title="Al-BatranSE , Van CutsemE , OhSC , BodokyG , ShimadaY , HironakaS , et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology2016;27((4)):673-9. [PMID: 26747859]WilkeH , MuroK , Van CutsemE , OhSC , BodokyG , ShimadaY , et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology2014;15(11):1224-35. [PMID: 25240821]">Wilke 2014</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Chemmotherapy combined with biological therapy versus chemotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/full#CD012078-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012078-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Chemotherapy versus chemotherapy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Chemotherapy compared to chemotherapy for advanced gastric and oesophago‐gastric junction adenocarcinoma</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> advanced gastric adenocarcinoma<br/><b>Setting:</b> second‐line<br/><b>Intervention:</b> chemotherapy<br/><b>Comparison:</b> chemotherapy </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with chemotherapy</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with chemotherapy</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival (non‐taxane monotherapy vs taxane monotherapy)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>mOS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.13<br/>(0.86 to 1.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>219<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared irinotecan to paclitaxel.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8.4 months (irinotecan)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9.5 months (paclitaxel)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival (taxane‐containing doublet therapy vs taxane monotherapy)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>mOS weighed for study size</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.05<br/>(0.72 to 1.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>121<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared docetaxel‐oxaliplatin to docetaxel and the other study compared docetaxel‐cisplatin and docetaxel‐S1 to docetaxel. Heterogeneity was moderate (I<sup>2</sup> = 44%, P = 0.17). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7.0 months (taxane‐containing doublet therapy)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8.8 months (docetaxel)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Overall survival (non‐taxane containing therapy vs another non‐taxane containing therapy)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>mOS (P = 0.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>107 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1 study compared FOLFIRI to EOX.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>18.5 months (FOLFIRI)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>19.3 months (EOX)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression‐free survival (non‐taxane monotherapy vs taxane monotherapy)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>mPFS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.14<br/>(0.88 to 1.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>219<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared irinotecan to paclitaxel.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2.3 months (irinotecan)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3.6 months (paclitaxel)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression‐free survival (taxane‐containing doublet therapy vs taxane monotherapy)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>mPFS weighed for study size</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.75<br/>(0.52 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>121<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared docetaxel‐oxaliplatin to docetaxel and the other study compared docetaxel‐cisplatin and docetaxel‐S1 to docetaxel. Heterogeneity was moderate (I<sup>2</sup> = 59%, P = 0.09). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3.4 months (taxane‐containing doublet therapy)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.6 months (docetaxel)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Progression‐free survival (non‐taxane containing therapy vs another non‐taxane containing therapy) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>mPFS (P = 0.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>107 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1 study compared FOLFIRI to EOX.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>8.1 months (FOLFIRI)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>7.4 months (EOX)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse effects</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Grade ≥ 3 neutropenia was common occurring in &gt; 20% of participants receiving both mono chemotherapy and polychemotherapy except for docetaxel‐S1 and EOX arms. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>448<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study each compared docetaxel‐cisplatin and docetaxel‐S1 to docetaxel, irinotecan to paclitaxel, docetaxel‐oxaliplatin to docetaxel and FOLFIRI to EOX. All 4 studies measured serious adverse events, however, none of them reported the total number of participants with any serious adverse events. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tumour response rate (non‐taxane monotherapy vs taxane monotherapy)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.65<br/>(0.34 to 1.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>179<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared irinotecan to paclitaxel.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>136 per 1,000</p> <p>(71 to 263) (irinotecan)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>209 per 1,000 (paclitaxel)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tumour response rate (taxane‐containing doublet therapy vs taxane monotherapy)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.47<br/>(0.56 to 3.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>121<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>5 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study examined both docetaxel‐cisplatin and docetaxel‐S1 and the other study examined docetaxel‐oxaliplatin. Control arm was docetaxel in both studies. Heterogeneity was very low (I² = 0%, P = 0.92). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>147 per 1,000</p> <p>(56 to 389) (taxane‐containing doublet therapy)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1,000 (taxane monotherapy)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tumour response rate (non‐taxane containing therapy vs another non‐taxane containing therapy) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.89<br/>(0.48 to 1.67) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>107<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 study compared FOLFIRI to EOX chemotherapy.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>254 per 1,000</p> <p>(137 to 477) (FOLFIRI)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>286 per 1,000 (EOX)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Neutropenia, anaemia, diarrhoea and anorexia were some of the commonly experienced adverse events across all the studies. Neuropathy was associated with paclitaxel, docetaxel‐S1 and EOX treatment. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>448<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies measured any adverse events, however, none of them reported the total number of participants with any adverse events. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>No difference was observed for global QoL between docetaxel‐cisplatin, docetaxel‐S1 and docetaxel arms, however, worse QoL was reported for participants receiving the doublet chemotherapy for several symptom categories including physical functioning, fatigue and appetite loss. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>9 10</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study comparing docetaxel‐cisplatin to docetaxel‐S1 and docetaxel reported QoL. QoL was assessed using EORTC QLQ‐C30 and gastric modules QLQ‐STO22. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>HR:</b> hazard ratio; <b>mOS:</b> median overall survival; <b>mPFS:</b> median progression‐free survival; <b>RR:</b> Risk ratio; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by two levels for imprecision; the number of events analysed was small and 95% CI included both null effect and appreciable harm from irinotecan. </p> <p><sup>2</sup> Downgraded by two levels for imprecision; the number of events analysed was small and the 95% CI included both appreciable benefit and harm from taxane‐containing doublet therapy. </p> <p><sup>3</sup> Downgraded by two levels for imprecision; the number of events analysed was small and 95% CI included both null effect and appreciable benefit from taxane‐containing doublet therapy. </p> <p><sup>4</sup> Downgraded by two levels for imprecision; the number of events analysed was small and 95% CI included both appreciable benefit and harm from irinotecan. </p> <p><sup>5</sup> Downgraded by one level for unclear risk of selection bias, detection bias and confounders in <a href="./references#CD012078-bbs2-0004" title="KimJY , RyooHM , BaeSH , KangBW , ChaeYS , YoonS , et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Research2015;35(6):3531-6. [PMID: 26026121]">Kim 2015</a> and <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>. </p> <p><sup>6</sup> Downgraded by two levels for imprecision; the number of events analysed was small and 95% CI included both appreciable benefit and harm from taxane‐containing doublet therapy. </p> <p><sup>7</sup> Downgraded by two levels for imprecision; the number events analysed was small and 95% CI included both appreciable benefit and harm from FOLFIRI. </p> <p><sup>8</sup> Downgraded by one level for performance bias in <a href="./references#CD012078-bbs2-0002" title="HironakaS , UedaS , YasuiH , NishinaT , TsudaM , TsumuraT , et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of Clinical Oncology2013;31(35):4438-44. [PMID: 24190112]">Hironaka 2013</a>. </p> <p><sup>9</sup> Downgraded by one level for attrition bias in <a href="./references#CD012078-bbs2-0005" title="LeeKW , KimBJ , KimMJ , HanHS , KimJW , ParkYI , et al. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine. Cancer Research and Treatment2017;49(3):706-16. [PMID: 27764906]">Lee 2017</a>. </p> <p><sup>10</sup> Downgraded by two levels for imprecision; the number of events analysed was very small. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Chemotherapy versus chemotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/full#CD012078-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012078-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Chemotherapy versus placebo, BSC or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.52, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>507</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.47, 0.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>503</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [1.20, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Tumour response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>435</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.17 [0.63, 7.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Any adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>503</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [1.00, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Subgroup analysis by line of treatment: overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.52, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Second line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.25, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Third line and beyond</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>507</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.56, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Subgroup analysis by geographical region: overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.54, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 East and South‐East Asia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.46, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Rest of the world</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.52, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Subgroup analysis by geographical region: progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>507</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.33, 0.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 East and South‐East Asia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.19, 0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 Rest of the world</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.49, 0.76]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Chemotherapy versus placebo, BSC or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012078-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Biological therapy versus placebo, BSC or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>781</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.41, 0.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>781</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.19, 0.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>638</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.95, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Tumour response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>687</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.12 [1.23, 21.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Any adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [1.00, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Subgroup analysis by line of treatment: progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.18, 0.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 Second‐line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.28, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.2 Third‐line and beyond</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.17, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Subgroup analysis by geographical region: progression‐free survival (VEGFR‐targeted therapy) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.11, 0.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 East and South‐East Asia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.12, 0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.2 Rest of the world</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.39, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Subgroup analysis by types of biological therapy: overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>781</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.41, 0.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.1 VEGFR‐targeted therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.31, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.2 Immunotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>493</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.51, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Subgroup analysis by types of biological therapy: progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>781</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.19, 0.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.1 VEGFR‐targeted therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.15, 0.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.2 Immunotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>493</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.49, 0.73]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Biological therapy versus placebo, BSC or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012078-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Chemotherapy versus biological therapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>395</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.66, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>395</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [1.03, 1.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.30, 0.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Tumour response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>395</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.72, 1.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Any adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.56, 0.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Subgroup analysis by geographical region: overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>395</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.66, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.1 East and South‐East Asia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.59, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.2 Rest of the world</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>291</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.61, 1.08]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Chemotherapy versus biological therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012078-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Chemotherapy combined with biological therapy versus chemotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2743</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.83, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2743</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.74, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1618</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.95, 1.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Tumour response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.99, 1.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Any adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1513</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [1.00, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 QoL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.74, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 Subgroup analysis by geographical region: overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2030</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.78, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.1 East and South‐EastAsia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1099</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.78, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.2 Rest of the world</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>931</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.73, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.8 Subgroup analysis by geographical region: progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1684</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.68, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.1 East and South‐East Asia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>942</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.68, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.2 Rest of the world</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>742</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.57, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.9 Subgroup analysis by extent of disease: overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>859</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.68, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9.1 Locally advanced</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.31, 7.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9.2 Metastatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>845</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.64, 1.35]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Chemotherapy combined with biological therapy versus chemotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012078-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Chemotherapy versus chemotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Overall survival (non‐taxane monotherapy vs taxane monotherapy) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.86, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Overall survival (taxane‐containing doublet therapy vs taxane monotherapy) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.72, 1.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Progression‐free survival (non‐taxane monotherapy vs taxane monotherapy) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.88, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Progression‐free survival (taxane‐containing doublet therapy vs taxane monotherapy) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.52, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Tumour response rate (non‐taxane monotherapy vs taxane monotherapy) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.34, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Tumour response rate (taxane‐containing doublet therapy vs taxane monotherapy) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.56, 3.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.7 Tumour response rate (non‐taxane containing therapy vs another non‐taxane containing therapy) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.48, 1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Chemotherapy versus chemotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012078.pub2/references#CD012078-tbl-0010">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012078.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012078-note-0018">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012078-note-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012078-note-0017">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD012078-note-0015">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD012078-note-0014">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD012078-note-0013">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD012078-note-0012">Português</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012078-note-0010">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD012078-note-0011">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012078\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012078\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012078\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012078\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012078\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012078\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012078\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012078\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012078\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012078\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012078\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012078\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012078\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012078\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012078\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012078\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012078\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012078\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9mpoajSI&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012078.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012078.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012078.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012078.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012078.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728321622"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012078.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728321626"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012078.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ec19f7bb4f46e',t:'MTc0MDcyODMyMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 